var title_f4_54_4960="HBV replication cycle";
var content_f4_54_4960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Replication cycle of HBV",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 390px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the replication cycle of hepatitis B virus (HBV). The replication cycle of HBV begins with attachment of the virion to the hepatocyte membrane, a process that may be mediated through the pre-S1 region of the virion envelope. The virion is uncoated in the hepatocyte cytoplasm and the viral genome enters the hepatocyte nucleus. Inside the hepatocyte nucleus, synthesis of the plus strand HBV DNA is completed and the viral genome is converted into a covalently closed circular DNA (ccc DNA). The pregenomic RNA, nucleocapsid, and polymerase proteins are encapsidated in the virus core particle inside which reverse transcription takes place. A new minus strand HBV DNA is produced followed by the synthesis of a new plus strand HBV DNA. Nucleocapsids with the partially double stranded HBV DNA can reenter the hepatocyte nucleus to produce more ccc DNA or be secreted as complete virions after coating with envelope proteins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_54_4960=[""].join("\n");
var outline_f4_54_4960=null;
var title_f4_54_4961="Pulmonary LAM microscopy High";
var content_f4_54_4961=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Microscopic features of lymphangioleiomyomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High magnification photomicrograph showing the abnormal spindle cells that characterize lymphangioleiomyomatosis. The proliferating spindle cells have many characteristics of modified smooth muscles cells and frequently stain for smooth muscle-associated intermediate filaments using immunohistochemistry.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey L Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_54_4961=[""].join("\n");
var outline_f4_54_4961=null;
var title_f4_54_4962="GB adenomyomatosis OCG";
var content_f4_54_4962=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80272&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gallbladder adenomyomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Oral cholecystogram showing localized adenomyomatosis in the fundus of the gallbladder. Note the appearance of Rokitansky-Aschoff sinuses (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Salam F Zakko, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_54_4962=[""].join("\n");
var outline_f4_54_4962=null;
var title_f4_54_4963="Wt height girls z 2 5";
var content_f4_54_4963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67900&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 628px\">",
"   <div class=\"ttl\">",
"    Weight-for-height girls: 2 to 5 years (z-scores)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 608px; height: 396px; background-image: url(data:image/gif;base64,R0lGODlhYAKMAfcAAP///7+/v6yjnsIpP5eXl5CQkOiZZneXhuyFRMPDw1Wne815huiYpLlpdOeJlqbJt9aao9yJVbuqp2BgYB8fH6SkpN/FyXBwcA+MStMhO9+/qlqWdtyHk+eid5fDrNhqetyTnkBAQNLCuACFPt23vNUvR8VFWDAwMGSReY+7ozCSXXW1k+yTW7N6g1BQUM9QYtm0ncaMaFtbWyAgIOOutrjSxO2NUKiRgg8PD+59NeuqgbaTfeR6itmackxMTLyMbZmZmWOrhDeZZHh4eFpaWsLTyu10JxAQEKqakBiLTbPKvpp7dkGZareci3OqjYmJieLi4klJScy5sm1tbd+tjWlpabeXnGxsbKysrOGhqgAAAD4+PuKRXtpabaeAhua9pGZmZqKioldXVygoKIWFhTg4OHZ2drW1tYKCgszMzNXV1cDAwICAgOUZN/RzIeYnQ/Dw8PR7LtDQ0PWEPODg4O/v76CgoP3w8i8vL+g1UJ+fn/indK+vr/728e5vgt/f3/rKq/3t4/vi5vWotOtSabCwsPzcx+lEXPB9jvaNSu1gdfaWWPOap/m5kPa3wM/Pz/vTufrT2fKMm4GBgfeeZviwgvjFzX9/f4+Pj/zk1frBnd/v5h+UVj+jbu/38l+yhi+bYo/Jqp/Rtr/gzm+6kn/Cns/o2k+req/YwuDT1eHZ1NLS0oyMjODQxuy8naiPk5ycnNmRY+RLYfCXX8dhcNFeb+E7VNLa1oyck+EuSO+fbOS+w9uosNCPZqqdn0ydcnx8fLKysrm5ueDIuLKKcampqeVZbubGsejXzefPv+Bgc0ijc92lgebM0EVFRUWgb+JvgPO6lq5ud+doeqampsnJye3Eq+uzj95SZ99GXOW0lsna0efb3NnZ2aVyevCoeYjCo+vFy7qHjrGLkMmwoejg29h/R+JWa9hMYKKVl+BvKPKxiMzBv9mmrd8gPKCxqJ6EiH+xlpScl8enk6y9tISUi66GbaauqqmJdKxga9x3N8ODjNnh3erq6tZWadGhgiH5BAAAAAAALAAAAABgAowBAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27eIfKmRBiAhwAcC70lZO3sOHDOgu5CMFG4N4QF/6WLES4gAsAcgoBKDQDsefPoFXaoQPARYHNhC9MSGlnNUEtoWPLnt1xgh2Ca0KgDHGC9EA7umkLH05coZwTlwlOaIyyUHDMM3wXn059+AXmAOycWAkbOmGDWIag/xlPfvyk8uXPoyevfn179EPEr0fzPv188/frk59yn37+/wCux1+A6OmHH4HlDTifgf4t2B+DChb4IIL2zRdhhQ5mqCF6F7I34YYYCkihhyCSaOGIB7qHIhodpqhiiS5y2N99Q2CBUG4CaSdZSQWQxoZucszwHXhqIASFkQkdeZCSBqlR5JJIRmkQkwXZKGVBVBKUpZYIWQnll1Mm2aWYYGJJJnhXmlmmmmiuyaWbA20pkJdshgknAHLOmeabdvbZpp918hkoQXQKOqhAeeYJQKEMqVEoG3DA4UJjOja3WGTZhaBpCEPO+SSgcZ55KABO7omoqIYOxGiodyqa56qntv+Kqqqzxgoqq3+OiqeptlbJ6653AptrqriOqiisrvJ67K+J/opsrcLqCmtCjhZUgKanASDYpjdh8amx0OZZqqzKjllusK+Gy6y55N7aK6Hrosuurs3y+uy57i4ar7vLytvusMWCG+y0CFVrlLf48lvwt8RGKzDAAUf8bsPT1ptvugk37DCt/l48r8YWu3vvvxqPrPDA+z4M8cYSs+yyvhAZXBTCJDcsLsMtJ3tnxRlTrG7HvvY8ccsmqzxq0TZDi3TOzqac9Mctuxxy0B7XzPFAfPDlAh8HyUwUHwlAIfbYYqdBNtlmnz122mqzfXYCYasNhdtoy1223XSPXYHdc+P/7fffau8N+Nl53z042YLLXXjfivO9eOKEO3543XJDTnnjmGd+tuVrS6755YFP3vnno1cuuuFtnw4F56inTnrrZ3NNUAh44KGFFn80SXBPNJ9sNak4D/3y1Ff7Ti/UTAMNr9DDI9+88sWD7HT0URMvPMxVG0/18b9jz732yw+UOwAhaPGI7kf1bvTTTQYv9c8rvw+9nszrHL/1z69s//fbSz+/9/4DH/Wuh79+ZW99A8wfAulHkEeU7wJd2x1P1Mc+AQKPefK7HwYx9rv9hc+CHkxgCAnovBEq8IMBXCAAq4fBpQkPfysk4e/4AAuD/OESeMDB+QritaFQMHm/G5cF/zPYvwqmEIVGZOFBeNY9DvLviCKEn8im98KEuJCIJaMiFpEoQwFiQgvZEp9ALqCFS6DvYO6DIf6EqEL8MXGITlygCd/YxhJK8WhanGMem/Y/GF6xgFbc45rqMAEc8KFQWsBD+bQQgDPOjABYiKQkI1mBSU6ykpaUJCYzuUlLEgCSmcRCJy8ZSkqWcpSSREMpRXnKVroyk6p8pSVRaUpZTjKWoaQlK3O5Sl3icpa9tCUpQ/nLYfLymMi0ZDE1GcxkGhOWwmSmM6VJzGjWkpPWxMIyr4nNaXKTFUfAAywiWRBMaMoFjXQkUX5YReaxMYlALGI8ochAECrtjkrUHz6JJv/InfVTWv/MYh/5eED2BQAHLqhDPRvSQ6Gwc4vzHMg7I0rRGLazoAmE6AkzCkh7BdRnA/VoSPP1xxZ+9HolJZceyshFhTQ0KA9VI68melEL0hGewrtpRV2m05ricaRTBOpPMerTlprQjyd9WUoVVkg9yNOlEtxJTJNKU41qtKdWjSNO9Vi/ewoVpETd6ELzqcKlljWpBnxiy7qBBwrssKXUiqpOpvpVgVRVpv7sqkg76FW+7lWtXXzqUfsKWKuaFacWHSzK6voIHIRAofErmFxzArbTLY5xrlMb3CzrucxurrORex3s9AZa0Jn2tGJj3WhXi1nPIk51i7vs42BLW9P/iba1qMXta28bW9WpVractdtvS1u6sT1BC0Tgm+we8tKXPMYvAnGOCzrlqQ3ONI1JxSpeNdhE52mUq2EFb2HFS0/DojWQdVVqQMmoh7QytFCKYcxAfgTdyVTmMnSYARyCRCTr3umu2d2nWC36XcLK0cBkLe9hExxFvS7xvHZ0sD7xVYcQ6FC9MSvUaEpzGjtcpgCuOUlrsgNBAPSmSthNL4DTq10ttvh/Lw7rggNrVAHzFMIPTq97GVzUBpPrERTAA2R3vJDm2gYAE9AMHDpzEt74iDkhWAOK/euuFYfXux3Nq1+1bM+/lpe8PB7wjM2rY/ReebFX1gMOQoxh5jLq/zjJibJAunMS5wCADVCWMqFSfOb2UXmoXebygb28VQTTOMxjBvOhezzWRZO5zwDtI3sj7WaEXId8eqbzSWBjhxKfmFCg7KaoR/3MSX7SmrrcJalT2cxVcxOY1UR1Nn3Zali7+tWs9iaud83rbar61qmmta5/XWpqQnPYukz2Kn0dbFmXktm1liQsZnCEcdr62KvMJCRvpJskA4bJJOnRnXWT3/2CW1V8Hu/C/gzWQAd1y+92N6C/bOgBK9reBFU3mvVN0uk9onbjo7RDeggpSVHqw2wWSXwxtZkQTLe/3f1vuumdY3jPu9CErui9FSvoMG9cwETG974p3m/l8WHNq//I93utha359mVHNKErpAliZX4/tcAZZ/S9cd5xR3+c3T6Wd40lLFiQm5l/l9ACJh498MniROY2p/nEPY5loDda5/XmebxJvnWq55zjAue6QGcetZTWwQU4SCdSM5y+qft83RHvusaznmW5Y/3rNtbq2/FO9KFb3O9CD7qZ/o2HgK+90kaprGiBK9rNLp64rFWtblnL+NAF17W5lXxveSvc2mK+uLv9POUhvzrPh1b0pef84zuvetFfdrh4K8ARxLCK3F52uU1vu9VdVnOxc3T3MS5s8BWc1Bun1/hkRymOJ/x3wROkCkofotNJNX2bQN33dnW7yLkLx6rH/eZ1v/j/3nu+fbuDfexRL/vyi26Qs6e9e9Nv7k+u73U/f7/dgya/1sV/d/KfH//1Z35GF2HNd3X/p3xuQnjVYFJsh0a7dzMP6H3dV3GBl1MD6H95R4ATyHwVmFgXyIH5B4InNwF1EH5wJVm6d38t03sBCFcmyE99B4MFiHzpJ4M1aIFlpoEhyH4zaDJJt3T7d4IRlD6hdm3FZmxHiAWnpmvNpmu+RmxIGIVSqE3RNoVNiG3ANmvPpoXItoVd+IVYmIRQyGupBm3OdmtUCIZGOIVp2E2wQAE4EGrKNmzxV301QX/jx0Pad4AE9oI4OIN6138CCHzFF4h8GHKHeHTY12Zm8ge1//NWQZhRKOiAKig8LJiHLkiIMfiHHWiIGUiBi0iDi4iIH8iDHYgsJ5dQOyiE6uRDeyhgl1h+mViJfaiJgKiDiOWJtniDpLiJHuiLsEJGQLiKkjiElLiBoxKLfDh8iFaKADh3fEeLiVZviYiL0AiKLah+BeF+6XSKESF/PoGHsihRr8g8zOho5yhmzmiDoaiL0rh+gEeMBriOC0V4CUCPBDaJRaF4rkd6i+N4/Xh5nyWQuTV5qbd6qDdbBAl6mWd6BamQCemQpNV6p1eRAxmRCGl5GBmQtiU2skd7lWeRDDk2uAcAjpAHbdAGiGCMNPEYDAccLqAZU0aLEEiTElhH2P94jXYXiZzYjtbIaKKYjQiYfIw4imb2g5iojQMhCX4gCW/QBoPQivGVLXBAX9QVEpShLavhYXCQX9JRXTbZNeX4O+m4c34YlDrJf3yIluPIjkJZlG/Ziz0IANwYl4q4lG0gCa04GnAQArexHACwBudWEjhiGQJxAtQljnyojAJWlnS3i/LIlmvpjsgYjxiXk20Jl0mJUkBWeEbpPCgpCK04X41hGoBxBCkBmH05AxdQYnsWgWIJm9yHk7OZizdpm5g5mT+ZVbt5ltM4cnaJEGKwZkS5Y3fgB1DJkgUxA1IWJA4nkyahHdHlAnBgB9Exk5W5gmNpU/gYiDzJlt9JmbT/aYrjaZlpaZ6CSJ6XWRCTVpyKeAeH8AZRqZwDMQEldgE9wgbbEZ0nIBlydmfYMSdFmIRXuIaRtIRZeIbKVIVkyKBtmKBoKGxMyIVhyIZz6IQUaqC9lqEEumwcaoUeqoYdakmwcARHcAEf2qCZ9AoD0AD9QBCEkJIpSQi4oYSMMgEhRmf/ORKVIhBsQJ1wcAJ6hm6yqYdFOovZeXXheZs7JZ64CYJPqp7n6XxTOo9E9wgzcAJ18JugMghvoAgSUBCDIAlkKgnzSXOFgqOz0xhBAnMhsS2aIhDXEpMQl6S8t50L5Jg5t6SYyadQ2qS96WLwSKXpiZ5at1IlxqV1cgeK//AGjJCP9LkpkAEYgjEBVxkTigmLeIpTeqp/Z+mdnxqoMFaIoip9g2qlW9ZUhMpzlpAHhxAJSqqP67SpFcWY5tidTAqUoAqZbymZn/inhbqqvnlejuhWhtpRkqCSrMhDdhhztMpotkqWuNqnoUqtvLqZPdmrTlqlvziXOnZQqnisyhIJh5AHlnBzsjoU/CiSrGWQ/xg3HBmvoSevIxl5/iiRqXWvFDmvD4mvB8muo3c6sJeRBTmw9NquBguwizMBWjAEHQmw7mo3C/ClqaA2JdkozToTmepOz3pV01qbgGqt73h826qrpXpWOZib+FQHPvB+KtszjOoOZ4qu9OlQHf+7Rje7p9UKsiYrsnaqqGr5q1IarKjqjULVmUMKrFhkCW9ACBZwl0WWsTKxsUGUs556rUQLnjs7tLz5siPrnieLWIqqZqshl75zB4iQl5oJVSlopzXptrnatTwrt+CHtbrptT97qt1qtH2mqmurWOSaB7C6tnHVtuWpnUf6e1/biXG7XVzruOI6qimrtMM6UMX6VmYLLozQBn5wB0qZewczoCCqoKYmuio6obGGuhHqhaqroWP4oBp6obdmhq2robQLobOboq9bhroruwsqopokA1rgAtQghreroekwAG8AAa5bh4YbpQ0Trdzpi7u6uJFZsnQbuTKmt0D7ueVFRmH/5L085ghN67lhh7HPG7JVZrU7ubVIerhK6r7CKqgkG7Y71b1DqVYV5rLnS2PH2QYOoHLoe4zwe6eJG79Y66d1a73aar/oyL0QrDyNFQIpB5yBFQmuGgmHB7ozw77J6MHPmLXVm7fU68DqWL94G5n4+7ei8kUQtMEBlKwryXQrR8DQi7hhObeQq7gkfIspfMNFW8ArnLnr+bgC4X6yA8MsJAjxea5A6byJB68Kq6+aJcW2R8UXebAGaZCat5D12sUE25D7Wq9c7K8hya9kvHmol7BXfFts3DnBEGTwqsYaCbFpAAIU28Zyc7FRaxPVyQbQiRlscBvYWcBva8iNS78+/6zDinyDvmq3+DjEUDs8Loyy7nIH2OCoptqAA0EHBcAGnVIIbJC0IlEABZAbzPGja0DKiwLCOAy3PivEH7vAPezI2LvDQVzE2mvJo7K/F6vEQ8O0hyCam4x4A3EBdsAZesYYa3CpIoEj+WVFrmyJ06y1CSy/CMzA2PrI2pyZRMytS9OZASe2aYK2eVm5xlwQeJYdCXcSbLAac+qXdYrIsZnDtCzLJRzLQLy3+EyU3My3vDjJW/JFE4DOdRK4sGrQNWwQ8uwCWsPKItGmd+YXQUrKVGtB0puns/y++9ypg9jNd0u5DAi2eIvE3zkym9u5WQvFBQEcAhECpyHRJREk3/+xzgBaJaa7uw6qSwgauzvNurgrhhIa1BYK1D4NvJF0vCOKoUj9uq+r1KOLhlB9uq5Lu2RAAWPAClRtvK30CtnwBi2w1FWdbaG0bS3dny+9zBDtETQ9EPxFPoHcygd8QfbM0ep7zx290fMruf58yyMd0BFWyeBsJORLCOY72JycI2gtp6sBB0fgpiARAjPALdlxApNayPt8yJmdyHzNuPp817tMfCgs0vAXwVNi0ro8QHdgDJoM0As9Z5Z92Rdg2YR8h9Ws2aDtltw6wv3s2aS9vaNtxKU9uU8lDEE2zittEK1qC4Pr2gPcwXOd0Zyq19lcy9drwj8H0pFs2gSRdK7/qcIFkbaSUI05uQeLkK42G923zdnAvch4ndu5DN/8nNfEHdr3u40WVgzbLRCBe67kPSyAMAdu4AboHRTrqsdaDJBT7MX/uuAbmcUObsesF8btCpESPsb5iuFbbOH9SuEZ/uAInsWyR8FnXK+vJzYc0AbTULEbzuBQUJKG0AgDXuBAcdELJN0V5dH8p8B23bO/LXyk+sOITdJ/QkZm5M1WJAiE8AaO8Jk5OeM1C1PrXc+wzMidfd2f7ePC3d62jN0CjK3L8m/GCuYJkQ9fethkjjxQPppSrt5zreMhzOM83Ns+KeRabt9PzL1qFq5pXhCM2tqAXRB9UAkwcBBrzqzp/3vnr0zPVs7lWN7oQB7ceH7CRL7lC1QHY4ADThXoA0G+hxCm9Q0JczAH5FAQgLAIA74IgMDmNT7l9lfl763o1U3nqZ2t2+zXVx6cdh6JAXDck2vOeinJAxEIlOAGjQBAMd4Iym4IrD5/Oe27Yl26pBvtuVa7RZ26RM1rT/3TTT3VOm1N3g7tUxju017trivuUCgGw0vuqtsCeWAL45DUvftKMRAHNoAEkvSNUouprm6kdT3n9O3ePZ69e+3oDbzrCq3rAOCI7yfsMjzpzZIJiRAHq16MzR6O/S51b07dtdjNch7fsj7f8i3sCI8vew5ZQ9zflt4w5VAJbrAHfUCzF//POxlPjhufz5Au2gJf8JHe115uwUjufpsO8hrlAJyL5kRvPaI+B8weWVHe6m7+77Me8L4d6wSf9I1c5z9Ozt+KA54J8Qah5O7Q5CW/JsQeBx0wyYVrw/KN2yHP21T/6FaPyyIf8iv8z+BdV3UAfUe+8gHDCBQr0FKkCXGwCIEQcmu/j1Zs4lhMNgoe4pD/4Vpc4pIf4R1ex5afxhN+4SA+kZ1f4Zt/+Znv+ZwvksEwBhRwBqGv+ZmTCrLwBjSwxW8csMOAAHHgCu3Kx2xbE38c1/s1z5tN5Yw+91lf69as3ZCc/N46c0k3Bc5c9/JT2MT8zS806G5QCTGfv68NAJ7/DMoFQQdfWcqnLF8CEaTPQaRST9ewPvB0D+e6LcI/j4HK79zjx/CNRP1S8+ePKr6OBhBf5iQyBMCgQSgHFRrEstChQzUNFV6wU2jGmoNyjrB52NHjx4drQhx0cWHkQixqOiZ8yLLlyo5qVL6kWXOhS5QecSrcebCnz44SbfKEWdShUIc/AShVujSo0aRQbz4dSrQq0IdIrV51yhWAVqxcWWLC4aIOQo9g0Uo9mOUNIUFTqUZlG4hSnEZe1X6M2JENRwBwTkwADNLw4YNsJhicYEfk0Zl0JU/eulAm27Vi51IOK5fr3q6cM4v+qhNzaNJ7mzI1nfU06sqec3plrfc1/9M/IXDwia1QdWuFdxS9YWSb9kJNcRYhew065t4QdgKHkPMX8XWQcmbAAWBn8WOUkWX37kwewGXNp5WCrk0a9kH26oHPTu9+/W38ro/vP5qfdNPfTisAhxD+GM83/wxy5I1DdmnOv0wSiQOS90ajD7G+HLLjpMYAsA47EBfSTg6DQjDxhCMuQIkALFp0scUKXnwxRhldpLHGG2UkgMUaschxxh5hDPJHF9EI0schk1SyRiOXlJFIIZ18sckeoUSyyiOtpPLJLKUEssctv8RyTDJlDNPGLssUk0kv0ZQRljKOkEHNKduMEgtf0GmDlitxPPLMO/0UIBY3YhEg0DXNPP8ySBY1PIE7AI4wcYYZpAsxxBEdAs838cxb7TT0/pvPvPjqS23U8lJVtTT5+LvQvApjjTVAUw9kKEFP08KVDwITeHC/BQ+JxMJVWbUPkjgIynWzwzI8yI5HHfrwUhBDmMHEkwzaFL5OV/2Uq1BtlbW9V5e1j1lzxZ0VVWLbdZdWUU+DV9xv+3M13XLdDa0OF3DAJFYAbxOuDUnwRZCrQBDAK179rnPWIC1OMFHFxAqj9mKQUmq11oPCNdhbdEG+Fz52AS65VIZPHVnf+1YeN+SXOSZ5P14LdDdgryBgcNiPb72qEeUCkdlnh53D+GjsNB7a5Ic8FnlolOk9uWRyxY3/uud1Xa4335jPbVjdqoudlyd+/cV6bAAGLjhlrncyJJE5IAlbX6MhqhtpvD9Smu2enb6ZapiZ9treobc+uPCptU58cLBhNvxpwtUd0Oaz2Qo2nI0j36qPStyopA/B1b1boYfzNh0xPhKAYnXWV0+j9dZfh5112WevHfYEVJ8dittj393133tnvYLfeQ/+eORnJz552IUHnvnWl9/deeOnL5566Zu/Hnrfd8++e+vDFx/272nffnzwleceigTKwGES9M3/vfznV08FmzYcqN729Venv3oqJCsZ8uNf/FjHG+yU7nQLTEu3/pY50jkwdFL7GgUZdzi+sSxwc+ta2wAn/y9cFatlF4ScBxdClhBUA4IY3EqweMZBnCUlEIuIgyYsKDoQKZCBO+TUCkvYMQlycIIzQxwIfdhBFvbscURrnMvQ9sDPhBCKmutMbnCghyHSDSbCecPapgirvejADZQQ2g3B6BBUlCIUm2ja6HiIt72ZsW9BlGLWihjFIy7RWBlEIhGbSEImwkqII/yjHP24lUuU5SxZlJVqBvGWuChRVwsxxBxyUJA7ao4UIwAFBjDARsu48Y1HiyPWOOg3RjLyaj9c1Sq/SKoPAnKPgqzjE1NJSFou7TePwMNuJBkyQciCOJm8UB8o4YZGqCKWODyIJ0aAAQCEYgSksNsorckQOv8qrmnZlCUuf4lHYsIyj4srZC6pqEEn1lGIe+nGBbRwgUWyspEOYcQbZBFJPsYwOYvIRB9f6cdRjKATAAjoQEN5TWtigUd+opObGFqjHdnJSn3iEpjS9NCKNhQLgEKUQzOK0TpJ1E4UDSlIE+XRj5Y0pSftKEqLNFIrxfRPPTIDBShgBo3KNEhbGkc23tCCierUpC9tgsJ+4FKkkjSpLVJIQQkq0Goi9I2llCcjUTlII4azlcs0J9cYqUdbYrWCIqylOn91EH5poQpcFdtBJNEGRdzBn6kUQOf2ADqy6lIhpuAkAFAxglNEVao7pOo/DXtVs45VnmBlKzrPaVjGahP/nOXM62P1uE6FoPAPl32QJQ6RB0tU1pAAgIQRlEXZf26iEylYCCdGgIpTjEAUgh3sAgt7S1BxE7V2zCc5RxtZrb4rsZPtanEPKdrKAeARusHiXIXoC0S0ARFyRe4PZxiHHgx3PJ74xAg+8Y6FmAIUz6QmbWtrutuKlTSIlaxXYejbb6osuLw1rmNNuDRv2vdsdXDnBOLJWa44IgOHCO1uydWHRowxEGHdmCdKgYFOjGKWhtHheUmp2/rGir3d3OAR6RtfqzV2rgxOZ3tDbOJiAcOmATAwWwShiDZ8QLtbqeQcMEnieImCE5xAxXFBUmELXyx1/aPe/rS3u9wR+XwF/1Sfkg1YP/It+chMpnL0pJw+LGfZf/0zspahbOUnd5mAVR4el6l3ZiS7bwhhRjP6OPAWC/yvyG3mXytY4IZ1qKLMbCbyAziBgVLQoXUILFqQQQIHO7ChEAcpBBvsAKke4je3HuagK3GrWMjCd7Gadi6nAUzc6r7yElpwAQFmHJZIEOINgwhkqAEGtEWU0ceddogpOjGCUnjisR4pHR0KwAYSBSbRi5ZqAQogEo6s4QLKzha3KD1pSYN601ntLbV/62kRf1i/rsbxDQNgU950O1d3eKsfqDvhbbfrbXHD9KcNsonuKgCUu37OQihiEYwYG9nn3RYAtACZZ4MLw67Ob/+mrQ1icc634O4+MYcPnm6m/cEFWrjEIsXtLUfkAbT3ZVsf9uAGA+DVsrF0MIRNEUMM7WVaAOj3NRWjkDXMAODRXu/AIV7wr3I65w83uLRp7XOGJ7zFLalDIinX6ps/5MUEa/cy95kJlGeYJaLAACckPM8EQsdSBnn5YLUDacFgJDwBrznZG15tn+887e/ledC3iuK3O1xDKx75CuuZDXxynIJviwMgtKi1Ufx5tm3N+kM2pJCve30GwQ7MCbbum4WutKWTt1JEc3pRyW8U8yxValI52nnQB3Wnm0+q6C2q0dCTvkUcNf1QJ8961SuVFWXQAhFGj3qhYqEFtvjpRGH/L1EBcKFQh5q85nHfowOoAAMbCEPmjb8oHYEFWpDOlFSr3/jHR5qPVrX5z91r9iROe+3gn7XbhQv388sdAPwlta8c98E7+EG6co26qwPIT2ZeEN4jkLdxCq2Q6cuIxasta8EWD5EUE2E8bCI/d9mwods1ths/mvu+CQw/7zs7qcO2jdEDHMADFqu/pKsnQuAZrCMhvvM798AxBxOokzurlFuIiJkYAChAEzG0jOk+83PADMQ0tZMvtPPBa2u7bFu4IXw/+QiAXmquEtwtGjiEVcu/QvI4z1Em/2uiUMAAULg6zCo8G4QjHBQxHSS4DqvAWetBDES4uHtAIBRDITyN/2qYOHg6o5GJv/lLQf94ulQKKx3jhMEzLHTjC1HqwgZiQA37wiOyNPWiwO3DuQhcw6RrQzJEuj4qOi04OsK7IBEkARekpROsqicaBeXLtdH6Q14LREF8iCF7sjnrnyRTxSsbMzBzRT7znlf8Mlj0sv8RM1vcRV6Us1rUxV40M2GkxVlkHTTAAQqABS7zxeThBd5jAGAsMmbcHSm4szzzMmnkniJgAv67BVncHUJ7wVPEmPQ6NYMIw0eEQEJExLIaJ0hcRCOMxD+sFyQ0my08F0GQv+nywydqBCOIte2DF0/YpFPYhEb0qnobx4spR/RDxwssw4MUuiCUQHhsunU0x//0a5zcoLhFukewkYS3IME8ZAtImIM5sAYPC5CSi7Ceo7c2UsiFNMShcUjzY8cSU7gxrMi6k8eLgzhbWoUJ0IIJMBBPPA1HyIU8cISAhIrraoQ+iMjyA4A97EMztMBShElqYUj1iyBCZMSLdEeKHEUi/MqtlEhVKToc2AIWG8WxEQRVc4BzSy664BwFa0mueYBOCoUf9Ko+MARZO0dTxMqvkEk+okkRs0lZQszdUswM68kRw0htew89sCklZEuooEM/EASolMSEAIRkwSS7TCJbwzVd20sLNIRjygvSCUysVCiRek2IijzOa73M+7zc4zzQs03YdD3dvDw7+T3f1Cj/4HQ92lSpNbkACsCBObnNpQJOWniDbGgByhspjtoBoyJO6nwRXPiFEfiFeog95nyRjnAD8lTNjmFNmNRKNeRKefRKnhQx4DLNNNxBoCtCiwwA3ai40IzKjMsDVhM/KrILzxE5NPSZFewEU3jIv3uIBDNPwBTMEFFP+rQMwhwtxuQ2+NS5zYxM8+NQ+7SsjfSvAv3DcFA1SYjLqvQjBHODRWiFDH2KK8xCNrRDAFgE8nSDg2jQg4LQpKnQOerKnBTLIDWlIa2qsXxP9NO2PxADoSTKEQWLfGyDzJwvofBMG1NQWUGBHaNKLP0JBIMBg8gEQxjTHEWmHV0gNtACNVXT/xNQwNOR0BmlUCDlwQ11T51URCG1SCQty/lkvxNYS/lkInJ7C00Ey/7gOxtKR1sZhU4AtNKc0NhAMOUgh44whI/bA9A8D/T8CDa4FmuZAUnhIThVVPa8U7ME0DNE1VPdz4yE1FXt0BFCyxAIAPOLoXrauFr1CCQ4ps9xVQtRrWm6B4x0iUDYA+UoiL24UfJczR0iDIOwCDv4tx1KRTLjxWj8nVasVmC8VmL8xinT1lyks28d1z3zVi8DxmnU1lXsVnK9RWvFHihYhSpAxmJ4VyejRQjIgzeARns119VRhQ5g0VbQVm5lsiJQAO8qAihI13a91lYwABY9hgPKoU31iP8QiJY0XQNpRQw6WANIYzk3XcD2jAkflacL9ckXDUsi1VNTjUpChIVEooDKzNWOEAcTjUuaVYjkSIR5GFYAONAE5UwRQ4aPW4RMJcWERDyxMwg4WAM6wI5oXdPoOILrKAAX6FRiO4ELKImZa9kGLFnDOtnHNNRUZVUPJcv1JA89OIIZqExSVZWlMzc+RY2SnAO/c0ymeDAZtcCgK1YWPVpJvEqFmIAJuIAZeFo6mAE2OAFiQ4wNCYELgAM6CFmPgJRCGIk1cAGDoNqxG9ltmlN13NNAjcwUbdU4LVtYXYjJnIEr8FmFiFI/sALXNQQackqh9aGpZNkb8ttF0IBJ+r//g4CUC+AINigAAJCDZgOJQoAUONDcS7EDzf2QEFhakfXaQgRdPF3Z0LVesY1PXzXdtw2LyZTZeUxZcmsDQggtvF0Jv70rvuWqwMOAIPjdoePdggBBQOyICTDe6YWY61hcOYi5jcUOOBhA6aXewcTeUs1TRzRbO2Xg7DXSeOReyEyI8VXC9X2JQU1fl5WZPvgGFv3L260PRnVU/L2s9gVN/BVcEdmOGRS7Ac6OIzgCNbUYxBAMSzngFdnNzKs82Sw98Ly94HQ+LQni4zu9IcbNIj5i18tNmBqpCbApMVAUJu7h58yDBqDiJr5NAeiFOECAHRBiIk4SXBCC7sSF4htO/8lDAuHjAiRwvs9jFLCovv71NwK2Fso9NMc7iMzd3K6FYPMwzENM2QYuXdKt0wkG5A7OoAvW3Y8ZBI37T71LF0AwSUA44ZIpgu76hHlbwuJCTTfQBRFeUHEUQMYr3uNN3o4wCWyJQRBxgRP4C8DQWq7tXOtVCkGGGkIuW0N+YO2dZAl2ZMipA0ygzCNlG0h+Aw6g3x0syRoiZeM60KuTw8GhXTfYg0DwyGbRiiO4WkcDgMRd3Mb9iBBYU3MGkQBeA3XmY8odVSzNZT7qXg1F24ls4NQV5gdCS/I92/pI5hPFZPWgXbwQOYC2iZV8gE0kK2vGZn6k2IVQZ3UOtqZ9Wv8edeccBFtV2uVV7eUi9cNjVuQR/g99ntlEzhXP6iLqKmjRCAQbuGYC9eTKukI+HEmv0AAbZeii5EIeRQyLBkOMrjSNns8R9eVg3kkKXpk/uABkdFt+Jg0auFlqLie/NYBRhmkNyt2GvoqFHmVtprCKPUVqbdh11dZsFetfhNd7bVh0PethbDJ/7Ve3VmtxbViGxbIEmLgyqNcnq+tb5AVhcoBUIFi+rp+HZdFkmOtYVGsn+LMVMOv5gR4NaOk9EIG0hp1w3Oadvo6ePiJ4ttCgBl8H7uhLM2qQLl+jeISgnFXvFS1LIATpSoWE1iBJNdqsFo0SFkXLrAmBbgSh2dD/QASyvPlYwvppaLtl0U5Eq0RkOqXn031V08BPoXwElN2P1pbSuOhqfVEFWMtU7IYNRsU1fkhJmACE2iVo8e4IS7CEvNNUazqCCaDo4VZgIJLvwFXu7S1teX5H/H6NJyjnoWzM22jtN0AEfOpuL/VHu13KmvhuTjbkvXCFORjoeuaaN2gDC5dk9h4lF6BhG0Yv4hY4+iZF+45gjz7udpzbpj6IycQB/VzM07AEnzrR3OYMoJkDVzjvqADWBjdbsKhkCR/dvfADS2CENngDZr0mORjnN/3wsvPc+/7l5GZuVRXq8AVtnCg6m7qEVTjxA0lmuNQrm6jkBPftjtiGTe5k/wdXCB9Pps9G2jso8iNH05MoBM4V1R+eTh52EcvDzjxfPSPeYjHu4SdGYj4HdEJX4kFnkzFhhX6hgAnAc+F0kgbQV1rwhfAEveerqB8wyaOCdDiuke0cASFA40L/dCzY9DjohUMpTiA+EoNABEKIdYV4Ky/K8NNhA2v5i4kbpc2eSSbn5RGPctGdcOeW8qVA7UoMR+R2WX9OaRy/CTFHwSlnov3rBIQmW98Qc00wb2xPG0aAAIMYBEkYd7eS0jM1HXNWU1Ve8hDv7J7Jb5UtahIfbWAuccWC7gkAVHm3QG6QBI1jBJx99oOIdip9t+5iyZxVCARThwRPWwsRBER4g/88AHeHoMP0tYRzA25qWYMJOAGITqhfD+SQp/LQXu5hH+qS3vdDWnEXcNL9XohB9c+CV3OT1IY2x4Jqn+aEBwBJnYN/cF0AsAQY42C1sAQLP/oCs/UF6tiPn6qR/9oQh/dCDnaINPZ7thcsp4CKu/oLyUcGAYGbN4ie97udP4hNUAGBmuYqd4mxN23EGYRDsG4fu4P0rvuM/+qHKIR05/Wnv14nn/dlr29j52h8pnff+IMJWOrmfrso5eCyh4+2X3uH2D8hUPvFd4rId/sMugMHeAOURsiXZKByHt6VY6Cwxka2RjLdUdfUj2vHJli0futtjX3WL8Yos/1zdZ4wOIH/StRrd+XFsSYfv5ZSEvj9gm1YVfBiG5frtD5YgXqAwT7+1hEBA1COL7h92IceC1CGNrAFfp2dy/bqZl13jFmDdu57XEZ/E7/J0SVqeydtKNcDPKhEl7/8ChmEEniDKf3engCIQI3i5AAE4CBCAFASMlzI8KDDhw43fRrRadRBLA8hbuS4MSLCQHvcLDK0UePHjgo7RrREqI0iSyAZolT5UE1NlXDW0LGZUM6aAkfWEF3jcyOcEEYB0DlxYcKJh1jUsKxqVWJHNVRTcu3asGPOr14TziQLVmVZj1iv0kTL1uxbhGERplUrlmudSxRwXKoz1+7dwIHvMMrzhtadsXDX/zIGIJKkob8r4wKmS9EiRrmUK9t9vEiDSsl1J0u8M8gwIkGcMx5liPMhnSMIC51gE+JC6xBadvPW0vpniKEH2bA5qJTm1saLldPNmlxw8811JZOGvrp6Qup1t7s92Z359embsUf/+GcCDjx6NCsub92jIERv8gwCIPr7e4eeTdofz/3hJgpgJpV/Vhky0h4mjXYfZYLwMB8jibnX1m8HvZaQHbohdBwAvh1lB3EhEldhQhyucYQdcMwAB3LS4bdcQlq5OCOBNL5HHms2wrhjju3h+OOPDPpYVwAnaOFCABSCt9poUFjiRxuEOMLekj9uZ8gibiSYXYFjXaZCZjVWef9llnsEMiGXPmIXCZSy1FcldVn95SEAbJxAVAgV0lEUUSySCACHcLhwwQy4tTjki2ha+ByPQP4n5pKPLqmdjo1SiuhmQkbKUB167CXGH96pKWlCg2TThh+RKHkjqQdBUuaZqzZqJUKjVPTJKAt2yZAhNmgZq6I9sorQIC+l2iqVv13IEJ1yuDDBEYVUyEZvu0lLIocT2HGQC9tmRwAW4YobbgXjjluuueKim+665hIAbrpYtHtuvOTWO6+4aNQr7739+puuvv+ai6+9Ao8bcLwE85vwvgojPHDD/7IiBg4UyACLwwbTy/C4vtBiGC2vxPvwxhyza+4Pc8TRCxL1kqz/bsQMHyDECL/gUvDIGsM8bspxxNLyyS7rTK4vDYAs8sJB57xvvOBuROcMPanYU2u2ERfCCSfM8CeH3R50QQGHblrpomQzeZbZTaKN6Zhrj922qHBjFcAEWoSw3mqa5oeQIH7MN8gd4o1qVR+NzDFHI33oOvhGD3QywiebzKr3YoConDiywjYqCDR/S3i2260tmxCdR1B9ghy/uVAcACcWQudRdLAxg7YAyFHoBSf4KRejwarto4xsvy1ro5kHmSjoPl46/HuUB1sAHlpM8Ejzu37lyEsxBes8k4FUEsccBl3HPXmigIIBKZLfSD4UhR+eePKQ7miJIlFOyXyaFY7e/zq1bBhlxwzY8KwKuSBaa3CBFtYAO5/shCipO8gaHii2vZktePjzXeiKZ738XdBRGcQg4+QXLOzkZS99Ud4GD3IHB6BGNZZKoWN0QRJIrM96ouAEBkpxi/Fwrw8dAJ/4QBi3wAziEKgSROYWp7+w7IkoVNsJ1X6jQN6AbWt/+s1UzEarjViQgsLjoBeHNcQwzkpwXxyhGcUIgEfUTT2/E2F4GNK3N+QCcCgM4UGw5AYD8KeGg/NEKTjBiVJ4YotjRJNI4rCIIGrwgyu5gyQMIwkJJTE0G8lLCG5ThxjF6YoJkR0bruVJLPYufmRESBcbeUbNqVKNxBOiK8HYyjI6Uv9tetDNBJLkwUPG8SDFgolMkNefEFouDmYyHvmKUAoMcEIUs5RlZ0ZSkko6shlQOsSbYDm5jQQAByHAgfQ4OcpxkrMjfEgAFNKpznSmYZ3rbKc71QnPeM7TnQlAZzyhUM935pOd/dynOivQT33+s6AGjadAD+pOgPpToetMaD4ZStCIDlSiEF1oP1cxgRngYAj4bChF83lRfv7TAjxAjQVASs9+jlSeFW3FD+cQDVWolKQidWg6iyCgTnhgpSG9aUg14Ks9HKOmLv0pQuMJAVnAhAZItSlG+8mHS24yAEcSZzkZEgLiVCurNsniKk2JylIasoPLO+X2hGm8NKJ1l3D/JA8btTAGvMUyWY2yhDLagM26snI1mTAASRhZ1ldiZxSnGMEpaqBF0QACVs8cH0JMg1K18vAgjwgAZhFyAQpQgHqo7OQVL2CHDGUyk14NDVnXuplUavOxwwzrGwk7WDQ6cra9fCtIbim9AKiWl9iRbBumoSq5EbYsjXWDLvro2tfeRRSPi5xtgTSXPhQTfm3VVXwglJjYurYO1DAObxCihwuE87On3QhP5BDF82YntTD8EWvF2tq+ytetsqXmHWErzPuUkC+hiu7xusIm7fYWtwhxXxwqEQj84tYTocAhIecr3YQUDnzX6EPaVNICKBEim/Z9JhtxQIaN/LcOu8Eq/3ttdwQtsCF3KZ7gcjMXXwBn7qwxri2Dq5fhTHVEGG2ka30DXJoiAlPCQv5KJkYSPgkrMSGbWAEzRVFI1y4ukYkwCHfn+8tUEVeVnYqeC/jwl0t4kwJ2QzF7obVVBb64vVqUsXvx+MId57eDWaZvdO/M3IPoNpdhPTLfHpQHSbjQyGxFiCuyRAnl5tmSCbHVCFSACjpLxRCUgAxthQdJSUrgvdwJMQUwsck9W3YCmTyheV+8VeK8rs1ygZfSIDY0hb1r1jGL9cFuLWtcl8xcL9sZr3EWbCz8Wti9Pjayw4UwWIjhU2TQdbKNnS9zNeBU2JCGrYdGMiT0Yg5GYJnJdv8tbl+LCwU0+8UBFJa0cQMbZfpwAxeA1m52S7tgr+iCXhsQrkkMbd3JZraZo2CGdP1pf6eFygSgEhVX2yfOXQ7WjAusY/3ymNITt/N+1/jj2/J1mNkdNBIpW3EAHMgNV9YzMh0MYfWh/C190ITKeoDhhzMJe0W2a6aVQzcthHrUspVTm2PDG1G2GawdjG7EPY3jNy/9z4dmsjCvED0/57zjWPilIrLZ8kxRdw5aygTHXbsJJkR5ymEXoveA2Af2xYUwLTTwjOqAib3kssmiA+0o6VAANkjQ1UZvK9Id3vGn11fPNjZ0048+kz/oxb80/zAAsvuG1AweeZmIAPg0MfP/s4sVFY8TQphoiaiSL4KG9N36QeaYBxB8rrhq5cOPR233oxi8nGtwylIYzjumA0/wop+UyB9/+CATvtFX2fnd2I5HrLdA6WyhbiLcEAFGc96QKkffJpS/pER/3fUzckmULDFhOQOA8XT37AjxjmavTnE3LihA31/89xv3nvfAt/icKV7n67pFD1PXpfYNy8dRXgCKXpKBTyMEQgFikClURDNN2QIChvsYQQL6lp6lwmm8gR8U2uxxHB8gEB4UgM9tE4nUnu3ZxoqdGMOdE04Z1VH5VDzdUwtO1FO9oDu1lA1ClQ7uYDrhoAvSYFTVYA9W1AxKVALIQMUMwSo81AwC/yEPQkEqLIARKUIWMKEQ/qBEQQE7UEH0UcIXBFQTSpRExQPNfMID3GAYHlQrAFYiuEIW+mAWApQFKMN8MEAqBGFSXSFBJUAV0F0wOGEOrtNUlaD6XZEcFMAMqGBWRZBU+F7VNUrSkV/eBJ/VUeLv3VelIB+Q4Vz1lcWAgRzcrVKSGQHiAMvpWeImLFMSlIL6eB+ivIobLBpk4ZHNEUIWVJaaAAEC3Y3PIVPB4R0UtQYdFNBu1Eb8tUZS5B5tsEHYwBji1Z/TjRzGSSP/USOVJYT/Sc8jEB7qmYYR+YEjcCMlvlz07YE11FLwocJhdYIodCDkAUAfXIPKKBgJto3bTf+eaviiYvzBZuHABfzXchWihcxFbCSE1RCdSkzRCSBkhchBcCyFiuyOMxLfajliJyYe4BVfjuUfxjFexaCaOLrIk7RBHkTIJEriZJTcHGgeoD0iXQASDkHX+HXZARbE5qXfeFiA39DH5+hjY+jW3WwkJ9rE/mQInaxBnlQIHNgBtLhfM3LNUtjB+7HBemWERb4jfF0l6mFiNPqW8e2faxXCLm5iSLaHILCQBoofR15iQiCD4RgT2KWVJI6CgICClNWjGh3XovmkdWCdWgZkVfAjDvjjfwklngHdQ9DJBBBHAUhka9iBkSzQb3CIbRRCIZjORNJYRdrfxVUjWEKdNbb/VjZOz2d+mCPUjy3Y0f093HEt0k2eJHFdnwKYgpqwj0DEQRxUIIBpiiBE0htIQjMsVkcUgG64AFkKJyE+zYZMQFBYEQOhIG/IxhVRJuuMyLdkW7hFW61l57xFW8ZgJ73VG7FBW3eKp79NG3ZOTMWIAawNW7GpG7q8Qi0YRi14AXwKDXcC2w1wAfjEwg2Qp7L1G7ocwC+MACigQBgojLq9Z73sAAu4gQ38QHguqL+0AL4dgr6dp3hS6LgAQxRUjAuwQn5qKImOJ9Oki9Mk5oYsBYfYRPuFAPyNEocUQlLWjpt15ZJE4uNpJGdCU+FlnIsEwFhWH/lg4Et0mEueIksE/wLMaYnpGd543MKDYcAn0GaQ6c3LqYwuxCXgSQYGGgaXgaaofNmR8MFW4uXdKefXsE7UHIUcXABDkojs0I63JFzuOOb8PWOOaqUlDuVXruY0liaO1METmBlpJimpccYnElol+gggzILJAcJNQml7qKOB3iVgdoVKSqphktonmqRnSgWoXUJh9uksLhFDrEH/GEVSXMAA6R5CNBAjHoQcHGPD9SjE8anZDJ9memWn8mhCCCYFoBpbDiVIEMYU3iJK6s2BgE8HmCKiasomkEJMKtafiUaWakkfdWpOYB0NmOqgespuVV5t/iJDNBFPIES6wuoo5SlFQqPiheaPyuufdv/mYgip3eiBxPmoQzgClJTkdr0XgwiE1+0BDe2rsQKAJziXRThTvUKTIehC5r0mt0aefIDimU7IzlEAGIwgovJlmrKr7rlrr+4prsJmoAJqqNorXXSKoXoWwtJXM/hmmL7rW5UDIESfa+opYdXAJzBT+lyj22QrH+EfQjRA9nhYxnqE3BlqkkTgbpqryK7gR+HhEwLiD8rgFcbhDPog1n4t1wLV1qah2NpTAVHAEyxhIP7g17YUBzAVIdghDFrtE7YUDECqTLXC3F6tRblTETgBJ0BOT+3t2n4tFCSUBgCWTKlC2BKuUVnAB7zB5KUU3RauGBZAFGhBCKrt4ZKt4xr/7iCi6tT6na6GlY6S61s9rFzqn8oCAL6GQOjSn5hEwsUiggWAq5AdYIINA+6akSgcll3ukNEehADAnDFtK7iCxC91GNSWhfnhwKHya/I6muiOrvyVbgedbrGi7MqupdDml8tC7x/8KlggK0zcz9LmjfcU7JP2LljYCtCy3PQ+BCRc2pVR7PRKHuUlKlbmlm6EwBN4bMIOL/+qhAlabzmRbMxm5cm2pJi27gNXj7CK2ry2hyO8AEmC6kXGxcu9285+bKKkYhJAzqRtb1mlXYLNg/M9BAMcqYfxb8s9wgUM5j/OJOr6UfUi8Hkp8Aq7Bva2Fa8ucBC/FzDsYuyqrl30/6ZhvMBw3fBdUJf99gC0bnBXLCwoWMQBmJ0Jcwf0xaL4NK8cyYc77K8rggehglnsumP6uqMBC6QOtwYPo2RdaC8I+2oDD7GcyV0iTgBAfu9aDEL9dNgdgHFVQMIegE8lgB0hp8TvjgAnhILk3EMPJ4Q1KJkmmCIhe+P5qvGLbCwm9PGpOjFOJucb73B7eieAkuh2Dtt9jmixkaiCpvIrx/KIJo2H8twEXICYjSgtx8sS1ILk1gLSmOiwwXK97CducsEO5Fot97K5oADZcQK6MXMxOzMWIEEseBsX/CfACOi9WOh8hIx5Mqi/TMxeCJw1U3N4GnMtu/EBl/IVxfGOOv9HAwNrvNpxNPYZAM5vQmiyItyP9OrI+rrBLJheGZORKZACBmCAApTwQTdSF1MCIHByXAhCYaDKX4ZyGekBCOqB7OHiPJcrKcNzVsmzKJcNjrJsBUPwSgcregxrH+NxY4xkSXIDOs4Ik3Yhp940piR04J7CpJVlpNSvG6xkrFC0V5ymXrGeSIMHqE0BKINsHcOJ1JJ0Av+wa9ExFXPlPafuRn6gFpTBJuJZJSlxWnIvoqrCcSXCJa9ux23DgyEWpjow5OluIuPwsAzY5KmKVNtF0x7JWF/pJI9yDlt1u2K1hGl1/2Kk7HK1Fz3vP9rzezBA/WBT6wm1YEBxUbe1SnP/1yaEwhXbpRaj9W0N9B58AUi/hyBwwBQCdNRyBVjjAQVXrByndsga9jiZ9BbTc0p7bwT79o/GtkeTtill1xgXGnC/kSEjcjIAKdx8dmiHQhE4N6vkdGBhWF+TByDrlQYbmWT4GA2jHxLDMD+nLmLi9iix4NgWYT9p7ec2buV2LnvrYd/Otz31owv8Yd0SYUilQgu3gTFwAHxb4efq0zEcchwYgAawbX0XOD2AQ2g7QREwOEu1oCq4woMmAjPoreUOFByqEw3s5AdYgBg24UglwBNETxQUwHoX+Ifbd3xDwRHTnhuj94129XsodvrKdKN+EVjPlQDTtZUsqgtRKnhk/0Il5IAxGTSRxgV0Gygk97hgEPUcfAOXZqpExAeYAjRtAwBHay4mrEJ5P/Rv++l52zgAJCNDmFoj1jNv4zhwj7dkw8XzTo+RMwdh5AJGS/lyEGwsusJrNnlXPDkohMI2CKxVLHeCgV2XRxYjTKFqlnlG0E3F1PBiN/VJ2/BtI0RBJgQc1MbUOqRwIIRtJOWNZ+Rm9rZbd++qF8+X86KgJ3VlO0DrRWtVWPfOCjFLEHqUlyxhVTJuGqwfK4lpVDYHIPewH8QfTMFgTsARrzH1ZjobnzkAGKVWbZX1tihTImWbq/pq6Di48rgJHx6oWbqtV4VZc5muP0QfuEL0sbUprv+7k4E2lLeizcrKARqBsKdsW/grSSICX5e33IGZGQQ5tPM0v/toG6vpQWiLdU4th8hBVHB7Zi7wHCN2fYn7uXfFwB8JECB6R4CAC/ckyB+EZucAZ6N63BD6Cth7Y6cJkquMwR78Q1yw5NbspWNFp4DgJ5M3AS8yXm86QtBJAeDGw4ssh9wGG2yUt7waeE5ovawy1D89evKyNy8Nw4CBM2juxbCzK6eLFwDzGwgzK8tyuBADFxS1f7ZyNbsMLmxAaG/AzbD9OivMEmSzG7DADwiAeaazsYW9YZgAtrX9iE6AD4AoMKhztHn9OpOz1dfyK0f9nCDEEVxNi7JrxBNFAaD/TsUPNkrDeatLOl2HmD+Kt7z7czg28A4g+B5wafqSR0KPcKHb++vPhCFUgspINP7uGO3mAUzUB9BrXLPrEpm3dECz7s9x0eRDEFEkXFW62pzaKASZ+u55OwNb/5zzLBj9wdxpQRTMuK9zCU0zQpH3KJIHO5Nv9V34NGJlcW0nOutDQvAjxC4ggu9n3ecQsgwbqpkCBACBAwdiIUgQykGECgUmZOiQocGHDBtShHjw4kGJFBmq2ShwDRstbNYQZMOGY0qVFOGscSmHIByYGtVYtHlTYcaBampO9PkTI8WPQYEuxKlRYB09eLTg0VNHZ8WiRg8K+pDnjR9LRHMeJZqp/9IcN3sgDR0YVWpXi6NIcRpxSpQnAPe8UuWq8MueOHHIFqx71mskSXnaKBp0R6HZtGoVVsPE1MXTxUinAq4MAC0AxZg5ovXMcTNHjwfpuFxDhyAd1CtZt3aNpSfju7MtK+T5lzNutKE/X86dWI8LLRQw/alNe7JdAIMUtSlx+HJvhq00JXJDCVAfgZszSyeI6tMIDJ/iEuTe2WsfQJT29qUsG3nuSIgIG04FGvdvgX8eN5Ws3Lz8vAPQL98GPO691kZzjcEGHTQvtvi6w+226NC7jDfdLiSIjwlwoOCCR+BDkETLIvHjjTcQESRDCw/qozo3EskuQQKTWww8DMZ7QP8oAW8KZD035qgkk918ZGgX+gqDTr8aS5RKKabwwCSB/M7T0LcrXRyxQNcWfBDMMDniIwEozDzTzDTQRFPNNc9s000410ygTDehkJNNO9PUE88zK9DzTj4FHRQKIDzEwYUpAO1zTzsZNZMdBg5pwxgI/FyU0DXhVMUVSmRkRgQ9/3QUU0dv8eCUEThRIIVG3Rw1zlLdFCEa6xLpYZg3Rc1U0zVJUNIYDlLpdVdS9QygAOHwuKDORx+FAlZijY112ld5zbNabO3ko8Evxfz2W9iw3PKgCrls0kYjx40Psw5xwGECbjXbUEKGHGnuEEYQC3DdhSDxdMhMbpzXQIU2CWX/GVVJMSU+LeEDS6xFNAnkXIeJmq++Qe7Lsi6lhAPRuHTxK5hcJwdGd+DMQqPIW3BddlDckkXuKMKZZd6OXps5PDRek1M+ar4UEdmlx34FgkSXvYhs+EgADgZlBFBWYBhDH/uARK/rAFEl5y7ZzUJJw/Y90GuqPB7uAmGMLvtJlN1Wuel6i/Zy5ZftFqrmJye8zFy5byb474vchReIuc/9TBBG6nNk4BZlgzgOAyDBzWKETCEFalBC2cRttysXKBBtAHavc3VHdATFrJjUe+SczgZRxLetjFtnn/c+vHUF676b94Ly/nltAPqunXicg09o8J497/rGOxggpI1DVl9e/8NAGhELu9INJ/DyJN4qr23TZ8ukEesQWJpd8Y26g7k2snKE7M7N4k9KTGJnnWOScd8+/OAB1713AUxJzPb3t+Hh72+Oo41SojAc5T1JgcpBXRtyIQlBVO0vgbiGdbCjnZOp7zg5wsApPCCXc1FPLVjD3sTih8KDNIMR0MsDIiKBQHZthH5NGULICnhD2tnQdsyTHf9U0jIBHlEzBMDCEpm4xAo0sYlPhCITpTjFKkKRAEqcIhauGMUtOvGLXWQiGr7IxTAykRUycMZwfACMM26RjG+04hK90IUUdcELYqTiF+O4xSsK4Ac2cAMCYoCEOcoRin2EYgXsgIJf6OgXKP8Aox/LqEcsKJKJSPgBC9wQBy4QQwB7pCQim4hJL9BiUodogBcO2cpFlhENwHCBlGTACjOSUpSuTCQuc/nKUcKRl5PUZS+n2K3dIdFlBPRbDwlyQOAlUIhQeER/piSi2/nMbUkijB8Y90EiSuVfQqpEIFoIQk+IImGcIAUqlsm0gZDPfOhrp40kgrr6MMIC0fxLAC5wBC1Epg42GuIJP/dMH+pvnmwr4jGRGa7fDZSZO3loOSnXNX5SQAshKI5AQYigxE1KbOn7JgDyojSBGdSdTgsF1DgRBKpFFIJX28MKyanPvwhiAc1539hsKpvBueAKcEBo8Yx3wvjBbahA5Bf/3RqKTGUSFaLNnOgPG3chpfDsCQE16kgd8tHoMWJjW42IQiBHOqVC0BQrjdrmtJfUQGgiAkIy6zU5ShDBTKoENBTr4c4GL3kVNKptA+xRc1fXv/2PNUZs6t2eelaUStR/8QtNAjDxsQvIi6JjpYgFGJFKRlwwsBAcSCDCch1IELYu3XsLW/unP0OUNhG9OKlIDXQHexbms4OtSw5hF8TjFba1MC0qbYWL2JUodrEva+xjHevM0DLXuI+4gJQucT/oulAgXs0XaB3rubdykEbPvR143HKKA5iQuOxqxXr20kHjerMykWCELNqQB27u671tZcxFdchD3wYOuPAtrm4P/8vQnRg4uQ0i07VcRS0Hz6lOD9aWhHVlJ1gZCqNRQMMZGByoDsPKApKK3gJIQIdsVfjEnBJkIpjRCmm9eMKa8sAndMSqW0Crwx6m8DAqYSsDaGBN0YrxkBucBT8QhhAktnCOH4WsQ2l4FTq21olRDOMqB5nJHX6WkK9MZCl7GQryYmqCe7fc5z7XuZk9FzWCowW/OpauBdHuZ6F7O/UALAYUA/BBzpmq8bBzqek1inqyhh1kfDPODZEv9HaK3eDuBxMhQJuYT0bgAVP1zJZO6HATi+AEs2EmdDhBCE5gh8RMNakDSzOmM5LDZVm3zl0TjC2+yt1Y2yScAcuveAfSZ/+F1QDRQkxGjIY0uaoO1bZHbgMhGFFDeh6JDxfA6JTUlr+9bjq/ic40q2fHIMW6YCCFGPUJZtJQOZxACyUBAB2ESocjnDqyFEL1tY0iXYxqlBU9Ja4lwtYAWxMVLZAwQBx0rdA6Py1qCzv2tWUasYlV7EiCkaEfsoDflMbnD08QDrz+00JNQ/Xj3Q35dT3dMjvMQAsDmYkdwJ3cEKh7IHBIOU3izbd5C3oghsLBP/8Twe6mAnUpCqnPUYq1vejC2Ng8EMI1x7lnFywTmliEXCHBtYpeRhAgQBFuna1ti/FTSiG6dKq3TXaPc9vaAFTIzAlSiBAk+OUHYcMF4H3Y+K3/GqEee9cDDc7rqrTPvt3sO2qNzpfJdfSZl4NaJ1bgdIhX5moGcPhsve4VRyBiUrZAhOAfHeiF/CE474rMH1CrWXqLHO0ETf1Bx3wQtg8kBIWAO8wBYIcTCFUjWhymMHd/yylmMZiWNCMrJrBGCrgAGJbEpBd/6UsseKEWqaQFK4EZ/C/agwt7+STzp7h8YlLxAL9wyzNQEAbf997750dCDDg5hwiAsvfnL+UZvdAARnehAa+wpPCVv0UwRGHagIr7nI8Ad6n5CvD7eM8A42//gumSHLABD3D+ymiLlIghXg8AJmACyCzuBML2cI/m7E7egucPhiDs7gfxnosbBmHr/wwDtFJwQIzOCMxKtOoCFUjBe+ACvfQriCABthpBYNTMSQRhEKbhDZat2aDKdKZp40Zvz0wP50hu9QRq5Mqu9Qji9TQwwVriBAoAJgrhCArBJUBwO27OsM4F7+DD1Tbq4tpp0epr8x7PRQqPLCoPJ0ToE0qI7MzirWahk/YgvK5LXWxLSQ4BGjhPCSkCFvRgAu6tungQ5KZQsCSx0ihRfoyJNNYg3VDjAk7ANBaLDk6CDUwtJERxNXyn5tDQDC3jES6hfkjv6iwk2ZCMEUhAiIiuD7RBLwyv8/ruFvAQ0IRwqV5LLBJBB2YL29BCHCRh4qBD2+gq2pgCRPhAqwQM2/+q8OzMrttOTwq9bShKkSRqTxRRgsxYw8yE8UnS8CCEQdp4rholi3kigQcmJfB4KhZl487EyRC40bh8TZ0ArbvQQgDYKw7c6xnpRb4UQeiS8AxFapokDVH0gAAsEan4MRstchuj0ArVrhzt5hwtUR0BwN7cUbgch322zhgYsiE9byG+S5yKBNM2wh9JAdhEkCBey1YqYR9XMnyIUNkOQRIsARsZgj9CYOc06n6GMu14shsxcil7sSk5siNdZsGo7Mu87FHoZFCCoR01LABkxcrMhMvehBcwr74+wFKcBSzRZCyhYBg6wFZarMsaLCyhpQjAIVVWRQnoci6vUlc4ZRf/Z4EKkCDLTiwVwIbWDgEth0UsC9PBEqAAGrEpXGAs2/JZ1NIqcSwzMZPCLmUztQxQLHMt+/JZKK3TptIjV9EabcS5uBKjAGo1a5AgEkcR3OENXDARoRAAjM4NZgEQ9Cw3CeJg3KLpNg0tMkEHrGNIdjLbesoSmLG+/IAB/o3ToBIAVqFDpu2yAgrxDvIpYzMqmXIjxfMipRI1xeQjtZFmDmIkYZM8i4YQCQMoaSAVkeKtRufwUvFy3KITNsDxjJMgZCoOevPh/utcdoERdEoRGLI76aUOotGB/kM2NbI83/M7IRH11FP1vPE8k0k1MVTVeuIPLuE19aAbLNEKYig6/5mk9LjEEGLBVoAQ4DqDLcqrPIhOdqJu6uagLxr0KHzyCAkhKOUwfR50uiK0Su7RQjfUKZmUQjNySVnPPDv0QdKzScvlDPrDPdFxMU6SFp1tRnGC0PbCHH7zCb+DxsYDfKrzrCDhGybv6YxqFqNn8+xwRIx0DCKUh+z0SS/UO500SqmQIgMsJZCLSl/jQ/90IFxNQgXRJu4KDh3BF/SNo3BSnCYHR6XD18bDA7gKJ4DEUyInEOMUOS6P1urROq/ESKVxAgrAv1J1UIPtt2T1TA0UQEeKZTztUHPP+noVC9JISlxgEnx1mHyhAfzhCM8h/8aokoh1idaPBfaCBX7AkP+Y1VmpCBc2IHN+4QAU0Fol0IluAEZlJBZuQP4GcAJbyRto4f6WlQH5aItgYQJmaTiiYAJs6Vy9NQEfEFz1NV//lV/ftV+FL/3471q/FQH3NQK/CBN3FUyslEKjpCk2KiSDC1Lz4BB1M0yvBrYq4Rg8dSpqdAQ6gbUmdDbGVGuAE0TzC0EV8jYZNCYHYlX1tLh8tFZZEjzH0zordGeh9Lh01WHLsD6TQg8aaEr8q2JPJhVY8AgX9IJgEDeOoXzkKryg1ifOKU1PIQV2kFS/QurE6QtidiCAdNmGNBkpggAglAImQA9gcWgNTlEFVUOlNFAncW7l9gqDFlHrkw8+ZgL/YE0gkhZd3nCGENFqH0cTPMUIKKFAu9ZGaiAUOkFhgvEWOeILSktiTopLNSM+6RR+KNUuQE8y17Zt69Zke9ZPQbcS79ZurxRvp1RvVwJi68pdegstBBciLo8WiQaDouM+B3QRgJBPZ+MG+TMUXipnhwJU22NUz0wn+K0EVhS/4hYhRFc7+WAiWfd0c5ZnuddnvTd1Z1VjFyp2G2R2n+QReIbSbvdDl9Zl/YBFlVQ5gGSmZEQnxTNDDsbPyOMWxBae7NcQWvRiVPQ2F4A6V1YnpskHdm5ZqBFuVXfh+hRQUXeCwbeCEfh7CxVog7YqO/PLEqAdQ6AArFIrs4UERCwP/z6AFzz4UdoyUFrBFeo3EQxgHlThM5fMTU4lCIgzCPaSL3/4h1VhB7JmFuQSiDlzTSyAAxRy2ZQMCsLAxDzYLz0sGDTuKCeAAOQAh6UYietSNEEzM7/YKruYLR2zLrfMjLESUEzzZ8uXQc4XSrT0Ke4O1fiNFvMpeBTjauCS6jxocz8irSR3VdY0IAniraZOHWjw1gRiTg8BEbbCVgmEnyQtoy4hALYXg+XXgumWgjl5k1/XdC+RQ8sX1AaiE0ut7s5lFdrsaJvrd+7AyIQufvN4IDhWOXXBTM82IjZBFGhsZI/X7ybCBycvU22C3+jxvmx2vy4BIqMAEy6ZSEPZ0f8+uXUl2JMz+YKpd3XzViBaDgDgIARIrdyQ6dzSTSDO7ZvfLQRHpHbFbtP6hjYj1XUHQgJ8UDkBkWIEWDk8oXgTDiAX2ZA1wQ/5IhCL+SDkyxjcx2kdd2DqAAiOFFHsZ2WVsnetGZQ7+aKpeZstuppPkyBOju0KgO4KwZubqgMLgBxDYJw1Y97sDV6KAYJvQ75SSRIiYXMzwhCmlqBVNpjVYhRKQZA/AQX+M0yPBraOcXyBh2wJgQfAtA2PQ3RZtXTx1xKnGZuvWZtFeZ43OpQrEnbZzgXUTZ0XqwNPQiA6EBUfog7kWKMBoB2uAre466YBIKenriA1oQkgGC1GYQX/JHeEgHnXjirqQhUQteNwDwJsUikOJ9oirLcpLqBt/7iqlflWkzqrvbqrCfWyCVU0FIPtOhADkamsU5r2kmiLJmALmqKW0JW1FVAa7Mgd0KEBfKH3DBaKbiAGbEBaY8Bclyj9/nVhseAANkByR4AJNqBbF7C2oUgAiIELIqYXentff/uKTqldXyFh/RWTgEGNAhAMYKG1Abb/+hW4m7X6BHa54ZW8gzu8Aza7y5u8C9a80/u8KbCJLHDtYE/dQhuJOrAQNhAAZoAMWZog0nfvABeD2ac5Ag93L2R53WARdIA5cbbOfrq4O6EURsGqh4h8dnQPvsCDohkhiJCJF9Sm/2OWCY/yAoCgGnU5MSabVoULszG6o2mcq21cq7/alE1N1BaLC73wm2egEArg7WhurV+TW7hUEBxAhvQqcBOVIvogL4qxEoztsJXDwsUDwzWcoW9Eg9jjOjRBcyv3IAgxF+gUkh31IALgEvK0kqH5qp+6ra16s2O8sl9ce3M8s3G1I4aiNDYRANbAEyeAHBsqFE/C1NaNDQpgwDUjWSb2HeNmptvAFuisXKD8JqeWRyEhxCNYQvgZqMXjFEJBCcj8JwhNLBCgESY8eQfiOZGZASyukAGAzSHSBcQAzqWZsoMzkuFMs/X618UXz7daz9uYIMBR3UIi0WOXAHDAnRMRY//imn2rJ3Hbi4U0eTJ4mRRUQFVG/aWGlyBUwZ77eHMlIEGbFmZvpg4m2c1cQKKb823ZNM67vM4tG9jtvKiHnaNvnHzduDXg2G0cARoyZnpZZhWvRheKcdWJKkNMoZeJ8xNSgKhb/SDqmmpVVgi9NHrMtqiNtJnfncKzms4heOSFvdcB+uR7OuX1ue9y1d9bo4PPeE1i+Q26QFg8uIQdbBg0nQtgwIZZuFjW5AFKgQkwYGRt7IhHszGhQAMawa6LWArAmFTKkh6VAQLSQemnOAEeWhpd4AKCYYrFGOg/LI37MuzLPumDvi6nmIw9k4ulfsrefozXuGFfXiUA3iGC7n3/0Oyh1gvMGTcIIVgiQN2vGY/LXfwme8GuAd/XFUIw6Os2B4G7DDop1JZtX3XXZ13fdR3fG9/eTT7k7/3zb7bl+9zuZfdDaZ6biGp4LDUR7td0N8EJMKfbAZvlpeJqnL6TzEHMnzAhm9YBnHrwLGJmSTdJK5rzR79mOx/lQx/0H/j55b3eN9/YTx80bi7Z3iAXHtmAauI+/xAQDk1D0+oT3CIJyGPibz8QLlc5GZ/yX4hpyxaSrxxPaZbiib3kbZL623rGAQIAACgCCxokaLAgwoQDGRbE4rBhxIUJKR6MCACiQ4sXN07EqBEjQzUhRZo8iTJlRCxqPt4ZpKhNHkSR/zgq/Ojwi4E5bhI1ynTTI06GD0KdwjCiEylUnkpWHPq0YCZNe3jO2QMoUEKnHRlSFDTIT542hxA5uhOVIdebdfhcwKOFwoQCf4Ta3Qo1rd69D/N25RtUrd/AgCU6XGvY6+DEeO8WtsnYIGLIkQVCpowYI0mVnDt73trSYZaYMyMRfmwwkCZKbozoAtRHseO/o0p1GpG01KjGsy1PNNRoURw3iypB6gM582WwYsmaTYUxucO2E+DK1VO3snbtk6Mv5v79svfD4RdjLt97e3fz39enF7+y8+bP9OuLxEIAi3790rq8yVOLF/vtV8GABhZooH4FEhMLT4n0cgMB+SWIBf+CCVqYoDwobHAbBs9sgAKGA6JBoYIlYojED7Ek4kYcLPSCz4Elkniiga800EUuZNUijS8ElljhjPvBAoYL1jkzASsX1shkgjQu2aSMUY445YAi/lilfk9KSeGVJnYJ5JZWAullkGAKeWaaXK5poJhYqjkmnAbKl5l9dnbGkkCO+PHGG35YAt9sqs3SIlaxCaRGaLItKpAnqJDS4SmhmPKXZON5BRwlwyWC1TCX8qYYc2OVlQVajBZGjVvWTYCddoGe2ld6rn5qqayvFuYerL7JmitqvKKnq3rA+koeZ/PdiSx9WEDAp5+OnAZtYJBU4qAOQI2kKGqOkgLKCBhIWsP/YsoZlAkglbAYByWNGHLodtIxFAkj2Lzh3Fm7BpvYH6rGxWp20c4q7rCVDixQrwS7G5+t7CWM763/ZiTwv+cp/B5IdCaLsWcQOBssZa0AomkchmqX6GCjBNEtBp9MKjHDDKkCSXCbVgJIMhEXXJAlkhBCLyE82EusV3/oUR2/erBCa8sBU9ywywcDnJ7BSuMr9b1Bg/q0w1Zj/bDWwhpbZ8ZiS5btwRxlcm5PlRhSWMl21dbhMix37LQhVFlFiSZsT62rIPsgckgbbygiiSVb8y3Q0BNQENcFreK8cNPFSk4514cjfnDVUBcGMdNX11q52RZ7LrrTJx07duqHla10/x+Q7DEcJYAgs5jbRNnmraSUUuY1FoGYu4gbxDUCCe0VD2UJI4qMlYEfg5j2+a6PYLK4FnhMQUAdk9NNeqyhd2365eLzHj7Cx2+fdeSCdT/+6N+3X75mYaueMR8JQIF//vinob/+IkTDmjkYAAb541//9ndA/CXgfvlTAjji5gQl9M+ACaTgBPWnCg00QlM9MQAVhqE/C4YwgVAQYf4sAAJEEKINbSDEByCQigqQsIQkNCEUwjAEF+BACyEgQgFWgcAEyrCGRKzgDG0IhSEeEIk0NGIRD6jECz5Rik6E4hSpiMURkjCKWqxiFgs4Qy6C8YpjXGIYyVjGLwYxgXy4GP/93vgQ1m0NbSzyybVKhy1TGAUpnSiFKbzmqnLtAV3qakLS4CcQnSmCXrbwAyOg5z3u1SEAlwiBFrRQhksEIGqH3Byubma+9b0vlJYjJR5FyTmvTWyUgNScKt2XEtTBsT5wmMAJTnABtcixIa6DXboAoYpOcmQTongGbvq4G8wRpg/AEQ5xaKYVyJ0vITRghB8C9wZCFO4O7+rNH57wFi3gwAWYeIQpIxm9c0ozlaB0ZTtB2Up4tkeev2KfJ0EXS6cU4gQhOIEcZpmSAuQSAP4EjUMCoY0A7gES4BMKMT/BiRGAQgEe8MQ0KyJIFs0hb8eIX6AiMQgVspAQZhHEJ4f/EgBMuIBxY+gXO9F3yvTBVHz3/Jc77XlT7s1UnTVdp0x1isqfprNzKpHlEeAAgEK4AKAoscMJ6ACAGUCVbOTSBIsQUIk7NjQhnvAAt0bAiaVY1Hafa6YR1JYVmx4yEgwQaQsR8Tzy7fQPQLiAJXl4CT7UAZDdBKpQ8fnXrZZSrqPM6VANG1PACjax6FysMn16OqfMoAAAsMMEmIqSfp6ADboEANp4sghNBIKvBqlNtzjxCVFsIiFkFV0gpkXIRnSUkzgBqVsbyQjDBXadlFwpv8o51L6mk7CDFWYnEetYyNL0leUjLmOVy9N42lO6RXXKGmZwy6liFiNs4CwdTrCG/4RIIAI8YcEPBPAmNlnpABswpoc2cIAySahKN4gBed0wBy784AbpjZOTKOSFBtRihWTpQgO8YSYoyUk/YJiAkcQZAjFcARZlqjCZ0LTgBKu3v/tx05cyXCYNUynDIuawibHg4RKf2MIY3vCHXRziFIeYxQr+L4lp7GIUA6lE+TEIHGaA1AKEYLsiCUEhBNJd8eqCoX4FwEOTkJtkiq+1QcnUcBbRgeNcNFa2JfAhppHbJgdGX5W8JB4cZ87nOrexj10zdN3MU+Qut7nGrScr5zldPN/Zzvk0yBpOUBAtEBkj+yxEIaRq0PM9qlugIMUDLBosKrtOB8GLwyLWNefZgP90wCw8hCN1y1yG0LWSO8TDBDARgHFtWa3q2y1RX1pYetJ2z1STNefk3NNXu5q6fTbIZtcwgYEO2iFyYEMBtBvHxdQgFB1K7Wp76rbfpW0Os9CEVjOtmC532gRhFrNhyByCHVLABZrUHpsRCetS9hTOuGa3rU9K61u/+2Ht1nO6n6vryCYEDnZgw5GH7Zk83cUTovgEH+f23GFQoSo9wYpWSGsQQThCErLo9KehW9NH2IHUcSF3APbq0VZnrs6xzvPS4g3vez8239g+7LxpWm8+o0SWALePwBUziq+GFRVwpshUOJgI47QL3RW5w8R5RhY/OEC36oZPAPRg10u2FNX/5mb1quNMcpW/Oesp3/VxX/41lNMb7KvUeq7nx1q01xwl9jtgETywDAxgYBnxKEIa1VhCDTpzET3QgDAYaEYv4o8XklCEjvJgjA/w4u75E+PdVxGGS4gBLjwkAhrC0ETBN/6IaMx84K3YeSQyEYmO9zzeR7/Fzpue8axPoupFr/rSo17zawT952/fRby7nva1z73v9ddGsK0dWTfPeURBEQQp/7WZLVLX3hC1S/HE65qC0yYNTNX1gzyCD5VkHA5CcAE+pNnVqvY2eETecsWmP7ksj+7XTV5r+Mtb/k+LefyrO/w7YUEJRsmdKCzKV65TCZWWNzbjEFS2NRKHCBX3/1aOYFJEh04pFXXWMwHlBoFW523uhn5YR38j14EY6HUyx368FoL3Z3YkqG/5Zx8pIFF+9DkCiADNZ23/goANoUj04mkOAEnpZAfc51vf5zjFsIHnd3UaWITvJ3YgOIJIeIL2VoLzl4Rh14QiaBI0p4KcgQVFsDACqFF74ArXNmVlA1J+YAvVt03rdy+PAHXh1nGa5C/rxoTDFYdqNodoyIFRSIRTaIJPWH9kB0t8OHbCd4XKEn0O0QdfMG0Od4EAkChGtzM4iAgM8IAqN0mTUDQ8dGqpxnXsV37BFXJXl4eAqIR2aIR6CIWm2IcfKIWiuIopOIgBNyEKJgAMwiI5oP9fSFBj/rUfAfYCh3cOB7ZiF8YKVyAGzuB9ZSAGEwAMbXJhINaMNuaMN9ZiMJYlLzZiuaiL2aiNWlKNKuaN3ihjz0iN03hi3ohjzCiN0Ugh4ViN5zgngviKeBJ9wEFIotVzAOCIBOZCWTCJiUVmZSBuHlcXwkWHJ5eBdbiIpciKobiEBsmKZfeQf9iQeziRpzhzahePVGUQzJcuM+hY8aIMY5EHF8eIhegRashxeOACF/BxwdKJ+EaQbYaQcOiQFZl9pIiQ90iF7reTOkmROLmT8pOR8uhZqxE7mmCATZOPIwUNDogteaGGF1AGZpaJj/WSKxeTCTmToeaSYMeQQDn/a6gYiFEIkTY5lmIJc240lCkhAVxwZZh2gSClDIGTB4rQbZBRg1AQlXdlapOwSVd3lYv4lVpZkzJZmDwZlguZlT5pkWaZlqpYlmDZmFWIkWspAd/AZMRyg2TxM/0Yhgaxl1SJao7ZfjSZmAV5moaZmojZlao4mIyZimQpkZIZm2jZipS5lipRCICnRqmQQiuUTYrXe62XABUABGVmPStJAK/XeaW3esMJndHpnLDHe8+5e7xHnbwne5xXnaTHnN2ZeuCJnWcknrjXetepe9mpe9sZeqoXfPiXmyhxc2khKm2QC460g+gGbqVWlVh5mKbZmkf4n1x5k6xZoLDpgbJJ/2cbGJkGepYRGT8RYYUZSQcuEAKXlWgMsQvKA4kOCGcJwH1saGqYYAcmGYWBmWtZCaAFuqIJapuvuYmj6KCPqaA7haA0apsNKpQJIWQhEF5XOAP/tDoGoTP6eIZbNUmX4FvjZoHQN4S9E6N3eJAD+qQLCoqLGaUwyqCzOaO32aUNeqNeuqMFYQdL9YpKJQc/uhVpcHSCQziA8h3FQD1w8X2atAoSaqK2iaIQF1SoGaBTupphqqVXaqWA2qe0+aCkCaZRqqMS6hTgtQbINnxsgEsXAGQJAQEyYZc7+CpRSXkhkFdviJd5yop7+k5bSqWEaqNZiqVVuqqo+qoCGquGWv9csHqoIiFLWjABlEpZKphkAHABvVoQEgAP1cgKYCAGdxUCLqCM7qgf86WO2GiNHSaO2/iNZZJi5tiN2FqtwViN7BitLgau0nqt5Dit3kquOpaO5Bpj29qOYeKu4XqNOzYgPWYQggYAcHAEV2hZAhGsGaoXvcU4cjGaz5WXYGeqOMWoW+mqtyqoraqqDruwhSqHFOuntSqrtzqmAoFo+nqFcHACdnBokjqfBiEMUEenoBoAd7qBB6uKCVtyGcuiBOqiimmx/jmrFZuzF6t+X8qlYdqoB+gUduCjwTaIcFAAx9ZZApGkIopmrOiyJzqxq9miMlq14mN/f2qzO6uaEmv/qxhLqz0LtFy6sQKxBv4Wn5JRAURDpx7Hp21DqqQJs2Y3t+Q3tVpLmoNqfhAbtuc2tjdLmFwbuBrrqGl7EgRgPY4jqmAXtXp6tzPbsE0XuWLLqoCbopZLs377uJT7tZwrsz1btobLEG03nu2ZQAtkuqVre+YZnbO3uqf3na/7e63LnbIbndbpuv3DnqrLuug5u7Rbnbvbu+qpu7ELu+HZu7jrnmopukMasXA7uVabuVi7udIbvVt3ve33sJg7hFlbmxAquFdbmoXbvCsRt4jqpM9bszxrvep7buLLt54Yvm/ruX2LvZ+ruZ2bv/iLceRbvku7t7Vzvl1at5xYvdSr/78IjIfxC5PcC4rem6jo66V/u1Oh+78ZMcBh2rilesCDCb+fGMDze6oL7MDmB8E4Cr5ey7/jK7QXDMDyG2kZHKUFbIc0LKU6i7cSrLcwDLY43MPse7/2q70dXJmMWMQZiR/vqsQJAq3s2q3nqq7yCsXg+MTa+q1V7KxQPK7jmGFbbK0zZq7lKsXcuK5cDI05lsXtWsZfvGPM68IYnL2jGscgzMOgO70efMcMjLMqHMJ87MP1+8f7K8QnLKb++8Zw7L6fmch4nL02rJBAvMMNLMIKC5k/S8R+WMIuB4+HXLJ7DL2LrKJ5TMeSrLGiPMkx+6J6PLg/3LWsvMqADMlFPP+h5dvJguk1Gyy3HRzKjazLmWy3rqnK4kvIi5rAQ1zMsnzE8VjLl5seuCzBjsywiwzNh7m9p0y3mGzN+DbMlnzMbuzCWDAEaCDO4yzOk0DO5GzO5zzO6azO7HzOQxDO6owG7ozO8lzO9kzP4zwF9jzP+OzP/6zO+wzQ55zP9zzQ5CzQ8lzQ/azQ/LzQCU3QDn3Q9SzPEE3RDY3RGX3OFr3OEq3RFx3QE93RHz3SFS3SBt3OJ40GHI3SKU3SLb3R/GzPQ5DMh2zTN43TOa3TO83TPe3TPw3UQS3UQ03URW3UR43USa3US83UTe3UTw3VUS3VU03VVW3VV43VJ7EGQpr/pmsQqcOWpgDX1V8NR3BA1gIR1gBl1to11pKaOmaNVAWx1UwF13Lt1WsQ12p91gCQ1rO01gXR1sM214J913lNP3SA134mpD69T8YmEBfaXWqqOkQbAiEwA5x1ASsJaHBE2ZbNWZDNBpKdOo0Nfv6q2bNE2gMF2qI9Nk5FqT+KSys5S64NXgKhBd3FBm6NMXSwrwJBB5d9Av+W2Rew2WLD2wXx25T6b6s9NsddEHDgowUR28KWMYUwZM8d3baN27ptJ9ZdEAXgAmwwA/823T79Y4ad3dsV3b3tAqxNP9Gd3nCU3fjK3u6dMfP92PY9Noj2ZwCwBmba22/E35uNr29E/7QF7thycN31LTYHXhAJft3xnTEOjtYhcAQ/+t8CEeAYQ9zXzdcWrqYFPjYd/twC4d0ZDgAbrtNlWgC5/di7yt2jPWRrcN2/itoRDuOz9No07t81zllvtOM47uJwVOCC9qsSPjZFrt0FYNipU+D4zeMAYOMZ8+Q/iq+QHeN2IuIAkN1Hrt/1EeUFkd63zeSpE+ZkulRe3tNsYGSFcARQVQhrYAdHsNhwNAPhFeVTLuA/GudzXuepIwfMegRHluc/Tj+BPgGDbuJyTudwNAETsAYFYOQ/juRi8+iRjq92cLaXSj9Vbts9jmSGTuVibuWL7udOnhBdTulfTh9nzuVqqv/p4t3kyOLqP/ZPas7Tvzrlej7Z113oAEW0DMHrYtOxUvXrAg5VP4Zsw97g/jYDUr7qs+3sqc7qWk7qn37sYuPpALDlzG7tBqHq+T02ro7klW4nZw6ydhDq4s7T3g0AE6DucQ3vAHXnBcHgs1TvAiHv6v5Gby4QBXXv9OPvBPVP+85USYbiKg7knJXXiNbpD05ZCq7hAtHeqI5kEX/dBp/k1G62AG7mHs7uDZ/lre7h6S7XHu/Tj07cSDUDF2BLs97aID/cxW3gIN/yL8/Zl82spk3cs63zGHrzJwDzGVNsExACcV3ecFT0R8/Xl32h9HO2tx1eyR3cPE/zyRL1oQ3/AFT/b0E/9GDOBlK/9eI97wQ13K09AZcNVXRA9uouB06PoROe9i7uApv1q0nv03JQ54M9S3IgqX2t9JLK92W914D/Rn8t13+uOoif+HqNbIyfOojt1VMF+YafLJJP1pA/+Lt918l+14u9+cky1khl1l4tpJCPMaPP13etpqGf1a8P+7Ev+7NP+7Vv+7eP+7mv+7vP+73v+78P/MEv/MNP/MVv/MeP/Mmv/MvP/M3v/M8P/dEv/dNP/dVv/deP/dmv/dvP/d3v/d8P/uEv/uNP/uVv/ljdbxFxtiN//u3v/kS9Bjz02Frg3nYVEWEv2QrO7+/P/wABQOBAggUNHkSY/1DhQoYNHT6EGFHiRIoVF67REkJgCC1rBNphYwcOADkeAdAJucYjGy2FQNIBUEDLBJMHC7EpQAfOGjog4aAsZFHoUKJFjR5FmlTpUqZNnT6FGlUqAIwnVJ7oCOfEEY4nAHAkeYTrES0AWJLVcgSOFrZlD2INMSMERrRb2dacmlfvXr59/f4FHFjwYIxt79rRwmaNCy1ywDL2CJalHQCQMbJBiBgzgEIYJwDASqdQ4sGlTZ9GnVr1atanq17tyPJECNqOy4L9Wpblyo6XEe4e6Bus79bFjR9Hnlz58qkYNeZeM3rCyEJ0wE7IitVsx+0qtVwYySbESIHSTyomPZw0c7b27d2/hx+fcMaN3C8Yth2WLdnu3eGgBWAGFwq6jy0XhCuLOPkWZLBBBx+EEICd5BCoJPJ2WmOkkiQsaY0ZZjgpwxBHmpAO7grCUEKeSPJoJ5gihDFGGWekkbXC0qJsITueq7FHH38EMki+OhSySCOPRDJJJZdkskknn4QySimnpLJKK6/EMkstt+SySy+/BDNMMccks0wzz0QzTTXXZLNNN9+EM04556SzTjvvxDNPPffkk6mAAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The WHO Child Growth Standards. World Health Organization, Geneva, 2008. Available at file://www.who.int/childgrowth/standards/en/. Copyright &copy;2008 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_54_4963=[""].join("\n");
var outline_f4_54_4963=null;
var title_f4_54_4964="Fulvestrant: Drug information";
var content_f4_54_4964=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fulvestrant: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/8/11396?source=see_link\">",
"    see \"Fulvestrant: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/21/2388?source=see_link\">",
"    see \"Fulvestrant: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F174701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Faslodex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12817149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Faslodex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F174718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Estrogen Receptor Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F174702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Breast cancer, metastatic (postmenopausal women):",
"     </b>",
"     I.M.: Initial: 500 mg on days 1, 15, and 29; Maintenance: 500 mg once monthly",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). However, renal elimination of fulvestrant is negligible.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F174704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate impairment (Child-Pugh class B): Decrease initial and maintenance dose to 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment (Child-Pugh class C): Use has not been evaluated.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F174679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Faslodex&reg;: 50 mg/mL (5 mL) [contains benzyl alcohol, benzyl benzoate, castor oil, ethanol 10% w/v]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F174667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F174681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      For I.M. administration only; do not administer I.V., SubQ, or intra-arterially.",
"     </b>",
"     Administer 500 mg dose as two 5 mL injections (one in each buttocks) slowly over 1-2 minutes per injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F174680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F174716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions reported with 500 mg dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flushes (7% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (&gt;15%; grades 3/4: 1% to 2%), transaminases increased (&gt;15%; grades 3/4: 1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site pain (12% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Joint disorders (14% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Ischemic disorder (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (8%), headache (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (10%), anorexia (6%), vomiting (6%), constipation (5%), weight gain (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone pain (9%), arthralgia (8%), back pain (8%), extremity pain (7%), musculoskeletal pain (6%), weakness (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (5%), dyspnea (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening; reported with 250 mg or 500 mg dose): Angioedema, hepatitis, hypersensitivity reactions, leukopenia, liver failure, osteoporosis, thrombosis, vaginal bleeding",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F174684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fulvestrant or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F174670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment is recommended in patients with moderate impairment. Safety and efficacy have not been established in severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F174711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F174674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F174676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F174686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetal loss and abnormalities were observed in animal studies. Approved for use only in postmenopausal women. If used prior to confirmed menopause, women of reproductive potential should be advised not to become pregnant.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F174706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F174687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Approved for use only in postmenopausal women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Faslodex Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg/5 mL (5 mL): $1053.29",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Faslodex (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HK, HN, IE, IL, IN, IT, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, RU, SE, SG, SK, SV, TH, TR, TW, UY, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F174669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Estrogen receptor antagonist; competitively binds to estrogen receptors on tumors and other tissue targets, producing a nuclear complex that causes a dose-related down-regulation of estrogen receptors and inhibits tumor growth.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F174683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.M.: Steady state concentrations reached within first month, when administered with additional dose given 2 weeks following the initial dose; plasma levels maintained for at least 1 month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~3-5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%; to plasma proteins (VLDL, LDL and HDL lipoprotein fractions)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via multiple biotransformation pathways (CYP3A4 substrate involved in oxidation pathway, although relative contribution to metabolism unknown); metabolites formed are either less active or have similar activity to parent compound",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 250 mg: ~40 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~90%); urine (&lt;1%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Di Leo A, Jerusalem G, Petruzelka L,e t al, &ldquo;Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010 28(30):4594-600.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4964/abstract-text/20855825/pubmed\" id=\"20855825\" target=\"_blank\">",
"        20855825",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Breast Cancer,&rdquo; Version 2.2010. Available at  file://www.nccn.org/professionals/physician_gls/PDF/breast.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robertson JF, Llombart-Cussac A, Rolski J, et al, &ldquo;Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg as First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(27):4530-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4964/abstract-text/19704066/pubmed\" id=\"19704066\" target=\"_blank\">",
"        19704066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8784 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-F35B292492-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_54_4964=[""].join("\n");
var outline_f4_54_4964=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174701\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12817149\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174718\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174702\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062883\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896291\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174704\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174679\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174667\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174681\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174680\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174716\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174684\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174670\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174711\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174674\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174676\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174686\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174706\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174687\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323163\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539867\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174669\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174683\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8784\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8784|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/8/11396?source=related_link\">",
"      Fulvestrant: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/21/2388?source=related_link\">",
"      Fulvestrant: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_54_4965="Artesunate: Drug information";
var content_f4_54_4965=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Artesunate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13321348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antimalarial Agent;",
"     </li>",
"     <li>",
"      Artemisinin Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13321415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Treatment of severe malaria:",
"     </b>",
"     I.V.: 2.4 mg/kg/dose initially, followed by 2.4 mg/kg/dose at 12 hours, 24 hours, and 48 hours after the initial dose for a total of 4 doses over a period of 3 days; longer treatment duration (eg, an additional 4 days [Hess, 2010]) may be required in severely-ill patients or in patients unable to transition to oral therapy (Hess, 2010; Rosenthal, 2008).",
"     <b>",
"      Note:",
"     </b>",
"     Because of the short half-life of artesunate and a high risk of recrudescence, oral antimalarial therapy must begin &le;4 hours after the last I.V. artesunate infusion. Appropriate oral therapies include atovaquone-proguanil, doxycycline (in patients &gt;8 years of age and nonpregnant adults), clindamycin,",
"     <b>",
"      or",
"     </b>",
"     mefloquine (CDC, 2009, Hess, 2010; Rosenthal, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13321414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13321416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13332701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary (Rosenthal, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13332702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary (Rosenthal, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F13321344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Investigational agent &ndash; not approved for use in the U.S.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Artesunate is available in the U.S. for I.V. use in patients with malaria through an Investigational New Drug (IND) protocol. To obtain artesunate via the IND protocol, clinicians must contact the Centers for Disease Control (CDC) Malaria Hotline at 770-488-7788 (business hours) or 770-488-7100 (nonbusiness hours) and request to speak with a CDC Malaria Branch clinician.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Eligibility criteria under the IND protocol include (Hess, 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     -",
"     <b>",
"      Patients must have malaria:",
"     </b>",
"     Diagnosis by microscopy or strong clinical suspicion of",
"     <i>",
"      Plasmodium falciparum",
"     </i>",
"     or other",
"     <i>",
"      Plasmodium",
"     </i>",
"     spp. infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     -",
"     <b>",
"      Patients must require parenteral therapy:",
"     </b>",
"     Unable to take oral medications, high-density parasitemia (eg, &gt;5%), or diagnosis of severe malaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     -",
"     <b>",
"      I.V. artesunate must be the preferred treatment:",
"     </b>",
"     I.V. artesunate is at least as readily available as I.V. quinidine or the patient has experienced quinidine failure (eg, parasitemia &gt;10% baseline after 48 hours of quinidine therapy), quinidine intolerance, or contraindications to quinidine",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     For medical access to I.V. artesunate in Canada, please refer to special access information on the Public Health Agency of Canada website,  file://www.phac-aspc.gc.ca/tmp-pmv/quinine/.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13321427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Administer via I.V. bolus over 1&ndash;2 minutes through a 0.8-micron hydrophilic polyethersulfone filter (Hess, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13322725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of severe malaria",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13321360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Anxiety, dizziness, headache, restlessness, slurred speech",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Angioedema, erythema, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Anorexia, diarrhea, metallic taste, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic: Anemia, hemolysis, neutropenia, reticulocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: ALT increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Ataxia, hyperreflexia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: BUN increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Hypersensitivity reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13321352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to artesunate or any component of the formulation (Hess, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13321353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity: Severe allergic reactions have been reported with oral administration of artesunate (Leonardi, 2001); monitor for signs of hypersensitivity and discontinue treatment in patients who develop severe hypersensitivity reactions (eg, angioedema, dyspnea, erythema, anaphylaxis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; QT prolongation: QT prolongation has been reported with other artemisinin derivatives (eg, artemether); however, one report suggests that the mean QT",
"     <sub>",
"      c",
"     </sub>",
"     interval was unaffected by artesunate (Maude, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13321350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal reproduction studies. Limited studies in pregnant women have not revealed an increased risk of congenital abnormalities in newborns (McGready, 1998; McGready, 2008). Malaria infection in pregnant women may be more severe than in nonpregnant women. Because",
"     <i>",
"      P. falciparum",
"     </i>",
"     malaria can cause maternal death, congenital malaria, and fetal loss, pregnant women traveling to malaria-endemic areas must use personal protection against mosquito bites.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13321351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The benefits of breast-feeding to mother and infants should be weighed against the potential risk from infant exposure to artesunate.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13733211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      A-Keftal (IN);",
"     </li>",
"     <li>",
"      Altinate (IN);",
"     </li>",
"     <li>",
"      Falciat (IN);",
"     </li>",
"     <li>",
"      Junate (IN);",
"     </li>",
"     <li>",
"      Plasmotrim (BR);",
"     </li>",
"     <li>",
"      Spy (IN);",
"     </li>",
"     <li>",
"      Zesunate (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13321405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Artesunate, a semisynthetic derivative of artemisinin, is a prodrug which is converted to dihydroartemisinin (DHA).  DHA is an antimalarial agent active against all of the erythrocytic stages of the parasite including gametocytes; inhibits parasite metabolism and enhances the clearance of infected erythrocytes.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Antiparasitic activity is hypothesized to involve cleavage of the Fe",
"     <sup>",
"      2+",
"     </sup>",
"     of  endoperoxide bridge, thereby producing free radicals and damaging parasite proteins. DHA may also inhibit calcium adenosine triphosphatase (cATP) of the sarcoplasmic endoplasmic reticulum and impair parasite protein folding.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13321407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : Adults infected with severe malaria: Artesunate: 15.2 L/kg (range: 2.2-39 L/kg); Dihydroartemisinin (DHA): 1.9 L/kg (range: 0.8-11.5 L/kg) (Newton, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Dihydroartemisinin (DHA): 47% to 76%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Artesunate (prodrug) is rapidly hydrolyzed to an active metabolite, dihydroartemisinin (DHA). DHA undergoes hepatic metabolism via CYP2B6, CYP2C19, and CYP3A4 to inactive metabolites (Hess, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Artesunate: Adults infected with severe malaria: 0.22 hours (range: 0.08-0.61 hours); Dihydroartesiminin (DHA): 0.34 hours (range: 0.14-0.87 hours) (Newton, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: Dihyrdoartemisinin (DHA): Adults infected with severe malaria: Within 15 minutes (Newton, 2006)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barradell LB and Fitton A, &ldquo;Artesunate: A Review of Its Pharmacology and Theurapeutic Efficacy in the Treatment of Malaria,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1995, 50(4):714-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/8536555/pubmed\" id=\"8536555\" target=\"_blank\">",
"        8536555",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Calender DM and Hsue G, &ldquo;Artesunate: Investigational Drug for the Treatment of Severe Falciparum Malaria in Hawai'i,&rdquo;",
"      <i>",
"       Hawaii Medical J",
"      </i>",
"      , 2011, 70(4):77-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/21785506/pubmed\" id=\"21785506\" target=\"_blank\">",
"        21785506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clark RL, White TE, A Clode S, et al, &ldquo;Developmental Toxicity of Artesunate and an Artesunate Combination in the Rat and Rabbit,&rdquo;",
"      <i>",
"       Birth Defects Res B Dev Reprod Toxicol",
"      </i>",
"      , 2004, 71(6): 380-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/15617018/pubmed\" id=\"15617018\" target=\"_blank\">",
"        15617018",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clark RL, Brannen KC, Sanders JE, et al, &ldquo;Artesunate and Artelinic Acid: Association of Embryotoxicity, Reticulocytopenia, and Delayed Stimulation of Hematopoiesis in Pregnant Rats,&rdquo;",
"      <i>",
"       Birth Defects Res B Dev Reprod Toxicol",
"      </i>",
"      , 2011, 92(1) 2011, 92(1):52-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/21312322/pubmed\" id=\"21312322\" target=\"_blank\">",
"        21312322",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davis TM, Phuong HL, Ilett KF, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate in Severe Falciparum Malaria,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 2001, 45(1):181-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/11120963/pubmed\" id=\"11120963\" target=\"_blank\">",
"        11120963",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Clercq D, Vercruysse J, V&eacute;rle P, et al, &ldquo;Efficacy of artesunate against Schistosoma mansoni infections in Richard Toll, Senegal,&rdquo;",
"      <i>",
"       Trans R Soc Trop Med Hyg",
"      </i>",
"      , 2000, 94 (1):90&ndash;1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/10748910/pubmed\" id=\"10748910\" target=\"_blank\">",
"        10748910",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dondorp A, Nosten F, Stepniewska K, et al, &ldquo;Artesunate versus Quinine for Treatment of Severe Falciparum Malaria: A Randomised Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2005, 366(9487):717-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/16125588/pubmed\" id=\"16125588\" target=\"_blank\">",
"        16125588",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Franco-Paredes C, Dismukes R, Nicolls D, et al, &ldquo;Neurotoxicity Due to Antimalarial Therapy Associated With Misdiagnosis of Malaria,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 40(11):1710-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/15889385/pubmed\" id=\"15889385\" target=\"_blank\">",
"        15889385",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gasasira AF, Kamya MR, Achan J, et al, &ldquo;High Risk of Neutropenia in HIV-infected Children Following Treatment With Artesunate Plus Amodiaquine for Uncomplicated Malaria in Uganda,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2008, 46(7), 985-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/18444813/pubmed\" id=\"18444813\" target=\"_blank\">",
"        18444813",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hess KM, Goad JA, and Arguin PM, &ldquo;Intravenous Artesunate for the Treatment of Severe Malaria,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2010, 44(7-8):1250-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/20551300/pubmed\" id=\"20551300\" target=\"_blank\">",
"        20551300",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Inyang-Etoh PC, Ejezie GC, Useh MF, et al, &ldquo;Efficacy of Artesunate in the Treatment of Urinary Schistosomiasis, in an Endemic Community in Nigeria,&rdquo;",
"      <i>",
"       Ann Trop Med Parasitol",
"      </i>",
"      , 2004, 98(5):491-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/15257799/pubmed\" id=\"15257799\" target=\"_blank\">",
"        15257799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leonardi E, Gilvary G, White NJ, et al, &ldquo;Severe Allergic Reactions to Oral Artesunate: A Report of Two Cases,&rdquo;",
"      <i>",
"       Trans R Soc Trop Med Hyg",
"      </i>",
"      , 2001, 95(22):182-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/11355556/pubmed\" id=\"11355556\" target=\"_blank\">",
"        11355556",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li Q, Cantilena LR, Leary KH, et al, &ldquo;Pharmacokinetic Profiles of Artesunate After Single Intravenous Doses at 0.5, 1, 2, 4, and 8 mg/kg in Healthy Volunteers: A Phase I Study,&rdquo;",
"      <i>",
"       Am J Trop Med Hyg",
"      </i>",
"      , 2009, 81(4):615-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/19815876/pubmed\" id=\"19815876\" target=\"_blank\">",
"        19815876",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li Q, Si Y, Smith KS, et al, &ldquo;Embryotoxicity of Artesunate in Animal Species Related to Drug Tissue Distribution and Toxicokinetic Profiles,&rdquo;",
"      <i>",
"       Birth Defects Res B Dev Reprod Toxicol",
"      </i>",
"      , 2008, 83(4):435-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/18636509/pubmed\" id=\"18636509\" target=\"_blank\">",
"        18636509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGready R, Cho T, Cho JJ, et al, &ldquo;Artemisinin Derivatives in the Treatment of Falciparum Malaria in Pregnancy,&rdquo;",
"      <i>",
"       Trans R Soc Trop Med Hyg",
"      </i>",
"      , 1998, 92(4):430&ndash;3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/9850401/pubmed\" id=\"9850401\" target=\"_blank\">",
"        9850401",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGready R, Cho T, Samuel, et al, &ldquo;Randomized Comparison of Quinine-Clindamycin versus Artesunate in the Treatment of Falciparum Malaria in Pregnancy,&rdquo;",
"      <i>",
"       Trans R Soc Trop Med Hyg",
"      </i>",
"      , 2001, 95(6):651-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/11816439/pubmed\" id=\"11816439\" target=\"_blank\">",
"        11816439",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGready R, Tan SO, Ashley EA, et al, &ldquo;A Randomised Controlled Trial of Artemether-Lumefantrine versus Artesunate for Uncomplicated Plasmodium Falciparum Treatment  in Pregnancy,&rdquo;",
"      <i>",
"       PLoS Med",
"      </i>",
"      , 2008, 5(12):e253",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/19265453/pubmed\" id=\"19265453\" target=\"_blank\">",
"        19265453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller LG and Panosian CB, &ldquo;Ataxia and Slurred Speech After Artesunate Treatment for Falciparum Malaria,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 336(18):1328.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/9132599/pubmed\" id=\"9132599\" target=\"_blank\">",
"        9132599",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Newton PN, Barnes KI, Smith PJ, et al, &ldquo;The Pharmacokinetics of Intravenous Artesunate in Adults With Severe Falciparum Malaria,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 2006, 62(12):1003-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/17089111/pubmed\" id=\"17089111\" target=\"_blank\">",
"        17089111",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olliaro P, &ldquo;Disease and Drug Interactions: Treating Malaria With Artesunate Plus Amodiaquine in Patients Also Receiving Treatment for Concomitant HIV Infection,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2008, 46(7):992-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/18444814/pubmed\" id=\"18444814\" target=\"_blank\">",
"        18444814",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Onyamboko MA, Meshnick SR, Fleckenstein L, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Artesunate and Dihydroartemisinin Following Oral Treatment in Pregnant women With Asymptomatic",
"      <i>",
"       Plasmodium falciparum",
"      </i>",
"      Infections in Kinshasa DRC,&rdquo;",
"      <i>",
"       Malar J",
"      </i>",
"      , 2011, 10:49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/21352601/pubmed\" id=\"21352601\" target=\"_blank\">",
"        21352601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenthal PJ, &ldquo;Artesunate for the Treatment of Severe Falciparum Malaria,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(17):1829&ndash;36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/18434652/pubmed\" id=\"18434652\" target=\"_blank\">",
"        18434652",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shapira MY, Resnick IB, Chou S, et al, &ldquo;Artesunate as a Potent Antiviral Agent in a Patient With Late Drug-Resistant Cytomegalovirus Infection After Hematopoietic Stem Cell Transplantation,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2008, 46(9):1455-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/18419454/pubmed\" id=\"18419454\" target=\"_blank\">",
"        18419454",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zoller T, Junghanss T, Kapaun A, et al, &ldquo;Intravenous Artesunate for Severe Malaria in Travelers, Europe,&rdquo;",
"      <i>",
"       Emerg Infect Dis",
"      </i>",
"      , 17(5):771-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/54/4965/abstract-text/21529383/pubmed\" id=\"21529383\" target=\"_blank\">",
"        21529383",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17088 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-E03BC582ED-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_54_4965=[""].join("\n");
var outline_f4_54_4965=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13321348\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13321415\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13321414\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13321416\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13332701\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13332702\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13321344\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13321427\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13322725\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13321360\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13321352\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13321353\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13321350\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13321351\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13733211\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13321405\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13321407\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17088\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17088|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_54_4966="Certolizumab pegol: Patient drug information";
var content_f4_54_4966=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Certolizumab pegol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"     see \"Certolizumab pegol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6019485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cimzia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9477197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cimzia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700828",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       TB (tuberculosis) has been seen in patients started on this drug. These patients were exposed to TB in the past, but never got the infection. You will be tested to see if you have been exposed to TB before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may add to your chance of getting lymphoma or other cancers.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad infections have happened in patients who take this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691796",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Crohn's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat rheumatoid arthritis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701755",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to certolizumab pegol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hepatitis B testing may be done. A hepatitis B infection may get worse during care.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-term use may raise your chance of cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad infections have been reported with use of this drug. If you have any infection, are taking antibiotics now or in the recent past, or have many infections, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697192",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have cancer, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697206",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. You may be more likely to get infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697311",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have MS (multiple sclerosis) or other nerve disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699033",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3424302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Night sweats.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3424303",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698578",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will need a TB (tuberculosis) test before starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to give closely if you or a family member is giving the shot at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694561",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Before giving the shot, bring it to room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Move the site where you give the shot with each shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw syringe away after use. Do not use more than one time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11748 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-0D0D3C1A28-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_54_4966=[""].join("\n");
var outline_f4_54_4966=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6019485\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9477197\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023350\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023352\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023351\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023356\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023357\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023359\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023354\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023355\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023360\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023361\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=related_link\">",
"      Certolizumab pegol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_54_4967="New lentigo maligna melanoma";
var content_f4_54_4967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lentigo maligna melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 423px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lentigo maligna melanoma usually arises in areas of sun-damaged skin, particularly on the head and neck. It begins as a freckle-like, tan-brown macule and gradually enlarges and develops darker or lighter asymmetric foci and raised areas, which signify dermal invasion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Susan Swetter, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_54_4967=[""].join("\n");
var outline_f4_54_4967=null;
var title_f4_54_4968="Prenatal sonographic diagnosis of fetal cardiac anomalies";
var content_f4_54_4968=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prenatal sonographic diagnosis of fetal cardiac anomalies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/54/4968/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/54/4968/contributors\">",
"     Joshua Copel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/54/4968/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/54/4968/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/54/4968/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/54/4968/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/54/4968/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/54/4968/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital anomalies are the leading cause of infant death and congenital heart disease accounts for 30 to 50 percent of these deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. As the major cause of the largest single category of mortality, the identification and management of fetal cardiac abnormalities has been the subject of tremendous interest.",
"   </p>",
"   <p>",
"    Most cases of fetal cardiac anomalies occur in low-risk populations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/3\">",
"     3",
"    </a>",
"    ]. Population screening studies have shown that congenital heart disease occurs in",
"    <span class=\"nowrap\">",
"     5/1000",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     8/1000",
"    </span>",
"    newborns, with about one-half causing major disease and one-half causing minor disease. While there are no formal definitions of \"major\" and \"minor\" disease, the former can be considered to be congenital heart disease that is clearly evident at or shortly after birth, such as cyanotic disease, severe valve stenosis, and large ventricular septal defects (VSD). Minor disease would include small VSDs, and mild valve stenosis.",
"   </p>",
"   <p>",
"    The types of heart disease seen in fetuses include the full spectrum of lesions seen in a postnatal population, with the exception of the minor lesions that are less likely to be diagnosed in the prenatal period. The distribution of lesions seen is somewhat different from postnatal populations, probably because fetal anomalies are usually found either at abnormal screening study or when other fetal anomalies are diagnosed and prompt a more careful examination of the heart [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A detailed review of normal and abnormal fetal cardiac anatomy and echocardiography can be found elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard, basic obstetrical ultrasound examination as described by the American College of Obstetricians and Gynecologists (ACOG), the American College of Radiology (ACR), and the American Institute of Ultrasound in Medicine (AIUM) includes visualizing the four chambers of the fetal heart. The rationale for this has been that:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It is easily obtainable.",
"     </li>",
"     <li>",
"      Major distortion of the chambers would be expected with many significant lesions.",
"     </li>",
"     <li>",
"      Large VSDs will be visible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the four chamber view alone has been disappointing in its performance as a screen for fetal cardiac defects, for a number of reasons including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some VSDs (especially anterior) are not apparent.",
"     </li>",
"     <li>",
"      Outflow tract abnormalities that do not obstruct flow do not distort the four chamber view (eg, transposition of the great arteries).",
"     </li>",
"     <li>",
"      The view may be difficult to obtain in cases of maternal obesity, abdominal scarring, in the early midtrimester, and with some fetal positions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The inclusion of views of the outflow tract increases the likelihood of identifying conotruncal anomalies such as tetralogy of Fallot, transposition of the great arteries, double outlet right ventricle and truncus arteriosus. For these reasons, in 2008, ACOG, ACR, and AIUM jointly suggested that \"if technically feasible, views of the outflow tracts should be attempted as part of the cardiac screening examination\" [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In 2013, the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) recommended that the cardiac screening examination include both the four-chamber and outflow tract views [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimum time for visualization of the heart and outflow tracts is 18 to 22 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/10\">",
"     10",
"    </a>",
"    ]. It can be more difficult to obtain good images after 30 weeks as the fetus becomes more crowded within the amniotic cavity. A systematic review of the accuracy of first-trimester ultrasound examination for detecting major CHD included 10 studies (involving 1243 patients) using transabdominal or transvaginal ultrasound transducers or a combination of both methods [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/11\">",
"     11",
"    </a>",
"    ]. Most of the studies were in populations with fetuses at increased risk of CHD. Pooled sensitivity and specificity were 85 percent (95% CI, 78 to 90 percent) and 99 percent (95% CI, 98 to 100 percent), respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Four chamber view",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard four chamber view can be obtained either from the long axis or apical view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61751 \" href=\"UTD.htm?2/5/2128\">",
"     image 1",
"    </a>",
"    ). Usually it is easiest to start with a standard abdominal circumference plane of the fetal abdomen and angle the transducer cephalad on the fetus. The four chambers of the fetal heart are seen with the left atrium most posterior and the right ventricle most anterior. The right and left atria and ventricles should be approximately symmetric in size. The heart should occupy about one third of the chest area.",
"   </p>",
"   <p>",
"    Two sets of investigators have proposed analyzing the fetal cardiac axis as a tool to extend the sensitivity of the four chamber view. Both groups found that the mean axis of the fetal heart is approximately 45 degrees to the left of the midline (normal range 30 to 60 degrees), and that there was often an increase in the axis with outflow tract abnormalities, the lesions most likely to be missed with standard four chamber screening [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A full fetal echocardiogram should be performed in pregnancies in which more than general screening is indicated (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Indications for fetal echocardiography'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Performance of four chamber screening has been assessed in numerous studies. Unfortunately, the sensitivity for major heart disease has been highly variable, ranging from 0 to 80 percent detection rates [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. Factors affecting sensitivity include operator experience, gestational age, maternal weight, fetal position, and type of defect [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1997, a review of 13 published screening studies described over 100,000 screened pregnancies and reported a composite sensitivity of only 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/14\">",
"     14",
"    </a>",
"    ]. The largest study performed in the United States was also included in the above review. The RADIUS Trial randomly assigned 15,000 low-risk women to have either two scans routinely during pregnancy or scans only for indications. Among women scanned at primary care sites, there were no cases of fetal congenital heart disease correctly identified, including a failure to detect any of eight cases of complex heart defects. Among those women seen at referral practices,",
"    <span class=\"nowrap\">",
"     5/11",
"    </span>",
"    cases of complex heart disease (45 percent) were detected by prenatal ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, experienced ultrasonographers go beyond the standard four chamber examination by expanding the views obtained to include the cardiac outflow tracts. This adds to sensitivity in the detection of fetal cardiac anomalies, resulting in detection rates of 50 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2006, the Italian group described above conducted another multicenter prospective observational study in 15 obstetric units in the Piedmont Region of Italy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/23\">",
"     23",
"    </a>",
"    ]. Over 7000 women were screened and complete follow-up information was available for 90 percent. Fifty-eight cases of congenital heart disease were observed at birth or postmortem; 38 of which were diagnosed in utero. Sensitivity of ultrasound for detection of congenital heart disease was 65.5 percent. The authors attributed the higher sensitivity to inclusion of the outflow tract view in the examination, technological developments, and better training of the operators.",
"   </p>",
"   <p>",
"    Attempts to perform full cardiac studies as part of routine second trimester fetal ultrasound have yielded high sensitivity rates, approximately 90 percent at 20 to 22 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The practicality of this approach for routine application has yet to be proven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Nuchal translucency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nuchal translucency screening is another technique that holds promise for identifying fetuses at increased risk of congenital heart disease. This test, performed between 11 and 14 weeks of gestation, has been used alone or in combination with maternal serum analyte levels to screen for fetal aneuploidy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link\">",
"     \"Sonographic findings associated with fetal aneuploidy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=see_link\">",
"     \"First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Analysis of large numbers of screened pregnancies has shown that increasing thickness of the nuchal skinfold confers greater risk of all major types of congenital heart disease, even among euploid fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. At least 25 percent of fetuses with CHD have increased nuchal translucency (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Fetal risk factors'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/28\">",
"     28",
"    </a>",
"    ]. A meta-analysis estimated that nuchal thickness screening could detect 52 percent of cardiac abnormalities for which prenatal diagnosis was potentially useful (ie, knowledge of the abnormality may lead to an antepartum intervention, such as termination, in utero treatment, or altered postnatal management); the false positive rate was set at 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/30\">",
"     30",
"    </a>",
"    ]. Nuchal translucency appears to predict the presence of congenital heart disease better than most traditional risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As has been found for Down syndrome screening, careful training and ongoing audits are necessary to maintain the strict criteria that allowed the Fetal Medicine Foundation investigators to achieve the high level of performance they reported for this test. By comparison, a meta-analysis of other, smaller studies reported sensitivity of only 30 percent for nuchal translucency above the 99th percentile [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/27\">",
"     27",
"    </a>",
"    ]. Data from first trimester screening for Down syndrome trials in the United States have also shown similar lower sensitivity rates, although these trials support the need for detailed fetal echocardiography in fetuses with nuchal translucency measurements over 3.5 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR FETAL ECHOCARDIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetuses may be at risk of congenital heart disease for a number of reasons, which can be roughly divided into familial, maternal, and fetal risk factors. Examples of some specific risk factors are listed below [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Familial risk factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First or second degree relatives with congenital heart disease (eg, the fetus&rsquo; siblings, parents, and grandparents)",
"     </li>",
"     <li>",
"      Syndromes including congenital heart disease (eg, Noonan, tuberous sclerosis, Holt-Oram, velocardiofacial [DiGeorge] syndrome)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Maternal risk factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal congenital heart disease",
"     </li>",
"     <li>",
"      Cardiac teratogen exposure (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , folate antagonists, organic solvents [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/34\">",
"       34",
"      </a>",
"      ],",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      , anticonvulsants,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/62/1000?source=see_link\">",
"       isotretinoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"       paroxetine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Maternal medical illness (eg, diabetes, phenylketonuria, anti",
"      <span class=\"nowrap\">",
"       Ro/SSA",
"      </span>",
"      or anti",
"      <span class=\"nowrap\">",
"       La/SSB",
"      </span>",
"      antibodies)",
"     </li>",
"     <li>",
"      Exposure to prostaglandin synthetase inhibitors (can cause premature closure of the ductus arteriosus in the third trimester)",
"     </li>",
"     <li>",
"      Rubella infection in the first trimester",
"     </li>",
"     <li>",
"      In vitro fertilization [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Fetal risk factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Suspected cardiac anomaly during basic sonogram",
"     </li>",
"     <li>",
"      Extracardiac anomaly",
"     </li>",
"     <li>",
"      Aneuploidy (",
"      <a class=\"graphic graphic_table graphicRef52621 \" href=\"UTD.htm?20/19/20798\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nonimmune hydrops",
"     </li>",
"     <li>",
"      Arrhythmia",
"     </li>",
"     <li>",
"      Abnormal fetal situs",
"     </li>",
"     <li>",
"      Increased nuchal translucency at 11 to 14 weeks of gestation (",
"      <a class=\"graphic graphic_table graphicRef74699 \" href=\"UTD.htm?1/50/1835\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chromosomal abnormality",
"     </li>",
"     <li>",
"      Monochorionic twins, with or without twin-twin transfusion syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The magnitude of risk associated with each of these factors varies, but each places the fetus at higher risk than would be expected for the general population.",
"   </p>",
"   <p>",
"    Fetuses with increased nuchal translucency measurements are at increased risk of a broad range of cardiac defects; increased nuchal translucency is not strongly associated with a specific cardiac anomaly.",
"   </p>",
"   <p>",
"    The risk of inheritance of congenital heart disease is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link&amp;anchor=H31#H31\">",
"     \"Pregnancy in women with congenital heart disease: General principles\", section on 'Inheritance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FULL FETAL ECHOCARDIOGRAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of ultrasonographic imaging techniques are used for prenatal diagnosis of fetal cardiac anomalies. A synopsis of this equipment and the fetal cardiac examination is described below. The sonographic appearance of individual anomalies is beyond the scope of this topic, but can be found in topics on specific anomalies and is reviewed elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound systems used for fetal echocardiography should be capable of performing 2-dimensional, M-mode, and Doppler imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/10,39\">",
"     10,39",
"    </a>",
"    ]. Fetal cardiac imaging should always be performed with the highest possible transducer frequency to maximize image resolution, and at the highest possible frame rate, due to the rapid movement of the heart, which normally beats at 120 to 160 beats per minute.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Full fetal echocardiography includes multiple views of the heart, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Four chamber (atria, ventricles, septae, pulmonary veins, semilunar valves, coronary sinus)",
"     </li>",
"     <li>",
"      Long axis (superior and inferior vena cava, great vessels, ductus arteriosus)",
"     </li>",
"     <li>",
"      Short",
"      <span class=\"nowrap\">",
"       axis/ductal",
"      </span>",
"      arch (pulmonary veins, caval connections, ductus arteriosus, ventricular outflow, branch pulmonary arteries)",
"     </li>",
"     <li>",
"      Aortic arch (head vessels)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of the views is obtained to provide specific information about the structure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    function of the fetal heart. Additionally, color and spectral Doppler are used to identify small vessels such as the pulmonary veins, ductus venosus, and ductus arteriosus, to assess valvular competence and flow patterns, and to examine the ventricular septum for defects. Improved sensitivity of color Doppler flow mapping now permits identification of even small muscular VSDs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/40\">",
"     40",
"    </a>",
"    ]. M-mode of atrial and ventricular wall motion can be useful for analyzing rate and rhythm disturbances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24202?source=see_link\">",
"     \"Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several steps can be taken to obtain an optimal ultrasound image [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use the echocardiography settings on the ultrasound equipment as these settings are designed for enhanced image contrast and tissue characterization and a faster frame rate. Individual preferences can be used to adjust features such as harmonic and compound imaging, and speckle reduction modes.",
"     </li>",
"     <li>",
"      Minimize the depth on the display monitor",
"     </li>",
"     <li>",
"      Adjust the focal zone(s) to the area of interest",
"     </li>",
"     <li>",
"      Avoid insonating the heart at an angle that creates shadowing by the fetal ribs and sternum",
"     </li>",
"     <li>",
"      Zoom in on the area of interest",
"     </li>",
"     <li>",
"      Select appropriate velocity scales when using color Doppler. The color Doppler image is optimized and wall motion artifact is reduced by adjusting the filters and by directing the angle of insonation of the ultrasound beam parallel to the direction of blood flow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ASSOCIATED ANOMALIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As for any fetal anomaly, the identification of a fetal cardiac defect should prompt a search for any associated abnormalities.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of extracardiac abnormalities when major structural heart disease is present varies from 20 to 44 percent, depending on the population (eg, liveborns versus liveborns and stillborns) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/41-43\">",
"       41-43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiac anomalies are part of numerous fetal syndromes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. As an example, data compiled from 20 registries of congenital malformations noted 2454 cases of cardiac anomalies of which 104 (4.2 percent) were in individuals with an identifiable syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fetal chromosome abnormalities are also common when cardiac defects are present, even when occurring in isolation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/20,43,46-48\">",
"       20,43,46-48",
"      </a>",
"      ]. In one series of 1510 fetuses with prenatally diagnosed structural cardiac defects, 624 (41 percent) had an abnormal karyotype (aneuploidy in 562, structural chromosomal abnormalities in 62) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If conotruncal anomalies are seen (tetralogy of Fallot, truncus arteriosus, malalignment ventricular septal defect, interrupted aortic arch), consideration should be given to testing for fetal DiGeorge Syndrome, which is associated with a deletion on the short arm of chromosome 22 (22q11) and detectable by fluorescence in situ hybridization (FISH) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/50\">",
"     50",
"    </a>",
"    ]. In the series described above, 3 percent of fetuses with a structural heart defect and normal karyotype were subsequently found to have microdeletion 22q11.2 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/49\">",
"     49",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link\">",
"     \"Congenital cytogenetic abnormalities\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Women who are identified to be at increased risk of fetal cardiac abnormalities should not be subjected to the imperfect sensitivity of four chamber screening, but should undergo formal fetal echocardiography in a center equipped to identify affected fetuses and counsel affected families.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OUTCOME OF PRENATAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, there was little data regarding whether prenatal diagnoses had any impact on morbidity or mortality of affected fetuses, despite more than two decades of experience in the identification of fetal cardiac anomalies. The first analysis of this question showed significantly improved survival until discharge for infants with prenatal diagnosis of heart defects amenable to biventricular repair compared to those with similar lesions diagnosed postnatally (96 and 76 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/51\">",
"     51",
"    </a>",
"    ]. However, this study failed to find any statistically significant difference in survival among fetuses requiring single ventricle repairs (64 and 44 percent, respectively). Others have reported improvements in survival among fetuses with transposition of the great arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/52\">",
"     52",
"    </a>",
"    ] and hypoplastic left heart syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/53\">",
"     53",
"    </a>",
"    ] diagnosed prenatally. Lower neonatal morbidity and fewer complications, such as severe acidosis, have also been associated with prenatal diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The high mortality of left ventricular outflow obstructions has led to speculation that some cases might be treated in utero. One study attempted aortic valve dilation in fetuses with severe aortic stenosis at 21 to 29 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/56\">",
"     56",
"    </a>",
"    ]. Serial fetal echocardiograms after intervention demonstrated growth arrest of the left heart structures in unsuccessful cases (n = 6) and in those who declined the procedure (n = 4), while ongoing left heart growth was seen in successful cases (n = 14). Resumed left heart growth led to a two-ventricle circulation at birth in three infants. However, prenatal treatment is unlikely to become a standard of care for the foreseeable future.",
"   </p>",
"   <p>",
"    Referral to a maternal-fetal medicine specialist, pediatric cardiologist, geneticist,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neonatologist to discuss prognosis, obstetrical and neonatal management, and options is recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     FUTURE CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of improved processor speeds in three-dimensional imaging allows production of fast updates, providing what is variously termed \"real time 3D\" or \"4D\" imaging. The use of spatio-temporal image correlation (STIC) also allows generation of moving clips in all three planes from a 3D volume. There is a prolonged learning curve to use these techniques for cardiac assessment, and technical challenges remain, especially in image quality in the third dimension (C plane). Automated creation of planes from a standard four chamber view may make this technology more accessible [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4968/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fetal cardiac assessment should include a four chamber view; viewing the outflow tracts in an extended basic cardiac examination is also important. The optimum time for visualization of the fetal heart and outflow tracts is 18 to 22 weeks of gestation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A full fetal echocardiogram should be performed in pregnancies with risk factors for congenital heart anomalies. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Indications for fetal echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following interventions are recommended when a fetal cardiac anomaly is suspected: &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Full fetal echocardiography to evaluate cardiac structure and function, arterial and venous flow, and rhythm. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Full fetal echocardiogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Detailed scanning of the fetal anatomy to look for associated anomalies, particularly involving the digits and bones. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Associated anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thorough family history to evaluate for familial abnormalities or syndromes. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Familial risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thorough maternal medical history to identify chronic medical disorders, viral illnesses, or medications which are potential teratogens. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Maternal risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fetal karyotype, with screening for deletion in 22q11.2 when conotruncal anomalies are present (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Associated anomalies'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Referral to a maternal-fetal medicine specialist, pediatric cardiologist, geneticist,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neonatologist to discuss prognosis, obstetrical and neonatal management, and options. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Outcome of prenatal diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Delivery at an institution that can provide neonatal cardiac care, if needed. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Outcome of prenatal diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/1\">",
"      Mathews TJ, MacDorman MF. Infant mortality statistics from the 2006 period linked birth/infant death data set. Natl Vital Stat Rep 2010; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/2\">",
"      Gilboa SM, Salemi JL, Nembhard WN, et al. Mortality resulting from congenital heart disease among children and adults in the United States, 1999 to 2006. Circulation 2010; 122:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/3\">",
"      Sharland G. Routine fetal cardiac screening: what are we doing and what should we do? Prenat Diagn 2004; 24:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/4\">",
"      Smythe JF, Copel JA, Kleinman CS. Outcome of prenatally detected cardiac malformations. Am J Cardiol 1992; 69:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/5\">",
"      Cook AC, Yates RW, Anderson RH. Normal and abnormal fetal cardiac anatomy. Prenat Diagn 2004; 24:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/6\">",
"      Simpson J. Echocardiographic evaluation of cardiac function in the fetus. Prenat Diagn 2004; 24:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/7\">",
"      Abuhamad AZ, ACOG Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin, clinical management guidelines for obstetrician-gynecologists number 98, October 2008 (replaces Practice Bulletin number 58, December 2004). Ultrasonography in pregnancy. Obstet Gynecol 2008; 112:951.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aium.org/publications/clinical/obstetric.pdf. (Accessed 1/29/2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/9\">",
"      ISUOG Practice Guidelines (updated): sonographic screening examination&thinsp;of the fetal heart. Ultrasound Obstet Gynecol 2013; 41:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/10\">",
"      Rychik J, Ayres N, Cuneo B, et al. American Society of Echocardiography guidelines and standards for performance of the fetal echocardiogram. J Am Soc Echocardiogr 2004; 17:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/11\">",
"      Rasiah SV, Publicover M, Ewer AK, et al. A systematic review of the accuracy of first-trimester ultrasound examination for detecting major congenital heart disease. Ultrasound Obstet Gynecol 2006; 28:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/12\">",
"      Shipp TD, Bromley B, Hornberger LK, et al. Levorotation of the fetal cardiac axis: a clue for the presence of congenital heart disease. Obstet Gynecol 1995; 85:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/13\">",
"      Smith RS, Comstock CH, Kirk JS, Lee W. Ultrasonographic left cardiac axis deviation: a marker for fetal anomalies. Obstet Gynecol 1995; 85:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/14\">",
"      Todros T, Faggiano F, Chiappa E, et al. Accuracy of routine ultrasonography in screening heart disease prenatally. Gruppo Piemontese for Prenatal Screening of Congenital Heart Disease. Prenat Diagn 1997; 17:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/15\">",
"      Randall P, Brealey S, Hahn S, et al. Accuracy of fetal echocardiography in the routine detection of congenital heart disease among unselected and low risk populations: a systematic review. BJOG 2005; 112:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/16\">",
"      Tegnander E, Williams W, Johansen OJ, et al. Prenatal detection of heart defects in a non-selected population of 30,149 fetuses--detection rates and outcome. Ultrasound Obstet Gynecol 2006; 27:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/17\">",
"      Chew C, Halliday JL, Riley MM, Penny DJ. Population-based study of antenatal detection of congenital heart disease by ultrasound examination. Ultrasound Obstet Gynecol 2007; 29:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/18\">",
"      Tegnander E, Eik-Nes SH. The examiner's ultrasound experience has a significant impact on the detection rate of congenital heart defects at the second-trimester fetal examination. Ultrasound Obstet Gynecol 2006; 28:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/19\">",
"      Wong SF, Chan FY, Cincotta RB, et al. Factors influencing the prenatal detection of structural congenital heart diseases. Ultrasound Obstet Gynecol 2003; 21:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/20\">",
"      Friedberg MK, Silverman NH, Moon-Grady AJ, et al. Prenatal detection of congenital heart disease. J Pediatr 2009; 155:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/21\">",
"      Crane JP, LeFevre ML, Winborn RC, et al. A randomized trial of prenatal ultrasonographic screening: impact on the detection, management, and outcome of anomalous fetuses. The RADIUS Study Group. Am J Obstet Gynecol 1994; 171:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/22\">",
"      Friedman AM, Phoon CK, Fishman S, et al. The utility of fetal echocardiography after an unremarkable anatomy scan. Obstet Gynecol 2011; 118:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/23\">",
"      Ogg&egrave; G, Gaglioti P, Maccanti S, et al. Prenatal screening for congenital heart disease with four-chamber and outflow-tract views: a multicenter study. Ultrasound Obstet Gynecol 2006; 28:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/24\">",
"      St&uuml;mpflen I, St&uuml;mpflen A, Wimmer M, Bernaschek G. Effect of detailed fetal echocardiography as part of routine prenatal ultrasonographic screening on detection of congenital heart disease. Lancet 1996; 348:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/25\">",
"      Yagel S, Weissman A, Rotstein Z, et al. Congenital heart defects: natural course and in utero development. Circulation 1997; 96:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/26\">",
"      Hyett J, Perdu M, Sharland G, et al. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study. BMJ 1999; 318:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/27\">",
"      Makrydimas G, Sotiriadis A, Ioannidis JP. Screening performance of first-trimester nuchal translucency for major cardiac defects: a meta-analysis. Am J Obstet Gynecol 2003; 189:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/28\">",
"      Makrydimas G, Sotiriadis A, Huggon IC, et al. Nuchal translucency and fetal cardiac defects: a pooled analysis of major fetal echocardiography centers. Am J Obstet Gynecol 2005; 192:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/29\">",
"      Bahado-Singh RO, Wapner R, Thom E, et al. Elevated first-trimester nuchal translucency increases the risk of congenital heart defects. Am J Obstet Gynecol 2005; 192:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/30\">",
"      Wald NJ, Morris JK, Walker K, Simpson JM. Prenatal screening for serious congenital heart defects using nuchal translucency: a meta-analysis. Prenat Diagn 2008; 28:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/31\">",
"      Simpson, LL, et al. Nuchal translucency and the risk of congenital hesrt disease &mdash; A population based screening study (The FASTER trial). Am J Obstet Gynecol 2004; 191:S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/32\">",
"      Bahado-Singh, R, et al. Contingency screening: Modeling of an alternate pathway for first trimester Down syndrome risk assessment. Am J Obstet Gynecol 2004; 191:S53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/33\">",
"      Clur SA, Ottenkamp J, Bilardo CM. The nuchal translucency and the fetal heart: a literature review. Prenat Diagn 2009; 29:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/34\">",
"      Jenkins KJ, Correa A, Feinstein JA, et al. Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 2007; 115:2995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/35\">",
"      Olson CK, Keppler-Noreuil KM, Romitti PA, et al. In vitro fertilization is associated with an increase in major birth defects. Fertil Steril 2005; 84:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/36\">",
"      Reefhuis J, Honein MA, Schieve LA, et al. Assisted reproductive technology and major structural birth defects in the United States. Hum Reprod 2009; 24:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/37\">",
"      Bahtiyar MO, Dulay AT, Weeks BP, et al. Prevalence of congenital heart defects in monochorionic/diamniotic twin gestations: a systematic literature review. J Ultrasound Med 2007; 26:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/38\">",
"      Rajiah P, Mak C, Dubinksy TJ, Dighe M. Ultrasound of fetal cardiac anomalies. AJR Am J Roentgenol 2011; 197:W747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/39\">",
"      Abuhamad A. Color and pulsed Doppler in fetal echocardiography. Ultrasound Obstet Gynecol 2004; 24:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/40\">",
"      Bahtiyar MO, Dulay AT, Weeks BP, et al. Prenatal course of isolated muscular ventricular septal defects diagnosed only by color Doppler sonography: single-institution experience. J Ultrasound Med 2008; 27:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/41\">",
"      Greenwood RD, Rosenthal A, Parisi L, et al. Extracardiac abnormalities in infants with congenital heart disease. Pediatrics 1975; 55:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/42\">",
"      Wallgren EI, Landtman B, Rapola J. Extracardiac malformations associated with congenital heart disease. Eur J Cardiol 1978; 7:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/43\">",
"      Song MS, Hu A, Dyamenahalli U, et al. Extracardiac lesions and chromosomal abnormalities associated with major fetal heart defects: comparison of intrauterine, postnatal and postmortem diagnoses. Ultrasound Obstet Gynecol 2009; 33:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/44\">",
"      Copel JA, Pilu G, Kleinman CS. Congenital heart disease and extracardiac anomalies: associations and indications for fetal echocardiography. Am J Obstet Gynecol 1986; 154:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/45\">",
"      Pajkrt E, Weisz B, Firth HV, Chitty LS. Fetal cardiac anomalies and genetic syndromes. Prenat Diagn 2004; 24:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/46\">",
"      Copel JA, Cullen M, Green JJ, et al. The frequency of aneuploidy in prenatally diagnosed congenital heart disease: an indication for fetal karyotyping. Am J Obstet Gynecol 1988; 158:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/47\">",
"      Wimalasundera RC, Gardiner HM. Congenital heart disease and aneuploidy. Prenat Diagn 2004; 24:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/48\">",
"      Tuuli MG, Dicke JM, Stamilio DM, et al. Prevalence and likelihood ratios for aneuploidy in fetuses diagnosed prenatally with isolated congenital cardiac defects. Am J Obstet Gynecol 2009; 201:390.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/49\">",
"      Moore JW, Binder GA, Berry R. Prenatal diagnosis of aneuploidy and deletion 22q11.2 in fetuses with ultrasound detection of cardiac defects. Am J Obstet Gynecol 2004; 191:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/50\">",
"      Goldmuntz E, Clark BJ, Mitchell LE, et al. Frequency of 22q11 deletions in patients with conotruncal defects. J Am Coll Cardiol 1998; 32:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/51\">",
"      Copel JA, Tan AS, Kleinman CS. Does a prenatal diagnosis of congenital heart disease alter short-term outcome? Ultrasound Obstet Gynecol 1997; 10:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/52\">",
"      Bonnet D, Coltri A, Butera G, et al. Detection of transposition of the great arteries in fetuses reduces neonatal morbidity and mortality. Circulation 1999; 99:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/53\">",
"      Tworetzky W, McElhinney DB, Reddy VM, et al. Improved surgical outcome after fetal diagnosis of hypoplastic left heart syndrome. Circulation 2001; 103:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/54\">",
"      Verheijen PM, Lisowski LA, Stoutenbeek P, et al. Prenatal diagnosis of congenital heart disease affects preoperative acidosis in the newborn patient. J Thorac Cardiovasc Surg 2001; 121:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/55\">",
"      Kumar RK, Newburger JW, Gauvreau K, et al. Comparison of outcome when hypoplastic left heart syndrome and transposition of the great arteries are diagnosed prenatally versus when diagnosis of these two conditions is made only postnatally. Am J Cardiol 1999; 83:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/56\">",
"      Tworetzky W, Wilkins-Haug L, Jennings RW, et al. Balloon dilation of severe aortic stenosis in the fetus: potential for prevention of hypoplastic left heart syndrome: candidate selection, technique, and results of successful intervention. Circulation 2004; 110:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/57\">",
"      Allan LD, Huggon IC. Counselling following a diagnosis of congenital heart disease. Prenat Diagn 2004; 24:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4968/abstract/58\">",
"      Abuhamad A, Falkensammer P, Zhao Y. Automated sonography: defining the spatial relationship of standard diagnostic fetal cardiac planes in the second trimester of pregnancy. J Ultrasound Med 2007; 26:501.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6755 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_54_4968=[""].join("\n");
var outline_f4_54_4968=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Four chamber view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Nuchal translucency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INDICATIONS FOR FETAL ECHOCARDIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Familial risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Maternal risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Fetal risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FULL FETAL ECHOCARDIOGRAM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ASSOCIATED ANOMALIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OUTCOME OF PRENATAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      FUTURE CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6755\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6755|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/5/2128\" title=\"diagnostic image 1\">",
"      Four chamber view fetal heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6755|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/19/20798\" title=\"table 1\">",
"      Frequency of aneuploidy in congenital heart defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/50/1835\" title=\"table 2\">",
"      CHD by nuchal thickness",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=related_link\">",
"      First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24202?source=related_link\">",
"      Overview of the general approach to diagnosis and treatment of fetal cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=related_link\">",
"      Pregnancy in women with congenital heart disease: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=related_link\">",
"      Sonographic findings associated with fetal aneuploidy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_54_4969="Optic neuropathies";
var content_f4_54_4969=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Optic neuropathies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/54/4969/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/54/4969/contributors\">",
"     Benjamin Osborne, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/54/4969/contributors\">",
"     Laura J Balcer, MD, MSCE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/54/4969/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/54/4969/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/54/4969/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/54/4969/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/54/4969/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 27, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optic nerve carries the greater than one million axons that derive from the retinal ganglion cells and project to eight visual nuclei. Actually an extension or tract of the central nervous system, not a true peripheral nerve, the conventional designation of the optic nerve applies to that portion of this tract that extends from the eye to the optic chiasm.",
"   </p>",
"   <p>",
"    This topic will review functional anatomy of the optic nerve and the differential diagnosis of optic nerve pathologies. Specific disorders are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9464?source=see_link\">",
"     \"Optic neuritis: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27558?source=see_link\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optic nerve has four anatomic segments: the intraocular, intraorbital, intracanalicular, and intracranial sections [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The intraocular portion, or the optic disc, consists of the unmyelinated retinal ganglion cell axons and astrocytes. As the nerve exits the globe, crossing the collagenous lamina cribrosa, it increases in diameter as it becomes myelinated by oligodendrocytes.",
"     </li>",
"     <li>",
"      The intraorbital segment of the optic nerve is approximately 25 to 30 mm. Within the orbital apex, the optic nerve is surrounded by dura, arachnoid, and pia mater. The subarachnoid space contains cerebrospinal fluid continuous with that of the brain and spinal cord. The dural covering fuses with the sclera around the optic nerve and more posteriorly with the periosteum of the optic canal. The nerve courses through the annulus of Zinn, which contains the connective tissue origins of the superior, medial, lateral, and inferior rectus muscles.",
"     </li>",
"     <li>",
"      The nerve then passes through the optic foramen into the bony optic canal, which lies posteromedially in the lesser wing of the sphenoid bone, and is about 4 to 10 mm in length. The ophthalmic artery and ocular sympathetic nerve fibers also travel through the optic canal.",
"     </li>",
"     <li>",
"      Intracranially, the optic nerve courses medially and rises at an angle of 45 degrees toward the chiasm. This segment of the optic nerve is approximately 16 mm in length and lies superior to the cavernous sinus and inferior to the frontal lobe and anterior cerebral and anterior communicating arteries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The blood supply of the optic disc and nerve is distinct from that of the retina, which is supplied by the central retinal artery. The disc is supplied by anastomosing arterioles supplied by the posterior ciliary arteries, the pial arteriole plexus, and the peripapillary choroid. The intraorbital segment receives blood from perforating branches of the ophthalmic artery, while the intracanalicular and intracranial portions are supplied by pial branches of the ophthalmic, internal carotid, anterior cerebral, and anterior communicating arteries.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optic nerve lesions usually produce monocular visual loss. Pain is a variable feature that, when present, suggests optic nerve disease. Other features common to optic neuropathy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Afferent pupillary defect if the lesion is unilateral or asymmetric",
"     </li>",
"     <li>",
"      Central vision loss (scotoma) on visual field testing",
"     </li>",
"     <li>",
"      Dyschromatopsia often out of proportion to acuity loss",
"     </li>",
"     <li>",
"      Papillitis on funduscopic examination if the optic disc is involved (",
"      <a class=\"graphic graphic_picture graphicRef66013 \" href=\"UTD.htm?41/37/42591\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef50320 \" href=\"UTD.htm?31/5/31824\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Eventual optic atrophy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical presentation varies with etiology. Many are acute, but some etiologies are associated with a more subacute or even a chronic progressive course. Ophthalmologic examination and magnetic resonance imaging of the brain and orbits are often essential to the diagnosis. In other cases, lumbar puncture with spinal fluid examination and other tests are required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optic neuritis is the most common cause of optic nerve disease in younger adults, while ischemic optic neuropathy is the most common etiology in older patients. The clinical features of the more common optic neuropathies are summarized in the Tables (",
"    <a class=\"graphic graphic_table graphicRef75945 \" href=\"UTD.htm?20/31/20988\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef51786 \" href=\"UTD.htm?42/48/43788\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ischemic optic neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic optic neuropathy is more common in patients over age 50. Ischemic optic neuropathy is generally categorized as anterior (affecting the optic disc) versus posterior (retrobulbar) and as arteritic versus nonarteritic. Anterior involvement is usual with both arteritic and nonarteritic ischemic optic neuropathy (AION and NAION). Posterior ischemic optic neuropathy (PION) can also be either due to arteritic and nonarteritic etiologies, but should raise the suspicion of arteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Nonconventional etiologies, such as acute volume loss, hypotension, and associated surgical procedures (cardiac or spinal surgery) are more common in PION [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Nonarteritic ischemic optic neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonarteritic anterior ischemic optic neuropathy (NAION) is the most common form of ischemic optic neuropathy. It is an idiopathic, ischemic insult of the optic nerve head characterized by acute, monocular, painless visual loss with optic disc swelling (",
"    <a class=\"graphic graphic_picture graphicRef54510 \" href=\"UTD.htm?3/5/3152\">",
"     picture 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/7\">",
"     7",
"    </a>",
"    ]. Visual loss occurs due to poor perfusion in the circulation of the posterior ciliary artery, which supplies the optic nerve head [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients are usually older than 50 years and often have hypertension, diabetes mellitus, and other vascular risk factors.",
"   </p>",
"   <p>",
"    Patients frequently notice the vision loss first upon waking up in the morning [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/9\">",
"     9",
"    </a>",
"    ]. There is usually decreased visual acuity and an altitudinal visual field defect. The disc appears swollen and may have splinter hemorrhages (",
"    <a class=\"graphic graphic_picture graphicRef54510 \" href=\"UTD.htm?3/5/3152\">",
"     picture 3",
"    </a>",
"    ). The cup of the involved disc is typically small. If the fellow eye also has a small cup, it is considered to be at risk for future ischemic events. Magnetic resonance imaging (MRI) usually does not show enhancement or signal abnormality in the optic nerve. This is contrast to optic neuritis, which almost always produces an MRI abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis for visual recovery is relatively poor (in contrast to optic neuritis). There is no effective treatment; optic nerve decompression is not effective [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Recurrent events in the same eye are very rare. The cumulative risk of vision loss in the opposite eye is 14.7 percent over the next five years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/13\">",
"     13",
"    </a>",
"    ]. There is usually an interval of several months or years between these events. Involvement of both eyes in rapid succession strongly suggests arteritis. There is no evidence that antiplatelet therapy reduces the risk of contralateral involvement; however, most patients are treated with antiplatelet therapy on the basis of their underlying vascular risk factors.",
"   </p>",
"   <p>",
"    Nonarteritic ischemic optic neuropathy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=see_link\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27558?source=see_link\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9929?source=see_link\">",
"     \"Nonarteritic ischemic optic neuropathy: Prognosis and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35943?source=see_link\">",
"     \"Posterior ischemic optic neuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Arteritic ischemic optic neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arteritic anterior ischemic optic neuropathy occurs primarily in patients older than 70 years and is usually due to giant cell arteritis (GCA). GCA has a significant association with polymyalgia rheumatica, a constellation of symptoms that includes jaw claudication, proximal myalgias and arthralgias, scalp tenderness, headache, and fatigue along with a significantly elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).",
"   </p>",
"   <p>",
"    Funduscopic examination demonstrates a pale, swollen disc, peripapillary hemorrhages, branch or central retinal artery occlusions, or cotton wool spots. Temporal artery biopsy is the gold standard for diagnosis, but treatment with corticosteroids should not be delayed pending biopsy or results [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/8\">",
"     8",
"    </a>",
"    ]. Thrombocytosis has been associated with a higher risk of permanent vision loss in patients with GCA [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/14\">",
"     14",
"    </a>",
"    ]. Binocular involvement occurs in a third of cases, often within the first day.",
"   </p>",
"   <p>",
"    This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8166?source=see_link\">",
"     \"Pathogenesis of giant cell (temporal) arteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34599?source=see_link\">",
"     \"Diagnosis of giant cell (temporal) arteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34217?source=see_link\">",
"     \"Treatment of giant cell (temporal) arteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Optic neuritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optic neuritis is an inflammatory, demyelinating condition that is highly associated with multiple sclerosis (MS), occurring in 50 percent of individuals at some course of their illness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients typically present with acute, often painful visual loss, which is usually monocular. Individuals are typically between the ages of 18 and 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/15\">",
"     15",
"    </a>",
"    ]. Symptoms develop over a few to several days, reaching maximum severity within two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/18\">",
"     18",
"    </a>",
"    ]. Most cases (two-thirds) are retrobulbar with a normal fundus appearance (",
"    <a class=\"graphic graphic_picture graphicRef66013 \" href=\"UTD.htm?41/37/42591\">",
"     picture 1",
"    </a>",
"    ), while one-third have papillitis on presentation (",
"    <a class=\"graphic graphic_picture graphicRef50320 \" href=\"UTD.htm?31/5/31824\">",
"     picture 2",
"    </a>",
"    ). Gadolinium-enhanced magnetic resonance imaging (MRI) demonstrates optic nerve inflammation in 95 percent of patients (",
"    <a class=\"graphic graphic_picture graphicRef50320 \" href=\"UTD.htm?31/5/31824\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/19\">",
"     19",
"    </a>",
"    ]. Visual recovery is common and often complete; most patients achieve better than",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    vision at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/18\">",
"     18",
"    </a>",
"    ]. Visual recovery is less likely, but still common in those with more severe visual loss at presentation.",
"   </p>",
"   <p>",
"    Final visual outcomes are not influenced by treatment, but recovery can be hastened by intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/20\">",
"     20",
"    </a>",
"    ]. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy is not recommended because of increased risk of recurrent optic neuritis seen in one treatment trial. Patients at high risk for multiple sclerosis, assessed on the basis of MRI, may benefit from immunomodulatory therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9464?source=see_link\">",
"     \"Optic neuritis: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optic neuritis may complicate meningitis or encephalitis of any cause either as a direct effect of the infectious organism or from a secondary vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/21\">",
"     21",
"    </a>",
"    ]. West Nile virus in particular has been reported to produce optic neuritis in association with meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Typically in these conditions, other symptoms and signs of underlying infection, as well as MRI and CSF findings, point to the underlying cause. When the meningitis is more indolent, as with some cases of tuberculosis and cryptococcus, optic nerve involvement may be a primary manifestation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute viral infections, as well as cat scratch disease and toxoplasmosis and others, can cause an isolated infection of the eye. These typically produce inflammation of the retina along with the optic disc, so-called neuroretinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. Funduscopic examination usually reveals macular edema, in addition to optic disk swelling. Macular exudates form within days, often in a star-shaped pattern, \"macular star.\" This finding helps to distinguish neuroretinitis from optic neuritis. Systemic antibiotics when appropriate and corticosteroids have been reported to produce improvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37925?source=see_link\">",
"     \"Treatment of cat scratch disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=see_link\">",
"     \"Toxoplasmosis in immunocompetent hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Syphilitic optic neuritis may be monocular or binocular, and is associated with vitreal inflammation, a feature that helps to distinguish this from optic neuritis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Antibiotic therapy is associated with recovery, but patients may relapse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26312?source=see_link\">",
"     \"Neurosyphilis\"",
"    </a>",
"    .) Lyme disease is an uncertain cause of retrobulbar optic neuritis but may cause papillitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Inflammatory optic neuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory optic neuropathies may be due to: parainfectious causes, systemic connective tissue disease, and other local or systemic inflammatory conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Parainfectious",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postviral optic neuritis has been associated with measles, mumps, chickenpox, influenza, and Epstein-Barr, typically following the clinical infection by one to three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/35\">",
"     35",
"    </a>",
"    ]. It also can occur as a postvaccination phenomenon. More common in children than adults and more frequently bilateral than optic neuritis, an immune mediated process is likely. Papillitis, frequently with retinitis, is common, and there may also be a meningoencephalitis with typical MRI and CSF changes. Visual recovery is usually excellent, even with no treatment. Corticosteroids may or may not hasten recovery, but this treatment is reasonable to consider, particularly in cases of bilateral, severe visual loss. Some consider this a forme fruste of acute disseminated encephalomyelitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/52/25416?source=see_link&amp;anchor=H10#H10\">",
"     \"Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bilateral optic neuritis can also occur in the Guillain-Barr&eacute; syndrome. Papillitis is common in this setting. Published case reports frequently report an antecedent infection with mycoplasma pneumoniae and recovery with treatment of Guillain-Barr&eacute; syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=see_link\">",
"     \"Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Sarcoidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optic neuropathy occurs in about 5 percent of patients with sarcoidosis and may be the initial manifestation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/10,38\">",
"     10,38",
"    </a>",
"    ]. Clinical features are similar to optic neuritis. Bilateral involvement has been reported in 24 to 64 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. The optic disc may have a nodular appearance, representing the granulomatous infiltration. MRI can demonstrate signal abnormality and nerve thickening with gadolinium enhancement that may be generalized, nodular, or meningeal. Other cerebral parenchymal lesions and more widespread meningitis may also be seen on MRI. Visual recovery often follows corticosteroid treatment, but some patients have permanent vision loss [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/38\">",
"     38",
"    </a>",
"    ]. Relapsing vision loss following a short course of corticosteroids for presumed optic neuritis is a clue to this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=see_link\">",
"     \"Neurologic sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Systemic autoimmune disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optic neuritis is a rare manifestation of other systemic inflammatory or connective tissue disease and usually occurs in the setting of an established diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/40\">",
"     40",
"    </a>",
"    ]. The mechanisms and therefore presentations of optic nerve involvement vary with the disorder. In some cases, optic neuritis may represent shared coincidence of autoimmune diseases, rather than a primary manifestation of the systemic disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic lupus erythematosus (SLE). Optic nerve involvement occurs in about 1 percent of patients with SLE and may be due to vasculitis or to thrombosis secondary to antiphospholipid antibody syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/40-42\">",
"       40-42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sj&ouml;gren&rsquo;s syndrome (SS). Optic neuritis may be the presenting symptom of this disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/40,43\">",
"       40,43",
"      </a>",
"      ]. In one eight-year, retrospective review of 82 patients with SS, 16 percent had optic neuritis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Wegener's granulomatosis. Extension of inflammation in the sinus and parasinus areas can produce optic neuritis, usually with other orbital signs [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Beh&ccedil;et&rsquo;s disease. Despite producing severe meningitis and uveitis, optic neuritis is a rare complication in this disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/40,46\">",
"       40,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inflammatory bowel disease. The higher than expected incidence of optic neuritis in these disorders may reflect coincidence of autoimmune diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/47,48\">",
"       47,48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Paraneoplastic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paraneoplastic optic neuritis has been described in a few reports, usually in association with paraneoplastic encephalomyelitis or retinitis and small cell lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/49-51\">",
"     49-51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Compressive optic neuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this category of disorders, gradual vision loss is the more usual presentation, as expected with slowly growing lesions; however, the presentation can be acute. Pain is variable. MRI of the brain and orbits will confirm or rule out diagnoses associated with compressive optic neuropathy. Corticosteroid therapy may produce early visual improvement due to reduction in edema, and therefore may be misleading as to the underlying etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of tumors can produce optic nerve compression. Sellar and parasellar masses (craniopharyngioma, meningioma, or pituitary adenoma), optic nerve sheath meningiomas, and metastatic lesions are included in the differential diagnosis.",
"   </p>",
"   <p>",
"    Tumors, particularly optic nerve gliomas associated with neurofibromatosis, but also lymphoma and other hematologic malignancies, can also infiltrate rather than compress the optic nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optic nerve can be compressed by other, nonneoplastic processes within the orbit or subarachnoid space. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dysthyroid ophthalmopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=see_link\">",
"       \"Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Carotid-ophthalmic artery aneurysms",
"     </li>",
"     <li>",
"      Abscess",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Idiopathic intracranial hypertension or pseudotumor cerebri can lead to a bilateral optic neuropathy. Patients usually present with headache sometimes accompanied by horizontal diplopia. Vision loss may be slowly progressive or may appear abruptly. Funduscopic examination reveals papilledema. Visual field defects are characterized by enlarged blind spot",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    generalized constriction. If untreated, patients may become blind. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=see_link\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Genetic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two of the more common of the genetic causes of optic neuropathy are Leber's hereditary optic neuropathy and Kjer's disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H309502\">",
"    <span class=\"h3\">",
"     Leber's hereditary optic neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this disorder, vision loss is subacute and painless, with sequential involvement of both eyes over a period of weeks to months.",
"   </p>",
"   <p>",
"    This disorder effects young males predominantly (80 to 90 percent of patients) and is inherited through a mitochondrial DNA mutation. Three mutations at positions 11,778, 3460, and 14,484 are responsible for greater than 90 percent of all cases of Leber's [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/54\">",
"     54",
"    </a>",
"    ]. These genes are involved in complex I of the mitochondrial respiratory chain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Funduscopic examination usually shows circumpapillary telangiectasia, but up to one-third of patients can have a normal appearing disc. Nerve fiber layer swelling around the disc can be seen, although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography does not show leakage from the disc or papillary area [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/56\">",
"     56",
"    </a>",
"    ]. Central vision is affected more severely. MRI can show signal abnormality in the optic nerves, but enhancement usually does not occur [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/10,57,58\">",
"     10,57,58",
"    </a>",
"    ]. Prognosis for recovery varies depending on the mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link&amp;anchor=H23#H23\">",
"     \"Hereditary neuropathies associated with generalized disorders\", section on 'Leber hereditary optic neuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H309509\">",
"    <span class=\"h3\">",
"     Kjer type autosomal dominant optic atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;This entity primarily affects children in the first decade of life with slowly progressive, bilateral loss of vision. As with other optic neuropathies, there is pallor of the optic disc, cecocentral scotoma, and color vision loss. The OPA1 gene located on chromosome 3q28 has been implicated in the majority of patients with dominant optic atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Toxic and metabolic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxic metabolic causes of optic neuropathy include an extensive list of possible agents. Typically involvement is bilateral; onset may be abrupt or slowly progressive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Drugs and toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of toxins and drugs have been associated with optic neuropathy (",
"    <a class=\"graphic graphic_table graphicRef57497 \" href=\"UTD.htm?31/55/32636\">",
"     table 3",
"    </a>",
"    ). In many cases of toxin exposure, the visual loss is severe and permanent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients experiencing vision loss as an adverse effect of medications can have limited impairment if the vision loss is detected early and the drug discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/61\">",
"     61",
"    </a>",
"    ]. Most of these medications are believed to have direct toxic effects on the optic nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/62\">",
"     62",
"    </a>",
"    ]. Of these, the risks associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    are perhaps best characterized [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30757?source=see_link&amp;anchor=H15#H15\">",
"     \"Ethambutol: An overview\", section on 'Visual changes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other medications are believed to affect the optic nerve indirectly through other mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      is believed to cause an autoimmune optic neuritis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/64,65\">",
"       64,65",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"       \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Several cases of severe optic neuropathy in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      for glioblastoma were summarized in a 2009 report [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/66\">",
"       66",
"      </a>",
"      ]. The mechanism is uncertain, however, vascular etiologies, drug-induced sensitivity to radiation, and direct toxic effects are possible.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"       Sildenafil",
"      </a>",
"      and other drugs prescribed for erectile dysfunction have been reported to produce a nonarteritic ischemic optic neuropathy (NAION) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/67,68\">",
"       67,68",
"      </a>",
"      ]. An association is not proven; however, the close temporal proximity of drug administration and symptoms in these cases suggest cause and effect. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Ischemic optic neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      's association with optic neuropathy remains somewhat controversial [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/69,70\">",
"       69,70",
"      </a>",
"      ]. Some cases appear indistinguishable from NAION. Other reported cases of a more insidious onset with slow progression and simultaneous bilateral involvement suggest a more direct toxic effect. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link&amp;anchor=H14#H14\">",
"       \"Major side effects of amiodarone\", section on 'Optic neuropathy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Nutritional deficiencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional deficiencies are presumed to have played a role in endemic optic neuropathy reported under conditions of deprivation, such as in prisoners of war (eg, Cuba in the 1990s, southeast Asia during World War II) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. Specific deficiencies of vitamins B12, B1, and folate have been implicated. Most nutritional optic neuropathies appear to be exacerbated by tobacco and possibly alcoholism (tobacco-alcohol amblyopia) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/74\">",
"     74",
"    </a>",
"    ]. Vision loss may be unilateral or bilateral, and can have an acute, subacute, or slowly progressive presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/73\">",
"     73",
"    </a>",
"    ]. MRI is typically normal [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/10,75\">",
"     10,75",
"    </a>",
"    ]. Early vitamin supplementation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    smoking cessation have been anecdotally associated with visual recovery, but this is not guaranteed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation-induced damage of the optic nerves",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chiasm can occur 6 to 24 months after radiation therapy, usually for nasal carcinoma. In one series of 219 patients who received radiotherapy for carcinomas of the nasal or paranasal region, retinopathy occurred in seven, optic neuropathy with blindness in eight, and chiasm damage with bilateral visual impairment in one [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/76\">",
"     76",
"    </a>",
"    ]. These complications are rare with doses of radiation less than 50 Gy. The vision loss is usually slowly progressive, and there is no treatment proven to be effective. MRI may show signal abnormality with enhancement in the optic nerve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=see_link&amp;anchor=H32#H32\">",
"     \"Complications of cranial irradiation\", section on 'Optic neuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Closed head injury may damage the optic nerve, usually affecting the intraorbital or intracanalicular segments. The mechanism may be contusion or hemorrhage; rarely the optic nerve is transected or avulsed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. In the latter case, vision does not improve. Otherwise, the prognosis depends upon the extent of the injury; about half of patients recover. Imaging studies and an ophthalmologic consult are indicated to evaluate for pathologies (optic nerve sheath hematoma, orbital hemorrhage) that require surgery. Surgical decompression and high-dose corticosteroids are sometimes used but are not of proven benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4969/abstract/79-81\">",
"     79-81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/30/10722?source=see_link\">",
"       \"Patient information: Optic neuritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An optic nerve lesion produces visual loss, usually monocular. Other clinical features can include dyschromatopsia, pain (especially with eye movement), and papillitis, depending on the etiology. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The potential causes of optic neuropathy are diverse (",
"      <a class=\"graphic graphic_table graphicRef75945 \" href=\"UTD.htm?20/31/20988\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optic neuritis is the most common cause of optic nerve disease in younger adults, while ischemic optic neuropathy is the most common etiology in older patients. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Ischemic optic neuropathy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Optic neuritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Associated demographic and clinical features, including age and gender, the presence of pain, papillitis, or bilateral involvement, and the acuity of presentation, are useful to identify the most likely etiology (",
"      <a class=\"graphic graphic_table graphicRef51786 \" href=\"UTD.htm?42/48/43788\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef63122 \" href=\"UTD.htm?28/11/28848\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Giant cell arteritis should always be considered in the differential diagnosis of optic neuropathy in individuals over 50 years, because of its potential for permanent vision loss which can be prevented by prompt intervention. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Arteritic ischemic optic neuropathy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Glaser JS. Topical diagnosis: Prechiasmal visual pathways. In: Neuro-ophthalmology, Glaser JS (Ed), JB Lippincott, Philadelphia 1990. p.83.",
"    </li>",
"    <li>",
"     Sadun AA. The afferent visual system: Anatomy and Physiology. In: Ophthalmology, 2nd, Yanoff M, Duker JS (Eds), Mosby, St. Louis 2004. p.186.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/3\">",
"      Hayreh SS. Posterior ischaemic optic neuropathy: clinical features, pathogenesis, and management. Eye (Lond) 2004; 18:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/4\">",
"      Sadda SR, Nee M, Miller NR, et al. Clinical spectrum of posterior ischemic optic neuropathy. Am J Ophthalmol 2001; 132:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/5\">",
"      Buono LM, Foroozan R. Perioperative posterior ischemic optic neuropathy: review of the literature. Surv Ophthalmol 2005; 50:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/6\">",
"      Dunker S, Hsu HY, Sebag J, Sadun AA. Perioperative risk factors for posterior ischemic optic neuropathy. J Am Coll Surg 2002; 194:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/7\">",
"      Swartz NG, Beck RW, Savino PJ, et al. Pain in anterior ischemic optic neuropathy. J Neuroophthalmol 1995; 15:9.",
"     </a>",
"    </li>",
"    <li>",
"     Liu GT. Visual loss: optic neuropathies. In: Neuro-Ophthalmology: Diagnosis and Management, Liu GT, Volpe NJ, Galetta SL (Eds), WB Saunders, Philadelphia 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/9\">",
"      Arnold AC. Ischemic optic neuropathies. Ophthalmol Clin North Am 2001; 14:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/10\">",
"      Gass A, Moseley IF. The contribution of magnetic resonance imaging in the differential diagnosis of optic nerve damage. J Neurol Sci 2000; 172 Suppl 1:S17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/11\">",
"      Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. The Ischemic Optic Neuropathy Decompression Trial Research Group. JAMA 1995; 273:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/12\">",
"      Dickersin K, Manheimer E, Li T. Surgery for nonarteritic anterior ischemic optic neuropathy. Cochrane Database Syst Rev 2006; :CD001538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/13\">",
"      Newman NJ, Scherer R, Langenberg P, et al. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol 2002; 134:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/14\">",
"      Liozon E, Herrmann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 2001; 111:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/15\">",
"      Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med 2006; 354:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/16\">",
"      Foroozan R, Buono LM, Savino PJ, Sergott RC. Acute demyelinating optic neuritis. Curr Opin Ophthalmol 2002; 13:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/17\">",
"      Frohman EM, Frohman TC, Zee DS, et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005; 4:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/18\">",
"      The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol 1991; 109:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/19\">",
"      Rizzo JF 3rd, Andreoli CM, Rabinov JD. Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2002; 109:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/20\">",
"      Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/21\">",
"      Lee AG, Brazis PW. Systemic infections of neuro-ophthalmic significance. Ophthalmol Clin North Am 2004; 17:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/22\">",
"      Anninger WV, Lomeo MD, Dingle J, et al. West Nile virus-associated optic neuritis and chorioretinitis. Am J Ophthalmol 2003; 136:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/23\">",
"      Chan CK, Limstrom SA, Tarasewicz DG, Lin SG. Ocular features of west nile virus infection in North America: a study of 14 eyes. Ophthalmology 2006; 113:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/24\">",
"      Golnik KC. Infectious optic neuropathy. Semin Ophthalmol 2002; 17:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/25\">",
"      Venkatesh P, Garg SP, Verma L, et al. Combined optic neuropathy and central retinal artery occlusion in miliary tuberculosis. Retina 2001; 21:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/26\">",
"      Rex JH, Larsen RA, Dismukes WE, et al. Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine (Baltimore) 1993; 72:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/27\">",
"      Fukushima A, Yasuoka M, Tsukahara M, Ueno H. A case of cat scratch disease neuroretinitis confirmed by polymerase chain reaction. Jpn J Ophthalmol 2003; 47:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/28\">",
"      Gilden DH, Mahalingam R, Cohrs RJ, Tyler KL. Herpesvirus infections of the nervous system. Nat Clin Pract Neurol 2007; 3:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/29\">",
"      K&uuml;&ccedil;&uuml;kerd&ouml;nmez C, Akova YA, Yilmaz G. Ocular toxoplasmosis presenting as neuroretinitis: report of two cases. Ocul Immunol Inflamm 2002; 10:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/30\">",
"      Benz MS, Glaser JS, Davis JL. Progressive outer retinal necrosis in immunocompetent patients treated initially for optic neuropathy with systemic corticosteroids. Am J Ophthalmol 2003; 135:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/31\">",
"      Ray S, Gragoudas E. Neuroretinitis. Int Ophthalmol Clin 2001; 41:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/32\">",
"      Smith GT, Goldmeier D, Migdal C. Neurosyphilis with optic neuritis: an update. Postgrad Med J 2006; 82:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/33\">",
"      Sibony P, Halperin J, Coyle PK, Patel K. Reactive Lyme serology in optic neuritis. J Neuroophthalmol 2005; 25:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/34\">",
"      Krim E, Guehl D, Burbaud P, Lagueny A. Retrobulbar optic neuritis: a complication of Lyme disease? J Neurol Neurosurg Psychiatry 2007; 78:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/35\">",
"      Farris BK, Pickard DJ. Bilateral postinfectious optic neuritis and intravenous steroid therapy in children. Ophthalmology 1990; 97:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/36\">",
"      Ginestal RC, Plaza JF, Callejo JM, et al. Bilateral optic neuritis and Guillain-Barr&eacute; syndrome following an acute Mycoplasma pneumoniae infection. J Neurol 2004; 251:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/37\">",
"      Pfausler B, Engelhardt K, Kampfl A, et al. Post-infectious central and peripheral nervous system diseases complicating Mycoplasma pneumoniae infection. Report of three cases and review of the literature. Eur J Neurol 2002; 9:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/38\">",
"      Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM 2009; 102:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/39\">",
"      Joseph FG, Scolding NJ. Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatry 2009; 80:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/40\">",
"      Theodoridou A, Settas L. Demyelination in rheumatic diseases. J Neurol Neurosurg Psychiatry 2006; 77:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/41\">",
"      Jabs DA, Miller NR, Newman SA, et al. Optic neuropathy in systemic lupus erythematosus. Arch Ophthalmol 1986; 104:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/42\">",
"      Giorgi D, Balacco Gabrieli C. Optic neuropathy in systemic lupus erythematosus and antiphospholipid syndrome (APS): clinical features, pathogenesis, review of the literature and proposed ophthalmological criteria for APS diagnosis. Clin Rheumatol 1999; 18:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/43\">",
"      Rabadi MH, Kundi S, Brett D, Padmanabhan R. Neurological pictures. Primary Sj&ouml;gren syndrome presenting as neuromyelitis optica. J Neurol Neurosurg Psychiatry 2010; 81:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/44\">",
"      Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sj&ouml;gren syndrome: a study of 82 patients. Medicine (Baltimore) 2004; 83:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/45\">",
"      Monteiro ML, Borges WI, do Val Ferreira Ramos C, et al. Bilateral optic neuritis in wegener granulomatosis. J Neuroophthalmol 2005; 25:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/46\">",
"      Kansu T, Kirkali P, Kansu E, Zileli T. Optic neuropathy in Beh&ccedil;et's disease. J Clin Neuroophthalmol 1989; 9:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/47\">",
"      Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005; 129:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/48\">",
"      Ernst BB, Lowder CY, Meisler DM, Gutman FA. Posterior segment manifestations of inflammatory bowel disease. Ophthalmology 1991; 98:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/49\">",
"      Pillay N, Gilbert JJ, Ebers GC, Brown JD. Internuclear ophthalmoplegia and \"optic neuritis\": paraneoplastic effects of bronchial carcinoma. Neurology 1984; 34:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/50\">",
"      Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/51\">",
"      Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003; 54:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/52\">",
"      Lee AG, Tang RA, Roberts D, et al. Primary central nervous system lymphoma involving the optic chiasm in AIDS. J Neuroophthalmol 2001; 21:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/53\">",
"      Grimm SA, McCannel CA, Omuro AM, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology 2008; 71:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/54\">",
"      Howell N. LHON and other optic nerve atrophies: the mitochondrial connection. Dev Ophthalmol 2003; 37:94.",
"     </a>",
"    </li>",
"    <li>",
"     Miller NR, Newman NJ, Biousse V, Kerrison JB. Walsh and Hoyt's Clinical Neuro-ophthalmology, Lippincott, Williams and Wilkins, Philadelphia 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/56\">",
"      Smith JL, Hoyt WF, Susac JO. Ocular fundus in acute Leber optic neuropathy. Arch Ophthalmol 1973; 90:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/57\">",
"      Kermode AG, Moseley IF, Kendall BE, et al. Magnetic resonance imaging in Leber's optic neuropathy. J Neurol Neurosurg Psychiatry 1989; 52:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/58\">",
"      Lamirel C, Cassereau J, Cochereau I, et al. Papilloedema and MRI enhancement of the prechiasmal optic nerve at the acute stage of Leber hereditary optic neuropathy. J Neurol Neurosurg Psychiatry 2010; 81:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/59\">",
"      Votruba M, Thiselton D, Bhattacharya SS. Optic disc morphology of patients with OPA1 autosomal dominant optic atrophy. Br J Ophthalmol 2003; 87:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/60\">",
"      Alexander C, Votruba M, Pesch UE, et al. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet 2000; 26:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/61\">",
"      Kerrison JB. Optic neuropathies caused by toxins and adverse drug reactions. Ophthalmol Clin North Am 2004; 17:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/62\">",
"      McKinley SH, Foroozan R. Optic neuropathy associated with linezolid treatment. J Neuroophthalmol 2005; 25:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/63\">",
"      Melamud A, Kosmorsky GS, Lee MS. Ocular ethambutol toxicity. Mayo Clin Proc 2003; 78:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/64\">",
"      ten Tusscher MP, Jacobs PJ, Busch MJ, et al. Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ 2003; 326:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/65\">",
"      Foroozan R, Buono LM, Sergott RC, Savino PJ. Retrobulbar optic neuritis associated with infliximab. Arch Ophthalmol 2002; 120:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/66\">",
"      Sherman JH, Aregawi DG, Lai A, et al. Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology 2009; 73:1924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/67\">",
"      Hayreh SS. Erectile dysfunction drugs and non-arteritic anterior ischemic optic neuropathy: is there a cause and effect relationship? J Neuroophthalmol 2005; 25:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/68\">",
"      Pomeranz HD, Bhavsar AR. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases. J Neuroophthalmol 2005; 25:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/69\">",
"      Chen D, Hedges TR. Amiodarone optic neuropathy--review. Semin Ophthalmol 2003; 18:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/70\">",
"      Nagra PK, Foroozan R, Savino PJ, et al. Amiodarone induced optic neuropathy. Br J Ophthalmol 2003; 87:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/71\">",
"      Epidemic optic neuropathy in Cuba--clinical characterization and risk factors. The Cuba Neuropathy Field Investigation Team. N Engl J Med 1995; 333:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/72\">",
"      Newman NJ. Optic neuropathy. Neurology 1996; 46:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/73\">",
"      Sadun AA. Metabolic optic neuropathies. Semin Ophthalmol 2002; 17:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/74\">",
"      Solberg Y, Rosner M, Belkin M. The association between cigarette smoking and ocular diseases. Surv Ophthalmol 1998; 42:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/75\">",
"      Kermode AG, Plant GT, Miller DH, et al. Tobacco-alcohol amblyopia: magnetic resonance imaging findings. J Neurol Neurosurg Psychiatry 1989; 52:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/76\">",
"      Jiang GL, Tucker SL, Guttenberger R, et al. Radiation-induced injury to the visual pathway. Radiother Oncol 1994; 30:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/77\">",
"      Simsek T, Simsek E, Ilhan B, et al. Traumatic optic nerve avulsion. J Pediatr Ophthalmol Strabismus 2006; 43:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/78\">",
"      Sarkies N. Traumatic optic neuropathy. Eye (Lond) 2004; 18:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/79\">",
"      Yu Wai Man P, Griffiths PG. Surgery for traumatic optic neuropathy. Cochrane Database Syst Rev 2005; :CD005024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/80\">",
"      Levin LA, Beck RW, Joseph MP, et al. The treatment of traumatic optic neuropathy: the International Optic Nerve Trauma Study. Ophthalmology 1999; 106:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4969/abstract/81\">",
"      Steinsapir KD. Treatment of traumatic optic neuropathy with high-dose corticosteroid. J Neuroophthalmol 2006; 26:65.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5244 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-593C6D74E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_54_4969=[""].join("\n");
var outline_f4_54_4969=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ischemic optic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Nonarteritic ischemic optic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Arteritic ischemic optic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Optic neuritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Inflammatory optic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Parainfectious",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Systemic autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Paraneoplastic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Compressive optic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Neoplasia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Genetic causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H309502\">",
"      - Leber's hereditary optic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H309509\">",
"      - Kjer type autosomal dominant optic atrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Toxic and metabolic causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Drugs and toxins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Nutritional deficiencies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5244\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5244|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?28/11/28848\" title=\"algorithm 1\">",
"      Approach to acute optic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5244|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/37/42591\" title=\"picture 1\">",
"      Normal fundus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/5/31824\" title=\"picture 2\">",
"      Optic neuritis fundus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/5/3152\" title=\"picture 3\">",
"      NAION fundus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5244|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/31/20988\" title=\"table 1\">",
"      Causes of optic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/48/43788\" title=\"table 2\">",
"      Clinical features of common optic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/55/32636\" title=\"table 3\">",
"      Toxic optic neuropathies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/52/25416?source=related_link\">",
"      Acute disseminated encephalomyelitis in children: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/22/37226?source=related_link\">",
"      Complications of cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34599?source=related_link\">",
"      Diagnosis of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30757?source=related_link\">",
"      Ethambutol: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17417?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20616?source=related_link\">",
"      Neurologic sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/44/26312?source=related_link\">",
"      Neurosyphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27558?source=related_link\">",
"      Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20442?source=related_link\">",
"      Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9929?source=related_link\">",
"      Nonarteritic ischemic optic neuropathy: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/15/9464?source=related_link\">",
"      Optic neuritis: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=related_link\">",
"      Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8166?source=related_link\">",
"      Pathogenesis of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/30/10722?source=related_link\">",
"      Patient information: Optic neuritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/6/35943?source=related_link\">",
"      Posterior ischemic optic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=related_link\">",
"      Toxoplasmosis in immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=related_link\">",
"      Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/2/37925?source=related_link\">",
"      Treatment of cat scratch disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34217?source=related_link\">",
"      Treatment of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_54_4970="Overview of endoscopic resection of gastrointestinal tumors";
var content_f4_54_4970=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of endoscopic resection of gastrointestinal tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/54/4970/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/54/4970/contributors\">",
"     Naresh T Gunaratnam, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/54/4970/contributors\">",
"     Mustafa Kathawala, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/54/4970/contributors\">",
"     Christopher Gostout, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/54/4970/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/54/4970/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/54/4970/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/54/4970/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/54/4970/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic resection (ER) is an endoscopic alternative to surgical resection of mucosal and submucosal neoplastic lesions and intramucosal cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/1\">",
"     1",
"    </a>",
"    ]. ER includes endoscopic mucosal resection (EMR), which involves snare resection of dysplastic lesions, and endoscopic submucosal dissection (ESD) in which endoscopic tools are used to dissect lesions from the submucosa. ER offers both diagnostic and therapeutic capability. Lesions limited to the mucosa and the superficial layers of the submucosa appear to be the most amenable to endoscopic cure.",
"   </p>",
"   <p>",
"    This topic will provide an overview of ER for gastrointestinal tumors. Additional information on ER for the removal of superficial esophageal cancer, high-grade dysplasia in patients with Barrett's esophagus, early gastric cancer, and large colon polyps can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20426?source=see_link\">",
"     \"Management of superficial esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10858?source=see_link\">",
"     \"Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=see_link\">",
"     \"Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28968?source=see_link\">",
"     \"Endoscopic removal of large colonic polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1942271\">",
"    <span class=\"h1\">",
"     LESION CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The greatest experience with ER has come from Japan, where the Japanese Society for Gastroenterological Endoscopy (JSGE) has developed a classification system based upon visual and endosonographic features. The system was developed in an attempt to codify the indications and outcomes related to ER [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/2\">",
"     2",
"    </a>",
"    ]. Although it was developed for early gastric cancer, it can also be applied to cancers at other sites in the gastrointestinal tract. The system recognizes four types of early endoluminal cancers (",
"    <a class=\"graphic graphic_table graphicRef71003 \" href=\"UTD.htm?18/35/19003\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef82731 \" href=\"UTD.htm?2/59/2994\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I lesions are polypoid or protuberant and are subcategorized as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ip &ndash; pedunculated",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Ips/sp",
"      </span>",
"      &ndash; subpedunculated",
"     </li>",
"     <li>",
"      Is &ndash; sessile",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type II lesions are flat and are further subcategorized as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      IIa &ndash; superficial elevated",
"     </li>",
"     <li>",
"      IIb &ndash; flat",
"     </li>",
"     <li>",
"      IIc &ndash; flat depressed",
"     </li>",
"     <li>",
"      IIc+IIa lesions &ndash; elevated area within a depressed lesion",
"     </li>",
"     <li>",
"      IIa+IIc lesions &ndash; depressed area within an elevated lesion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type III lesions are ulcerated",
"     </li>",
"     <li>",
"      Type IV lesions are lateral spreading",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A newer classification system, the Paris system, was proposed at a consensus development meeting held in Paris in 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/3\">",
"     3",
"    </a>",
"    ]. Superficial lesions (type 0) can be classified as polypoid, nonpolypoid or excavated (",
"    <a class=\"graphic graphic_table graphicRef50239 \" href=\"UTD.htm?12/56/13195\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef61277 \" href=\"UTD.htm?43/19/44348\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 0-I lesions are polypoid are subcategorized as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Type 0-Ip &ndash; protruded, pedunculated",
"     </li>",
"     <li>",
"      Type 0-Is &ndash; protruded, sessile",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 0-II lesions are nonpolypoid and are subcategorized as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Type 0-IIa &ndash; slightly elevated",
"     </li>",
"     <li>",
"      Type 0-IIb &ndash; flat",
"     </li>",
"     <li>",
"      Type 0-IIc &ndash; slightly depressed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 0-III lesions are excavated",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for ER are evolving and include the treatment of early esophageal, gastric, and colon cancers. Endoscopists in the United States are increasingly utilizing ER techniques as commercially available devices evolve that are easier to use, such as band assisted polypectomy devices. ER is also used to treat dysplasia in the setting of Barrett's esophagus and for the removal of large colon polyps. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10858?source=see_link\">",
"     \"Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28968?source=see_link&amp;anchor=H7#H7\">",
"     \"Endoscopic removal of large colonic polyps\", section on 'Endoscopic mucosal resection using piecemeal excision'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1942720\">",
"    <span class=\"h2\">",
"     Esophageal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have described successful ER in patients with superficial esophageal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/4-13\">",
"     4-13",
"    </a>",
"    ] or with high-grade dysplasia (HGD) in Barrett's esophagus (BE) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/4,14,15\">",
"     4,14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20426?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of superficial esophageal cancer\", section on 'Endoscopic mucosal resection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=see_link\">",
"     \"Management of Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10858?source=see_link\">",
"     \"Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with esophageal cancer or high-grade dysplasia, ER is increasingly used in conjunction with radiofrequency ablation (RFA) techniques. If adenocarcinoma or HGD that is confined to the mucosa is identified, then RFA and further ER may be appropriate treatment. However if invasion into the sub-mucosa is identified, then other treatment options should be considered given the high rate of nodal metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/53/41817?source=see_link\">",
"     \"Radiofrequency ablation for Barrett's esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Esophageal cancers are amenable to ER if they (",
"    <a class=\"graphic graphic_table graphicRef61975 \" href=\"UTD.htm?0/61/988\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/4,17,18\">",
"     4,17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Have a diameter of &le;2 cm",
"     </li>",
"     <li>",
"      Involve less than one-third of the circumference of the esophageal wall",
"     </li>",
"     <li>",
"      Are limited to the mucosa of the esophagus",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gastric cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies suggest that ER is an effective treatment for early gastric adenocarcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4842?source=see_link&amp;anchor=H757935984#H757935984\">",
"     \"Early gastric cancer: Treatment, natural history, and prognosis\", section on 'Endoscopic mucosal resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A review summarized the results of 12 Japanese studies of EMR with 1852 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/19\">",
"     19",
"    </a>",
"    ]. Ten studies adhered to the JSGE criteria for ER. Complete resection was possible in 1353 patients (74 percent). Recurrent cancer was detected in 35 of the completely resected patients (3 percent). In the nine studies reporting follow-up from four months to 11 years, there was only one death secondary to metastatic cancer (a disease-specific survival of 99 percent).",
"   </p>",
"   <p>",
"    Whether these results can be generalized to other populations is unclear since the criteria used by Japanese pathologists in establishing the diagnosis of early gastric cancer versus high-grade dysplasia have not always been the same as criteria used in other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=see_link\">",
"     \"Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For early gastric cancer, the following lesions are appropriate for EMR (",
"    <a class=\"graphic graphic_table graphicRef61975 \" href=\"UTD.htm?0/61/988\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/18,21\">",
"     18,21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      JSGE type I lesions that are &le;2 cm",
"     </li>",
"     <li>",
"      JSGE type IIb and IIc lesions that are &le;1 cm",
"     </li>",
"     <li>",
"      Cancers that are limited to the mucosa",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, larger lesions and nonulcerated lesions that involve the submucosa may be appropriate for treatment with ESD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4842?source=see_link&amp;anchor=H757935977#H757935977\">",
"     \"Early gastric cancer: Treatment, natural history, and prognosis\", section on 'Standard and expanded criteria for endoscopic resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ESD has also been used in the treatment of gastric subepithelial tumors, such as gastrointestinal stromal tumors and leiomyomas. In one study with 37 patients undergoing ESD for a gastric subepithelial tumor, complete en bloc resection was achieved in 30 patients (81 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/22\">",
"     22",
"    </a>",
"    ]. Higher resection rates were seen for tumors in the submucosa compared with those from the muscularis propria (110 versus 68 percent). There were no recurrences in the patients who had complete resections after a median follow-up of 21 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Colorectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;ER can be used in the treatment of colorectal cancers, including adenocarcinoma and rectal carcinoid tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\", section on 'Rectum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inject-and-cut methods of EMR for colonic neoplasms have been reported in many series, with complete removal rates of 86 to 97 percent (see",
"    <a class=\"local\" href=\"#H10\">",
"     'ER Techniques'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Factors associated with incomplete removal include size greater than 2 cm and a large sessile configuration. A modified needle-knife demarcation technique has also been employed. In a series of 32 patients with large (&gt;3 cm) sessile neoplasms, the needle-knife technique had a 100 percent success rate (see",
"    <a class=\"local\" href=\"#H14\">",
"     'ESD techniques'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to the JSGE, colonic neoplasms that may be amenable to EMR include (",
"    <a class=\"graphic graphic_table graphicRef61975 \" href=\"UTD.htm?0/61/988\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      JSGE type I lesions that are less than 3 cm in diameter",
"     </li>",
"     <li>",
"      JSGE type IIa lesions that are less than 3 cm in diameter",
"     </li>",
"     <li>",
"      JSGE type IIb lesions that are less than 5 mm in diameter",
"     </li>",
"     <li>",
"      JSGE type IIc+IIa lesions that are less than 1 cm",
"     </li>",
"     <li>",
"      JSGE type IIa+IIc lesions that are less than 1 cm in diameter",
"     </li>",
"     <li>",
"      JSGE type IV lesions that are less than 3 cm in diameter",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depressed lesions may have invasion into the submucosa, even when they are small, and deep invasion is a contraindication to EMR. The Paris classification notes that deep invasion is more likely when [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The lesion diameter is &gt;15 mm",
"     </li>",
"     <li>",
"      The border of an elevated or depressed lesion (Paris type 0-IIa or 0-IIc, respectively) presents as a smooth circle without indentations",
"     </li>",
"     <li>",
"      The lesion fails to lift after injection with saline into the submucosa",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When determining whether a lesion is amenable to EMR, we consider the presence of any of the criteria for deep invasion identified in the Paris classification, especially the failure to lift, to be contraindications to any mucosal resection method.",
"   </p>",
"   <p>",
"    In addition to EMR, ESD is being used in the treatment of colon lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28968?source=see_link&amp;anchor=H14#H14\">",
"     \"Endoscopic removal of large colonic polyps\", section on 'Endoscopic submucosal dissection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30945920\">",
"    <span class=\"h1\">",
"     ENDOSCOPIC ULTRASOUND IN ER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic ultrasound (EUS) is a sensitive in vivo method for determining the depth of tumor penetration and thus aids with the selection of patients who have lesions that are amenable to ER. On the other hand, ER may allow for more precise determination of the depth of tumor invasion compared with EUS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/27\">",
"     27",
"    </a>",
"    ]. The role of EUS for identifying patients who are candidates for ER is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27208?source=see_link\">",
"     \"Endoscopic ultrasound in esophageal carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35509?source=see_link\">",
"     \"High frequency catheter endoscopic ultrasonography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20426?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of superficial esophageal cancer\", section on 'Endoscopic mucosal resection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10858?source=see_link\">",
"     \"Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\", section on 'Endoscopic ultrasonography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=see_link\">",
"     \"Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ER TECHNIQUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62375199\">",
"    <span class=\"h2\">",
"     EMR techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The techniques for EMR can be broadly divided into two groups: suction (suck-and-cut) and non-suction (lift-and-cut) techniques. Regardless of the resection technique, submucosal injection is often used to separate mucosal and submucosal lesions from the muscularis propria (",
"    <a class=\"graphic graphic_figure graphicRef65182 \" href=\"UTD.htm?15/34/15904\">",
"     figure 3",
"    </a>",
"    ); however, EMR in the esophagus is increasingly performed without submucosal injection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1941275\">",
"    <span class=\"h3\">",
"     Submucosal injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Submucosal injection to create an undermining submucosal fluid cushion (SFC) may decrease the incidence of perforation during EMR. Puckering or non-lifting of the lesion during injection also suggests invasion of the muscularis propria [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normal saline can be used but is absorbed quickly. To overcome this limitation, hypertonic saline, 50 percent dextrose, 10 percent glycerol, 5 percent fructose, a fibrinogen mixture, sodium hyaluronate, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/35/43570?source=see_link\">",
"     hydroxypropyl methylcellulose",
"    </a>",
"    (HPMC) have all been used [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. Our preferred SFC solution is HPMC because it is widely available, less expensive than sodium hyaluronate, and appears to be as effective as sodium hyaluronate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. It is anticipated that a 0.075 percent solution will become commercially available in the near future. At least 10 to 40 mL of solution should be injected for an effective SFC [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. Injections are performed using an injection needle at one or multiple sites adjacent to the lesion in an attempt to lift the lesion away from the muscularis propria. An automated pump designed for rapid and uniform submucosal injection (ERBE USA, Inc., Marietta, GA) is also commercially available [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies suggest that 50 percent dextrose may be superior to normal saline for use as a lasting (more than five minutes) SFC during prolonged procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/40\">",
"     40",
"    </a>",
"    ]. However, a potential concern with 50 percent dextrose was raised in one study in which it was more likely to be associated with postpolypectomy electrocoagulation syndrome than the combination of saline and epinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3971?source=see_link\">",
"     \"Postpolypectomy electrocoagulation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a study comparing various solutions, the duration of the SFC was shortest with normal saline or normal saline plus epinephrine (less than three minutes), was slightly longer with 50 percent dextrose and glycerine (four minutes), and was longest with hyaluronic acid (22 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preliminary animal and human experiences have been reported that suggest that adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     MESNA",
"    </a>",
"    (sodium 2-sulfanylethanesulfonate) to the SFC may enable resection of flat lesions by further enhancing the ability to separate the mucosa from the submucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Suction methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the lesion has been lifted away from the muscularis propria by the SFC, it is aspirated and resected [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/43\">",
"     43",
"    </a>",
"    ]. This technique is most commonly performed with a transparent cap affixed to the tip of the endoscope (also known as cap-assisted EMR, EMRC) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/44\">",
"     44",
"    </a>",
"    ]. This cap is placed over the lesion and suction is applied, drawing the lesion into the cap. The lesion is then resected with a snare placed through the endoscope into the cap (",
"    <a class=\"graphic graphic_figure graphicRef76963 \" href=\"UTD.htm?38/20/39246\">",
"     figure 4",
"    </a>",
"    ). To decrease the risk of perforation, two groups have recommended injecting a sufficient volume of saline (20 to 40 mL) to raise the lesion with controlled suction and snaring at the middle of the SFC rather than the base [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variation of the suction technique is the band and snare procedure, which in many cases does not require submucosal injection. During the band and snare procedure, tissue is banded using an esophageal variceal banding device and then snared off in the standard fashion (",
"    <a class=\"graphic graphic_figure graphicRef53182 \" href=\"UTD.htm?26/62/27631\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50649 \" href=\"UTD.htm?5/5/5201\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/44,47,48\">",
"     44,47,48",
"    </a>",
"    ]. Commercial EMR kits designed for this technique are now available. A large channel endoscope is recommended since it facilitates generation of adequate suction prior to resection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Non-suction methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-suction methods use a grasping device to pull the lesion away from the muscularis propria, after which a snare is used to resect the specimen. These were the first techniques used for EMR and are technically more challenging than the suction methods described above. Non-suction methods include: strip biopsy (lift-and-cut), strip biopsy (cutting method), strip biopsy (using a partial hood), endoscopic double-snare polypectomy, endoscopic resection with local saline epinephrine injection, and endoscopic resection with local sodium hyaluronate injection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/36,49-53\">",
"     36,49-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Widespread EMR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of widespread EMR (WEMR) is in preclinical trials where it is being evaluated for resection of surface lesions larger than 2 cm at the esophagogastric junction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/54\">",
"     54",
"    </a>",
"    ]. WEMR can potentially benefit patients with high-grade dysplasia in Barrett's esophagus. It may also minimize the 5 to 47 percent residual or recurrent lesion rate associated with piecemeal resection of colonic polyps larger than 2 cm [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28968?source=see_link\">",
"     \"Endoscopic removal of large colonic polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A mucosal strip is created using a prototype porcelain ball-tipped needle-knife. The proximal and lateral margins of the strip are separated from the underlying tissue after a sufficient SFC is created. The mucosa is then stripped off its cushion moving in a distal direction using a grasping forceps. Next, the strip of mucosa, which is still attached at its distal end, is released into the gastric cavity and resected using a snare and forceps with the endoscope in retroflexion. WEMR can be technically challenging to perform and demands multiple maneuvers of the endoscopist.",
"   </p>",
"   <p>",
"    WEMR can be partial or circumferential. However, the circumferential method has been associated with an increased incidence of stricture formation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     ESD techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;ESD is a variant of EMR in which a specialized needle-knife is used to dissect lesions from the submucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/57-61\">",
"     57-61",
"    </a>",
"    ]. It offers the potential to remove mucosal and submucosal tumors en bloc. The greatest experience has been in treatment of early gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/57,58,62,63\">",
"     57,58,62,63",
"    </a>",
"    ], but it has also been applied to lesions in the colon [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/59,64,65\">",
"     59,64,65",
"    </a>",
"    ], the esophagus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/60,66-68\">",
"     60,66-68",
"    </a>",
"    ], the esophagogastric junction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/69\">",
"     69",
"    </a>",
"    ], and duodenum [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4842?source=see_link&amp;anchor=H757935984#H757935984\">",
"     \"Early gastric cancer: Treatment, natural history, and prognosis\", section on 'Endoscopic mucosal resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the technique has shown promise in highly experienced hands, complications and incomplete tumor removal have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/68,69,73-75\">",
"     68,69,73-75",
"    </a>",
"    ]. The technique requires advanced skill levels and focused training to acquire these skills, which have limited the use of this technique in North America, where the greatest potential use would be directed at large flat colorectal polyps.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62375506\">",
"    <span class=\"h3\">",
"     Comparison of ESD and EMR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies comparing ESD with EMR have shown the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 15 studies found that ESD, compared with EMR, had higher en bloc and curative resection rates (OR 13.9 and 3.5, respectively), as well as lower rates of local recurrence (OR 0.09) for malignant and premalignant lesions of the gastrointestinal tract [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/73\">",
"       73",
"      </a>",
"      ]. Similar results were noted in two other meta-analyses [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/76,77\">",
"       76,77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subsequent study of 239 patients with early gastric cancer found that patients who underwent ESD had lower recurrence rates than patients who underwent EMR (4 versus 18 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective study of 300 patients with squamous cell cancer of the esophagus, patients who underwent resection with ESD had significantly higher en bloc resection rates and lower local recurrence rates compared with patients who underwent EMR (100 versus 53 percent and 1 versus 10 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     LONG-TERM OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up studies suggest that ER in carefully selected patients can achieve long-term cure, although the number of patients reported is relatively small.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Esophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up data are available for patients who have undergone EMR in the esophagus for cancer, high-grade dysplasia, or intestinal metaplasia. Several reports have suggested a low rate of recurrence following EMR of isolated lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/4-12\">",
"     4-12",
"    </a>",
"    ]. However, recurrence is more likely in patients with multiple or circumferential lesions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the largest reports with the longest follow-up included 142 patients with esophageal cancer who were followed for up to nine years [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/6\">",
"       6",
"      </a>",
"      ]. The five-year survival rate was 95 percent, and no cancer-related deaths were reported.",
"     </li>",
"     <li>",
"      Another group found no significant difference between the five-year survival of m1 and m2 esophageal cancer treated by EMR or esophagectomy (86 versus 83 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a report of 51 patients, local recurrence occurred in two of five patients (40 percent) with multiple esophageal cancers and in 2 of 46 patients (4 percent) with a solitary cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another group examined the use of EMR for mucosal esophageal cancers that were less than 2 cm in size or that were less than one-third of the esophageal circumference [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/7\">",
"       7",
"      </a>",
"      ]. Five-year survival rates of 95 to 100 percent were reported, with recurrence rates of 3 to 7 percent. All recurrences were successfully treated with local therapy.",
"     </li>",
"     <li>",
"      Long-term survival has also been described when combining EMR with photodynamic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/8,81\">",
"       8,81",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/27/26039?source=see_link&amp;anchor=H6#H6\">",
"       \"Photodynamic therapy for ablation of Barrett's esophagus\", section on 'Combination therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies suggest that when EMR is used in patients with Barrett's esophagus (BE), the rates of complete eradication of intestinal metaplasia and dysplasia are 75 to 100 percent and 86 to 100 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/14,82-88\">",
"     14,82-88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study examined 349 patients with BE undergoing EMR for HGD (61 patients) or early esophageal adenocarcinoma (288 patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/88\">",
"       88",
"      </a>",
"      ]. Complete eradication was attained in 97 percent. During a mean follow-up of 64 months, 22 percent of patients had a recurrence. Of these patients, 85 percent received further endoscopic treatment and achieved a second complete remission. Risk factors associated with recurrence included piecemeal resection (relative risk [RR] 2.4), long-segment BE (RR 1.9), no mucosal ablative therapies of BE after complete remission (RR 2.5), time to achieve complete remission of more than 10 months (RR 0.3), and multifocal neoplasia (RR 2.1). The analysis of data for 231 patients with early esophageal adenocarcinoma treated only by EMR demonstrated a long-term complete remission rate of 96 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    EMR has also been applied to patients with superficial isolated local disease after definitive chemoradiotherapy for more advanced esophageal cancer. In one such series of 16 patients, eight patients had local failures, five had metachronous cancers, and three had residual cancers following definitive chemoradiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/89\">",
"     89",
"    </a>",
"    ]. The three-year survival rate was 56 percent. Three of the local failures and two of three patients with residual disease were alive and relapse-free for 21 to 48 months after the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Stomach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence appears to be uncommon following ER of gastric cancer when an adequate resection margin can be achieved. The use of ER for the treatment of early gastric cancer is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4842?source=see_link&amp;anchor=H757935970#H757935970\">",
"     \"Early gastric cancer: Treatment, natural history, and prognosis\", section on 'Endoscopic therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Colon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both EMR and ESD have been used in the colon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62375661\">",
"    <span class=\"h3\">",
"     EMR in the colon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term outcome of EMR for colonic lesions was examined in a retrospective study with 100 patients who had a total of 125 flat and depressed colorectal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/90\">",
"     90",
"    </a>",
"    ]. The lesions included invasive cancer (3), carcinoma in situ (7), adenomas (91), hyperplastic polyps (21), and nonspecific abnormalities (3). After a mean follow-up of 4.5 years, there were no cases of advanced colorectal cancer or metastasis.",
"   </p>",
"   <p>",
"    A second study examined 390 patients who underwent endoscopic resection of submucosal invasive T1 tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/91\">",
"     91",
"    </a>",
"    ]. EMR alone was used in the treatment of 249 patients, whereas 141 were teated with surgery. Unfavorable outcomes (locoregional tumor relapse, lymph node metastasis, distal metastasis, or death related to advanced colorectal cancer) were seen in 39 patients overall (10 percent) and in 17 patients treated with EMR alone (7 percent). Factors associated with unfavorable outcomes included incomplete tumor resection at the time of endoscopic resection (OR 2.6), lymphatic invasion (OR 7.8), and the presence of a poorly differentiated tumor (OR 3.4).",
"   </p>",
"   <p>",
"    EMR has also been evaluated in patients with rectal carcinoids with good success rates. In a retrospective study of 304 patients with tumors that were 20 mm or less in diameter, complete resection was achieved in 268 patients (88 percent) based upon endoscopic appearance and in 183 (60 percent) based on pathologic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/92\">",
"     92",
"    </a>",
"    ]. Of the 85 patients with complete resection based upon endoscopic evaluation but incomplete resection based on pathologic assessment, residual tumor was detected in eight at follow-up endoscopy (9 percent). Overall, local recurrence developed in two patients (0.6 percent). The three-year survival rate for patients treated endoscopically was 100 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62375668\">",
"    <span class=\"h3\">",
"     ESD in the colon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies are now looking at the use of ESD for the treatment of colonic lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28968?source=see_link&amp;anchor=H14#H14\">",
"     \"Endoscopic removal of large colonic polyps\", section on 'Endoscopic submucosal dissection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of ESD for colorectal neoplasms examined 310 consecutive lesions in 290 patients removed using ESD [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/93\">",
"       93",
"      </a>",
"      ]. Complete lesion resection was attained for 75 percent of the lesions. A colectomy was required in eight patients (3 percent) due to possible node-positive cancer detected on histopathology. Perforations occurred during the procedure in 5 percent of the procedures and after the procedure in 0.3 percent. All of the perforations that occurred during the procedure were treated successfully with endoscopic clipping. Two percent of the procedures were complicated by bleeding.",
"     </li>",
"     <li>",
"      A second study of ESD for colorectal neoplasms included 1111 lesions in 1090 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/94\">",
"       94",
"      </a>",
"      ]. En bloc and curative resection rates were 88 and 89 percent, respectively. Perforation occurred in 5 percent of patients, and bleeding occurred in 1.5 percent. Tumor size of 50 mm or greater was an independent risk factor for complications, as was a lower number of ESDs performed at an institution.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1942073\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In experienced hands, ER is a safe procedure that can be performed on outpatients. However, a variety of complications have been described, including stricture formation, bleeding, and perforations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1942080\">",
"    <span class=\"h2\">",
"     Esophagus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one report of 87 ERs, immediate complications were observed in 13 percent of procedures, including mediastinal emphysema (3 percent) and ulcer bleeding (10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/11\">",
"     11",
"    </a>",
"    ]. Late complications were seen in 7 percent, including esophageal stricture due to scarring (6 percent) and ulcer bleeding after five days (1 percent).",
"   </p>",
"   <p>",
"    A similar perforation rate was noted in a series of 143 patients with tumors of the esophagogastric junction treated with ESD. In that series, six patients (4 percent) suffered perforations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/69\">",
"     69",
"    </a>",
"    ]. No patients required surgical repair for the perforation, but two were treated with closed thoracic drainage for pneumothorax. The cap technique with submucosal injection and the ligation technique without submucosal injection had similar safety in a randomized controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'ER Techniques'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Strictures typically are seen in patients who had a mucosal defect involving more than three-fourths of the esophageal circumference [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/11,96\">",
"     11,96",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     Triamcinolone",
"    </a>",
"    injection at the time of resection may decrease the risk of stricture formation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/97\">",
"     97",
"    </a>",
"    ]. Strictures are typically treated with esophageal balloon dilation. The treatment of refractory strictures may include injecting depo-type corticosteroids such as triamcinolone into the stricture following dilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=see_link&amp;anchor=H22#H22\">",
"     \"Management of benign esophageal strictures\", section on 'Refractory strictures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1942087\">",
"    <span class=\"h2\">",
"     Stomach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate bleeding was observed in 4 out of 14 cases in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/98\">",
"     98",
"    </a>",
"    ]. The bleeding was controlled with injection therapy, monopolar electrocoagulation, ligation with a detectable snare, and endoscopic clipping. In another report, delayed bleeding (occurring from 6 to 166 hours after the procedure [median 33 hours]) was observed in 25 of 476 patients (5 percent). The only independent risk factor associated with delayed bleeding was immediate bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/99\">",
"     99",
"    </a>",
"    ]. Bleeding can be difficult to control. We have found endoscopic application of a hemoclip to be a reliable and safe method for controlling bleeding.",
"   </p>",
"   <p>",
"    Perforation has also been described and is more common with ESD. A meta-analysis found that the perforation rate for ESD was 4.5 percent, compared with 1.0 percent for EMR [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/76\">",
"     76",
"    </a>",
"    ]. Treatment of a perforation generally requires open or laparoscopic surgery, although endoscopic clipping can be used for small perforations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. Factors that have been associated with an increased risk of perforation with ESD include tumor location in the upper stomach and tumor size &gt;20 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1942094\">",
"    <span class=\"h2\">",
"     Colon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of endoscopic resection include bleeding and perforation. In one series of patients undergoing EMR, bleeding occurred in 7 out of 29 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/98\">",
"     98",
"    </a>",
"    ]. No patients developed perforation. Bleeding and perforation occurred in one patient each in a series of 23 patients undergoing EMR with a suction method for lateral spreading tumors of the colon [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/45\">",
"     45",
"    </a>",
"    ]. Both complications were successfully treated by endoclipping.",
"   </p>",
"   <p>",
"    In a study that included 297 patients who underwent ESD for colorectal neoplasms, there were 14 perforations (5 percent) and 5 cases of postprocedural bleeding (2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/103\">",
"     103",
"    </a>",
"    ]. One of the perforations required treatment with emergency surgery, whereas the other complications were managed endoscopically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1942101\">",
"    <span class=\"h2\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient bacteremia with Streptococcus salivarius and Corynebacterium species was reported in 2 of 38 patients (5 percent) who underwent cap-assisted EMR for upper gastrointestinal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/54/4970/abstract/104\">",
"     104",
"    </a>",
"    ]. The positive cultures after 10 minutes were negative when repeated after four hours. The authors concluded that routine antibiotic prophylaxis for EMR was not indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic resection (ER) is an endoscopic alternative to surgical resection of mucosal and submucosal neoplastic lesions and intramucosal cancers. ER includes endoscopic mucosal resection (EMR), which involves snare resection of dysplastic lesions, and endoscopic submucosal dissection (ESD) in which endoscopic tools are used to dissect lesions from the submucosa.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ER offers both diagnostic and therapeutic capability. Lesions limited to the mucosa and the superficial layers of the submucosa appear to be the most amenable to endoscopic cure. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The largest experience, mostly from Japanese reports, has been in the treatment of gastric and esophageal neoplasms. The role of ER for staging and treating dysplastic Barrett's in conjunction with mucosal ablative techniques like radiofrequency ablation is growing. ER is also being used in the treatment of colonic neoplasms. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The techniques for EMR can be broadly divided into two groups: suction (suck-and-cut) and non-suction (lift-and-cut) techniques. Regardless of the resection technique, a SFC is highly desirable to separate mucosal and submucosal lesions from the muscularis propria. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'ER Techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ESD is a variant of EMR in which a specialized needle-knife is used to dissect lesions from the submucosa. It offers the potential to remove mucosal and submucosal tumors en bloc. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'ESD techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Follow-up studies suggest that ER in carefully selected patients can achieve long-term cure, although the number of patients reported is relatively small. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Long-term outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In experienced hands, ER is a safe procedure that can be performed on outpatients. However, a variety of complications have been described, including stricture formation, bleeding and perforations. (See",
"      <a class=\"local\" href=\"#H1942073\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/1\">",
"      Technology status report evaluation. Endoscopic mucosal resection. Gastrointest Endosc 2000; 52:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/2\">",
"      The general rules for The gastric cancer study in surgery. Jpn J Surg 1973; 3:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/3\">",
"      The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc 2003; 58:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/4\">",
"      Takeshita K, Tani M, Inoue H, et al. Endoscopic treatment of early oesophageal or gastric cancer. Gut 1997; 40:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/5\">",
"      Soehendra N, Binmoeller KF, Bohnacker S, et al. Endoscopic snare mucosectomy in the esophagus without any additional equipment: a simple technique for resection of flat early cancer. Endoscopy 1997; 29:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/6\">",
"      Hamada T, Kondo K, Itagaki Y, Nishida J. [Endoscopic mucosal resection for early gastric cancer]. Nihon Rinsho 1996; 54:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/7\">",
"      Endo M, Takeshita K, Inoue H. [Endoscopic mucosal resection of esophageal cancer]. Gan To Kagaku Ryoho 1995; 22:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/8\">",
"      Pacifico RJ, Wang KK, Wongkeesong LM, et al. Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol 2003; 1:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/9\">",
"      Suzuki H, Masuda K, Fujisaki J, Okuwaki S. [Endoscopic treatment of gastrointestinal cancers--indication and limitation]. Nihon Rinsho 1996; 54:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/10\">",
"      Makuuchi H. Endoscopic mucosal resection for early esophageal cancer: Indications and techniques. Dig Endosc 1996; 8:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/11\">",
"      Yoshida M, Hanashi T, Momma K, et al. [Endoscopic mucosal resection for radical treatment of esophageal cancer]. Gan To Kagaku Ryoho 1995; 22:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/12\">",
"      Pech O, Gossner L, May A, et al. Endoscopic resection of superficial esophageal squamous-cell carcinomas: Western experience. Am J Gastroenterol 2004; 99:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/13\">",
"      Tanabe S, Koizumi W, Higuchi K, et al. Clinical outcomes of endoscopic oblique aspiration mucosectomy for superficial esophageal cancer. Gastrointest Endosc 2008; 67:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/14\">",
"      Seewald S, Akaraviputh T, Seitz U, et al. Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc 2003; 57:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/15\">",
"      Peters FP, Kara MA, Rosmolen WD, et al. Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett's esophagus. Gastrointest Endosc 2005; 61:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/16\">",
"      Wani S, Sayana H, Sharma P. Endoscopic eradication of Barrett's esophagus. Gastrointest Endosc 2010; 71:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/17\">",
"      Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology 2000; 118:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/18\">",
"      Raju GS, Waxman I. High-frequency US probe sonography-assisted endoscopic mucosal resection. Gastrointest Endosc 2000; 52:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/19\">",
"      Kojima T, Parra-Blanco A, Takahashi H, Fujita R. Outcome of endoscopic mucosal resection for early gastric cancer: review of the Japanese literature. Gastrointest Endosc 1998; 48:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/20\">",
"      Schlemper RJ, Itabashi M, Kato Y, et al. Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. Lancet 1997; 349:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/21\">",
"      Makuuchi H, Kise Y, Shimada H, et al. Endoscopic mucosal resection for early gastric cancer. Semin Surg Oncol 1999; 17:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/22\">",
"      Biaek A, Wiechowska-Kozowska A, Pertkiewicz J, et al. Endoscopic submucosal dissection for treatment of gastric subepithelial tumors (with video). Gastrointest Endosc 2012; 75:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/23\">",
"      Karita M, Tada M, Okita K, Kodama T. Endoscopic therapy for early colon cancer: the strip biopsy resection technique. Gastrointest Endosc 1991; 37:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/24\">",
"      Shirai M, Nakamura T, Matsuura A, et al. Safer colonoscopic polypectomy with local submucosal injection of hypertonic saline-epinephrine solution. Am J Gastroenterol 1994; 89:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/25\">",
"      Yokota T, Sugihara K, Yoshida S. Endoscopic mucosal resection for colorectal neoplastic lesions. Dis Colon Rectum 1994; 37:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/26\">",
"      Kanamori T, Itoh M, Yokoyama Y, Tsuchida K. Injection-incision--assisted snare resection of large sessile colorectal polyps. Gastrointest Endosc 1996; 43:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/27\">",
"      Young PE, Gentry AB, Acosta RD, et al. Endoscopic ultrasound does not accurately stage early adenocarcinoma or high-grade dysplasia of the esophagus. Clin Gastroenterol Hepatol 2010; 8:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/28\">",
"      Conio M, Rajan E, Sorbi D, et al. Comparative performance in the porcine esophagus of different solutions used for submucosal injection. Gastrointest Endosc 2002; 56:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/29\">",
"      Fujishiro M, Yahagi N, Kashimura K, et al. Different mixtures of sodium hyaluronate and their ability to create submucosal fluid cushions for endoscopic mucosal resection. Endoscopy 2004; 36:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/30\">",
"      Fujishiro M, Yahagi N, Kashimura K, et al. Comparison of various submucosal injection solutions for maintaining mucosal elevation during endoscopic mucosal resection. Endoscopy 2004; 36:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/31\">",
"      Lee SH, Park JH, Park do H, et al. Clinical efficacy of EMR with submucosal injection of a fibrinogen mixture: a prospective randomized trial. Gastrointest Endosc 2006; 64:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/32\">",
"      Yamamoto H, Yahagi N, Oyama T, et al. Usefulness and safety of 0.4% sodium hyaluronate solution as a submucosal fluid \"cushion\" in endoscopic resection for gastric neoplasms: a prospective multicenter trial. Gastrointest Endosc 2008; 67:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/33\">",
"      Feitoza AB, Gostout CJ, Burgart LJ, et al. Hydroxypropyl methylcellulose: A better submucosal fluid cushion for endoscopic mucosal resection. Gastrointest Endosc 2003; 57:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/34\">",
"      Polymeros D, Kotsalidis G, Triantafyllou K, et al. Comparative performance of novel solutions for submucosal injection in porcine stomachs: An ex vivo study. Dig Liver Dis 2010; 42:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/35\">",
"      Hirao M, Masuda K, Asanuma T, et al. Endoscopic resection of early gastric cancer and other tumors with local injection of hypertonic saline-epinephrine. Gastrointest Endosc 1988; 34:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/36\">",
"      Yamamoto H, Yube T, Isoda N, et al. A novel method of endoscopic mucosal resection using sodium hyaluronate. Gastrointest Endosc 1999; 50:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/37\">",
"      Narahara H, Iishi H, Tatsuta M, et al. Effectiveness of endoscopic mucosal resection with submucosal saline injection technique for superficial squamous carcinomas of the esophagus. Gastrointest Endosc 2000; 52:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/38\">",
"      Lee SH, Cho WY, Kim HJ, et al. A new method of EMR: submucosal injection of a fibrinogen mixture. Gastrointest Endosc 2004; 59:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/39\">",
"      K&auml;hler GF, Sold MS, Post S, et al. Selective tissue elevation by pressure injection (STEP) facilitates endoscopic mucosal resection (EMR). Surg Technol Int 2007; 16:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/40\">",
"      Katsinelos P, Kountouras J, Paroutoglou G, et al. A comparative study of 50% dextrose and normal saline solution on their ability to create submucosal fluid cushions for endoscopic resection of sessile rectosigmoid polyps. Gastrointest Endosc 2008; 68:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/41\">",
"      Sumiyama K, Tajiri H, Gostout CJ, et al. Chemically assisted submucosal injection facilitates endoscopic submucosal dissection of gastric neoplasms. Endoscopy 2010; 42:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/42\">",
"      Sumiyama K, Gostout CJ, Rajan E, et al. Chemically assisted endoscopic mechanical submucosal dissection by using mesna. Gastrointest Endosc 2008; 67:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/43\">",
"      Poppers DM, Haber GB. Endoscopic mucosal resection of colonic lesions: current applications and future prospects. Med Clin North Am 2008; 92:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/44\">",
"      Fleischer DE, Wang GQ, Dawsey S, et al. Tissue band ligation followed by snare resection (band and snare): a new technique for tissue acquisition in the esophagus. Gastrointest Endosc 1996; 44:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/45\">",
"      Yoshikane H, Hidano H, Sakakibara A, et al. Endoscopic resection of laterally spreading tumours of the large intestine using a distal attachment. Endoscopy 1999; 31:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/46\">",
"      Inoue H, Kawano T, Tani M, et al. Endoscopic mucosal resection using a cap: techniques for use and preventing perforation. Can J Gastroenterol 1999; 13:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/47\">",
"      Akiyama M, Ota M, Nakajima H, et al. Endoscopic mucosal resection of gastric neoplasms using a ligating device. Gastrointest Endosc 1997; 45:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/48\">",
"      Noda M, Kobayashi N, Kanemasa H, et al. Endoscopic mucosal resection using a partial transparent hood for lesions located tangentially to the endoscope. Gastrointest Endosc 2000; 51:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/49\">",
"      Tada M, Murata M, Murakami F, et al. Development of the strip-off biopsy [in Japanese with English abstract]. Gastrointest Endosc 1984; 26:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/50\">",
"      Matsushita M, Hajiro K, Okazaki K, Takakuwa H. Endoscopic mucosal resection of gastric tumors located in the lesser curvature of the upper third of the stomach. Gastrointest Endosc 1997; 45:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/51\">",
"      Takekoshi T, Fujii A, Takagi K, et al. [Radical endoscopic treatment of early gastric cancer-indication for and evaluation of endoscopic resection]. Gan To Kagaku Ryoho 1988; 15:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/52\">",
"      Yamamoto H, Koiwai H, Yube T, et al. A successful single-step endoscopic resection of a 40 millimeter flat-elevated tumor in the rectum: endoscopic mucosal resection using sodium hyaluronate. Gastrointest Endosc 1999; 50:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/53\">",
"      Kume K. Endoscopic mucosal resection and endoscopic submucosal dissection for early gastric cancer: Current and original devices. World J Gastrointest Endosc 2009; 1:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/54\">",
"      Rajan E, Gostout CJ. Future developments of EMR, techniques and devices. Techniques in Gastrointest Endosc 2002; 4:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/55\">",
"      Bedogni G, Bertoni G, Ricci E, et al. Colonoscopic excision of large and giant colorectal polyps. Technical implications and results over eight years. Dis Colon Rectum 1986; 29:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/56\">",
"      Vazquez-Sequeiros E, Geller A, Geller N, et al. Polypectomy of large polyps (&gt;2cm): Efficacy and safety (abstract). Gastrointest Endosc 2000; 51:AB101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/57\">",
"      Ono H. Endoscopic submucosal dissection for early gastric cancer. Chin J Dig Dis 2005; 6:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/58\">",
"      Gotoda T. A large endoscopic resection by endoscopic submucosal dissection procedure for early gastric cancer. Clin Gastroenterol Hepatol 2005; 3:S71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/59\">",
"      Yamamoto H, Yahagi N, Oyama T. Mucosectomy in the colon with endoscopic submucosal dissection. Endoscopy 2005; 37:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/60\">",
"      Oyama T, Tomori A, Hotta K, et al. Endoscopic submucosal dissection of early esophageal cancer. Clin Gastroenterol Hepatol 2005; 3:S67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/61\">",
"      Fujishiro M, Yahagi N, Nakamura M, et al. Successful outcomes of a novel endoscopic treatment for GI tumors: endoscopic submucosal dissection with a mixture of high-molecular-weight hyaluronic acid, glycerin, and sugar. Gastrointest Endosc 2006; 63:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/62\">",
"      Kim JH, Lee YC, Kim H, et al. Endoscopic resection for undifferentiated early gastric cancer. Gastrointest Endosc 2009; 69:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/63\">",
"      Nakamoto S, Sakai Y, Kasanuki J, et al. Indications for the use of endoscopic mucosal resection for early gastric cancer in Japan: a comparative study with endoscopic submucosal dissection. Endoscopy 2009; 41:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/64\">",
"      Fujishiro M, Yahagi N, Kakushima N, et al. Outcomes of endoscopic submucosal dissection for colorectal epithelial neoplasms in 200 consecutive cases. Clin Gastroenterol Hepatol 2007; 5:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/65\">",
"      Byeon JS, Yang DH, Kim KJ, et al. Endoscopic submucosal dissection with or without snaring for colorectal neoplasms. Gastrointest Endosc 2011; 74:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/66\">",
"      Fujishiro M, Yahagi N, Kakushima N, et al. Endoscopic submucosal dissection of esophageal squamous cell neoplasms. Clin Gastroenterol Hepatol 2006; 4:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/67\">",
"      Yoshinaga S, Gotoda T, Kusano C, et al. Clinical impact of endoscopic submucosal dissection for superficial adenocarcinoma located at the esophagogastric junction. Gastrointest Endosc 2008; 67:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/68\">",
"      Ono S, Fujishiro M, Niimi K, et al. Long-term outcomes of endoscopic submucosal dissection for superficial esophageal squamous cell neoplasms. Gastrointest Endosc 2009; 70:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/69\">",
"      Li QL, Yao LQ, Zhou PH, et al. Submucosal tumors of the esophagogastric junction originating from the muscularis propria layer: a large study of endoscopic submucosal dissection (with video). Gastrointest Endosc 2012; 75:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/70\">",
"      Jung JH, Choi KD, Ahn JY, et al. Endoscopic submucosal dissection for sessile, nonampullary duodenal adenomas. Endoscopy 2013; 45:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/71\">",
"      Matsumoto S, Miyatani H, Yoshida Y. Endoscopic submucosal dissection for duodenal tumors: a single-center experience. Endoscopy 2013; 45:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/72\">",
"      Maruoka D, Arai M, Kishimoto T, et al. Clinical outcomes of endoscopic resection for nonampullary duodenal high-grade dysplasia and intramucosal carcinoma. Endoscopy 2013; 45:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/73\">",
"      Cao Y, Liao C, Tan A, et al. Meta-analysis of endoscopic submucosal dissection versus endoscopic mucosal resection for tumors of the gastrointestinal tract. Endoscopy 2009; 41:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/74\">",
"      R&ouml;sch T, Sarbia M, Schumacher B, et al. Attempted endoscopic en bloc resection of mucosal and submucosal tumors using insulated-tip knives: a pilot series. Endoscopy 2004; 36:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/75\">",
"      Takenaka R, Kawahara Y, Okada H, et al. Risk factors associated with local recurrence of early gastric cancers after endoscopic submucosal dissection. Gastrointest Endosc 2008; 68:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/76\">",
"      Park YM, Cho E, Kang HY, Kim JM. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis. Surg Endosc 2011; 25:2666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/77\">",
"      Lian J, Chen S, Zhang Y, Qiu F. A meta-analysis of endoscopic submucosal dissection and EMR for early gastric cancer. Gastrointest Endosc 2012; 76:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/78\">",
"      Park JC, Lee SK, Seo JH, et al. Predictive factors for local recurrence after endoscopic resection for early gastric cancer: long-term clinical outcome in a single-center experience. Surg Endosc 2010; 24:2842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/79\">",
"      Takahashi H, Arimura Y, Masao H, et al. Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). Gastrointest Endosc 2010; 72:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/80\">",
"      Nomura T, Boku N, Ohtsu A, et al. Recurrence after endoscopic mucosal resection for superficial esophageal cancer. Endoscopy 2000; 32:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/81\">",
"      Buttar NS, Wang KK, Lutzke LS, et al. Combined endoscopic mucosal resection and photodynamic therapy for esophageal neoplasia within Barrett's esophagus. Gastrointest Endosc 2001; 54:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/82\">",
"      Nijhawan PK, Wang KK. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus. Gastrointest Endosc 2000; 52:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/83\">",
"      Giovannini M, Bories E, Pesenti C, et al. Circumferential endoscopic mucosal resection in Barrett's esophagus with high-grade intraepithelial neoplasia or mucosal cancer. Preliminary results in 21 patients. Endoscopy 2004; 36:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/84\">",
"      Peters FP, Kara MA, Rosmolen WD, et al. Stepwise radical endoscopic resection is effective for complete removal of Barrett's esophagus with early neoplasia: a prospective study. Am J Gastroenterol 2006; 101:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/85\">",
"      Conio M, Repici A, Cestari R, et al. Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma in Barrett's esophagus: an Italian experience. World J Gastroenterol 2005; 11:6650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/86\">",
"      Larghi A, Lightdale CJ, Ross AS, et al. Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma. Endoscopy 2007; 39:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/87\">",
"      Lopes CV, Hela M, Pesenti C, et al. Circumferential endoscopic resection of Barrett's esophagus with high-grade dysplasia or early adenocarcinoma. Surg Endosc 2007; 21:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/88\">",
"      Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008; 57:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/89\">",
"      Hattori S, Muto M, Ohtsu A, et al. EMR as salvage treatment for patients with locoregional failure of definitive chemoradiotherapy for esophageal cancer. Gastrointest Endosc 2003; 58:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/90\">",
"      Kaltenbach T, Friedland S, Maheshwari A, et al. Short- and long-term outcomes of standardized EMR of nonpolypoid (flat and depressed) colorectal lesions &gt; or = 1 cm (with video). Gastrointest Endosc 2007; 65:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/91\">",
"      Meining A, von Delius S, Eames TM, et al. Risk factors for unfavorable outcomes after endoscopic removal of submucosal invasive colorectal tumors. Clin Gastroenterol Hepatol 2011; 9:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/92\">",
"      Park CH, Cheon JH, Kim JO, et al. Criteria for decision making after endoscopic resection of well-differentiated rectal carcinoids with regard to potential lymphatic spread. Endoscopy 2011; 43:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/93\">",
"      Niimi K, Fujishiro M, Kodashima S, et al. Long-term outcomes of endoscopic submucosal dissection for colorectal epithelial neoplasms. Endoscopy 2010; 42:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/94\">",
"      Saito Y, Uraoka T, Yamaguchi Y, et al. A prospective, multicenter study of 1111 colorectal endoscopic submucosal dissections (with video). Gastrointest Endosc 2010; 72:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/95\">",
"      May A, Gossner L, Behrens A, et al. A prospective randomized trial of two different endoscopic resection techniques for early stage cancer of the esophagus. Gastrointest Endosc 2003; 58:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/96\">",
"      Katada C, Muto M, Manabe T, et al. Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions. Gastrointest Endosc 2003; 57:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/97\">",
"      Hashimoto S, Kobayashi M, Takeuchi M, et al. The efficacy of endoscopic triamcinolone injection for the prevention of esophageal stricture after endoscopic submucosal dissection. Gastrointest Endosc 2011; 74:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/98\">",
"      Ahmad NA, Kochman ML, Long WB, et al. Efficacy, safety, and clinical outcomes of endoscopic mucosal resection: a study of 101 cases. Gastrointest Endosc 2002; 55:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/99\">",
"      Okano A, Hajiro K, Takakuwa H, et al. Predictors of bleeding after endoscopic mucosal resection of gastric tumors. Gastrointest Endosc 2003; 57:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/100\">",
"      Binmoeller KF, Grimm H, Soehendra N. Endoscopic closure of a perforation using metallic clips after snare excision of a gastric leiomyoma. Gastrointest Endosc 1993; 39:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/101\">",
"      Kim HS, Lee DK, Jeong YS, et al. Successful endoscopic management of a perforated gastric dysplastic lesion after endoscopic mucosal resection. Gastrointest Endosc 2000; 51:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/102\">",
"      Ohta T, Ishihara R, Uedo N, et al. Factors predicting perforation during endoscopic submucosal dissection for gastric cancer. Gastrointest Endosc 2012; 75:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/103\">",
"      Kiriyama S, Saito Y, Yamamoto S, et al. Comparison of endoscopic submucosal dissection with laparoscopic-assisted colorectal surgery for early-stage colorectal cancer: a retrospective analysis. Endoscopy 2012; 44:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/54/4970/abstract/104\">",
"      Lee TH, Hsueh PR, Yeh WC, et al. Low frequency of bacteremia after endoscopic mucosal resection. Gastrointest Endosc 2000; 52:223.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2673 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-FCC50AAECF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_54_4970=[""].join("\n");
var outline_f4_54_4970=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1942271\">",
"      LESION CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1942720\">",
"      Esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30945920\">",
"      ENDOSCOPIC ULTRASOUND IN ER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ER TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62375199\">",
"      EMR techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1941275\">",
"      - Submucosal injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Suction methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Non-suction methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Widespread EMR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ESD techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H62375506\">",
"      - Comparison of ESD and EMR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      LONG-TERM OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Esophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Colon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H62375661\">",
"      - EMR in the colon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H62375668\">",
"      - ESD in the colon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1942073\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1942080\">",
"      Esophagus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1942087\">",
"      Stomach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1942094\">",
"      Colon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1942101\">",
"      Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2673\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2673|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/59/2994\" title=\"figure 1\">",
"      JSGE classification of early endoluminal cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/19/44348\" title=\"figure 2\">",
"      Subclasses of Type 0 superficial tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/34/15904\" title=\"figure 3\">",
"      Saline injection prior to EMR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/20/39246\" title=\"figure 4\">",
"      EMR suction technique cartoon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/62/27631\" title=\"figure 5\">",
"      Band snare cartoon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2673|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/5/5201\" title=\"picture 1\">",
"      EMR band snare technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2673|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/35/19003\" title=\"table 1\">",
"      JSGE classification of endoluminal cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/56/13195\" title=\"table 2\">",
"      Paris classification system of superficial lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/61/988\" title=\"table 3\">",
"      JSGE criteria for EMR",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=related_link\">",
"      Clinical features, diagnosis, and staging of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37033?source=related_link\">",
"      Early gastric cancer: Epidemiology, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4842?source=related_link\">",
"      Early gastric cancer: Treatment, natural history, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28968?source=related_link\">",
"      Endoscopic removal of large colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10858?source=related_link\">",
"      Endoscopic resection for treatment of high-grade dysplasia and early cancer in Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27208?source=related_link\">",
"      Endoscopic ultrasound in esophageal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35509?source=related_link\">",
"      High frequency catheter endoscopic ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35802?source=related_link\">",
"      Management of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39305?source=related_link\">",
"      Management of benign esophageal strictures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20426?source=related_link\">",
"      Management of superficial esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/27/26039?source=related_link\">",
"      Photodynamic therapy for ablation of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3971?source=related_link\">",
"      Postpolypectomy electrocoagulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/53/41817?source=related_link\">",
"      Radiofrequency ablation for Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=related_link\">",
"      Treatment and surveillance of non-metastatic carcinoid tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_54_4971="Causes congenital NS";
var content_f4_54_4971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of congenital nephrotic syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Congenital nephrotic syndrome of Finnish type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diffuse mesangial sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diffuse mesangial sclerosis with Drash syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Idiopathic nephrotic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Congenital syphilis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Congenital toxoplasmosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Certain viral infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Galloway syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_54_4971=[""].join("\n");
var outline_f4_54_4971=null;
var title_f4_54_4972="Granulomatous lung disease";
var content_f4_54_4972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common causes of granulomatous lung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Exposures/toxins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drugs (eg, methotrexate, etanercept)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foreign body granulomatosis (eg, intravenous drug use)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersensitivity pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumoconioses (eg, beryllium, cobalt, talc, zirconium)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immunodeficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic granulomatous disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Common variable immunodeficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inflammatory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchocentric granulomatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eosinophilic granulomatosis (pulmonary Langerhans cell histiocytosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoid interstitial pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacteria (eg, tuberculous/nontuberculous mycobacteria, Brucella)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fungi (eg, Aspergillus, Histoplasmosis, Coccidioides, Blastomyces)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parasites (eg, Leishmania, Toxoplasma, Echinococcus, Schistosoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphomatoid granuloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Churg Strauss syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulomatosis with polyangiitis (Wegener's)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_54_4972=[""].join("\n");
var outline_f4_54_4972=null;
var title_f4_54_4973="Conventional approach to cardioversion";
var content_f4_54_4973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72971%7ECARD%2F54077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72971%7ECARD%2F54077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Advantages and disadvantages of the conventional approach to cardioversion (one month of pretreatment with warfarin) in patients with atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use of warfarin for one month before cardioversion may lower the stroke rate from 5.6 percent to a very low stroke rate of &lt;2 percent.",
"       </td>",
"       <td>",
"        Delaying cardioversion to normal sinus rhythm for one month potentially decreases functional capacity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relatively easy to administer with regular monitoring of INRs.",
"       </td>",
"       <td>",
"        Prolonging treatment for&nbsp;seven to&nbsp;eight weeks one month prior to and one month after cardioversion increases the risk of bleeding complications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suitable for community hospitals.",
"       </td>",
"       <td>",
"        Not followed by routine clinical practice, especially in the elderly.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The conventional approach has withstood the \"test of time\" since the 1960s.",
"       </td>",
"       <td>",
"        Patients who are at the highest risk for developing systemic embolization who should receive more prolonged or intensive anticoagulation are not routinely identified.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the American College of Cardiology. J Am Coll Cardiol 2001; 37:691.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Advantages and disadvantages of the transesophageal echocardiography-guided approach to cardioversion of patients with atrial fibrillation undergoing cardioversion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transesophageal echocardiography (TEE) should be able to detect left atrial appendage thrombi, which increase the risk of embolic stroke after electrical cardioversion, thus sparing patients with thrombi from undergoing cardioversion.",
"       </td>",
"       <td>",
"        TEE is performed without any definitive guidelines about who should receive the procedure (high versus low risk)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        In the majority of patients without left atrial appendage thrombi, earlier cardioversion may shorten the period of anticoagulation and lower the corresponding risk of bleeding complications",
"       </td>",
"       <td>",
"        Residual thrombus on repeat TEE may diminish the cost-effectiveness of the TEE-guided approach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A TEE-guided approach may prove more cost-effective owing to the reduction in laboratory monitoring costs and the reduction in bleeding complications",
"       </td>",
"       <td>",
"        Transesophageal echocardiography requires a level III-trained physician and availability of expensive echocardiographic machines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Earlier cardioversion is believed to increase the likelihood of a successful return to and maintenance of sinus rhythm",
"       </td>",
"       <td>",
"        Transesophageal echocardiography may miss thrombi that may embolize after cardioversion. In contrast, TEE may render false positive results by erroneously indentifying spontaneous echocardiographic contrast, sludge, multilobed appendages or pectinate muscles as thrombus",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: The American College of Cardiology. J Am Coll of Cardiol 2001; 37:691-704.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_54_4973=[""].join("\n");
var outline_f4_54_4973=null;
var title_f4_54_4974="Medications for PCOS";
var content_f4_54_4974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly used medications for polycystic ovary syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drug type",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Active ingredient",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Examples",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Major mechanism",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Efficacy",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Indications",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Hirsutism",
"       </td>",
"       <td class=\"subtitle2\">",
"        Menstrual irregularity",
"       </td>",
"       <td class=\"subtitle2\">",
"        Insulin-lowering",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Oral contraceptive pills",
"       </td>",
"       <td>",
"        Ethinyl estradiol 30 mcg + drospirenone",
"       </td>",
"       <td>",
"        Yasmin",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td rowspan=\"3\">",
"        Suppress ovarian function",
"       </td>",
"       <td rowspan=\"3\">",
"        +",
"       </td>",
"       <td rowspan=\"3\">",
"        +",
"       </td>",
"       <td rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"3\">",
"        Menstrual irregularity, hirsutism",
"       </td>",
"       <td rowspan=\"3\">",
"        Contraindicated in patients with venous thrombosis, uncontrolled hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethinyl estradiol 35 mcg + norgestimate",
"       </td>",
"       <td>",
"        Ortho Cyclen",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethinyl estradiol 50 mcg + ethynodiol diacetate",
"       </td>",
"       <td>",
"        Demulen",
"        <sup>",
"         &reg;",
"        </sup>",
"        1/50; Zovia",
"        <sup>",
"         &reg;",
"        </sup>",
"        1/50",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Progestin",
"       </td>",
"       <td>",
"        Micronized progesterone",
"       </td>",
"       <td>",
"        Prometrium",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        Normalizes endometrial cycle",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        +",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        Menstrual irregularity",
"       </td>",
"       <td rowspan=\"2\">",
"        Less efficacious than oral contraceptive pills",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medroxyprogesterone acetate",
"       </td>",
"       <td>",
"        Provera",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Gonadotropin releasing agonists",
"       </td>",
"       <td>",
"        Leuprolide acetate depot",
"       </td>",
"       <td>",
"        Depot Lupron",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        Suppress gonadotropins",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Oral contraceptive alternative",
"       </td>",
"       <td>",
"        Contraindicated in patients with osteoporosis without add-back estrogen",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Antiandrogens",
"       </td>",
"       <td>",
"        Spironolactone",
"       </td>",
"       <td>",
"        Spironolactone",
"       </td>",
"       <td>",
"        Competitive inhibitor of androgen binding to the androgen receptor",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Severe hirsutism",
"       </td>",
"       <td>",
"        Use only with appropriate contraception, because of adverse effects on fetus. Contraindicated in kidney or liver failure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyproterone acetate",
"       </td>",
"       <td>",
"        Cyproterone acetate",
"       </td>",
"       <td>",
"        Competitive inhibitor of androgen binding to the androgen receptor",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Severe hirsutism",
"       </td>",
"       <td>",
"        Use only with appropriate contraception, because of adverse effects on fetus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flutamide",
"       </td>",
"       <td>",
"        Flutamide",
"       </td>",
"       <td>",
"        Nonsteroidal competitive inhibitor of androgen binding to the androgen receptor",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Severe hirsutism",
"       </td>",
"       <td>",
"        Use only with appropriate contraception, because of adverse effects on fetus. Monitor for liver failure. Contraindicated in liver disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Finasteride",
"       </td>",
"       <td>",
"        Finasteride",
"       </td>",
"       <td>",
"        Competitve 5&alpha;-reductase inhibitor",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Severe hirsutism",
"       </td>",
"       <td>",
"        Use only with appropriate contraception, because of adverse effects on fetus",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cell cycle inhibitor",
"       </td>",
"       <td>",
"        Eflornithine HCl 13.9 percent (topical)",
"       </td>",
"       <td>",
"        Vaniqa",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        Irreversible inhibitor of ornithine decarboxylase",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Focal hirsutism",
"       </td>",
"       <td>",
"        Contraindicated in pregnancy and lactation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Glucocorticoids",
"       </td>",
"       <td>",
"        Glucocortioid",
"       </td>",
"       <td>",
"        Prednisone",
"       </td>",
"       <td>",
"        Suppresses adrenal function",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Congenital adrenal hyperplasia",
"       </td>",
"       <td>",
"        Efficacy poor except in patients with congenital adrenal hyperplasia. Contraindicated in patients with uncontrolled diabetes, obesity.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Biguanide",
"       </td>",
"       <td>",
"        Metformin",
"       </td>",
"       <td>",
"        Glucophage",
"        <sup>",
"         &reg;",
"        </sup>",
"        , Glucophage XR",
"        <sup>",
"         &reg;",
"        </sup>",
"        , Glumetza",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        Reduces hepatic glucose production",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        Obesity and insulin resitance; type 2 diabetes",
"       </td>",
"       <td>",
"        Efficacy poor without weight control",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Thiazolidinedione",
"       </td>",
"       <td>",
"        Pioglitazone",
"       </td>",
"       <td>",
"        Actos",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        Peroxisome proliferator-activated receptor agonist",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &plusmn;",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        Type 2 diabetes",
"       </td>",
"       <td>",
"        Contraindicated in patients with hepatic or cardiac disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     +: usually effective; &plusmn;: marginally effective.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_54_4974=[""].join("\n");
var outline_f4_54_4974=null;
var title_f4_54_4975="Ultra mini radial probe";
var content_f4_54_4975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Endobronchial ultrasound (EBUS) ultra mini radial probe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) A 20 MHz ultra-miniature radial probe, designed to reach peripheral pulmonary nodules. B) A 20 MHz ultra-miniature radial probe in a guide sheath. The probe and guide sheath are in the 2 mm working channel of a flexible bronchoscope.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_54_4975=[""].join("\n");
var outline_f4_54_4975=null;
